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Schizophrenia is a debilitating disorder characterized by disturbances in thought with 
lifetime prevalence of one percent.  The public health burden of schizophrenia due to medical 
care, social disability, and co-morbid conditions is substantial.  Genetic variation, viral infection, 
or interaction of the two could influence schizophrenia risk.  An understanding of these disease 
pathways could lead to strategies for prevention and treatment of schizophrenia.   
We used a positional approach to identify schizophrenia candidate genes that could 
interact with cytomegalovirus and herpes simplex viruses (HSV). We focused on three groups of 
genes: TNF and MICB near D6S2672, which was associated with schizophrenia and CMV in our 
previous studies; IL1β, IL1RN, and IL10, immune related genes associated with schizophrenia in 
published articles; and IL-18, IL18BP, IL18RAP, IL12A, and IL12B, positional candidate genes 
in the IL-18 pathway.  We used multiple case-control and family-based samples to test these 
hypotheses.  
 We comprehensively sequenced TNF, and genotyped eight SNPs in a case-control 
sample.  We detected no significant associations.  We used a dual-luciferase expression assay to 
quantify TNF expression driven by common promoter haplotypes.  Differences in TNF 
expression did not correlate with schizophrenia. 
 iii
 To localize the D6S2672 association, we genotyped 26 SNPs spanning 100kb in a case-
control sample.  Based on suggestive associations, we selected five SNPs to assay among 
additional samples.  A SNP in MICB was associated with schizophrenia in these samples.  The 
opposite allele was associated with HSV1 in two non-schizophrenia groups. 
We used comprehensive sequencing data to select tag SNPs at IL1β, IL1RN, IL10, and 
IL-18 pathway genes.  Tag SNPs were evaluated in a case-control sample.  In IL1β, IL1RN, and 
IL10 significant associations were not detected.  However, meta-analysis of rs16944 (IL1β –511) 
studies suggests modest, but significant, risk for schizophrenia in Caucasian samples.  In IL-18 
pathway genes, a IL18RAP SNP was associated with schizophrenia, the opposite allele was 
associated with HSV1. 
Identified associations with schizophrenia may be due to host gene-virus interaction.  
These genetic variants could clarify which patients are vulnerable to viral infection.  Treatment 
or prevention may be feasible, if our results are confirmed.  Further replicate studies are 
warranted, as are functional studies of associated polymorphisms.
 iv
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1. INTRODUCTION 
 
 
 
1.1.SCHIZOPHRENIA 
Schizophrenia is a brain disorder characterized by distortions in thought.  Persistent 
hallucinations, delusions, or disordered thought are core components of the diagnosis and other 
more subtle characteristics such as incongruent mood, flattened affect, or psychomotor slowing 
may also be clinically apparent (A.P.A., 1994; WorldHealthOrganization, 1989).  In addition, 
cognitive dysfunction, including deficits in executive functioning, attention, and memory, has 
been shown to be a persistent, although non-specific, component of schizophrenia (Peuskens et 
al., 2005; Sharma et al., 2003).  These symptoms lead to chronic impairment in emotional and 
social functioning (Carpenter, 1994).   In the last half of the 20th century explicit diagnostic 
criteria for schizophrenia were established (A.P.A., 1994; Jablensky, 1997).   These have 
facilitated larger studies of schizophrenia epidemiology; but important symptoms are not always 
obvious, so specialized clinical skills are necessary to make accurate diagnoses (Jablensky, 
2000). Though schizophrenia is relatively rare compared with other complex diseases, such as 
diabetes and heart disease, the long-term impairment associated with schizophrenia make it the 
ninth leading cause of disability worldwide (Lopez et al., 1998).  In addition, high suicide rates 
and other medical complications are associated with schizophrenia and often lead to premature 
mortality (Heila et al., 2003; Mortensen, 2003) 
Numerous studies have suggested alterations in brain structure and function, but the 
specific pathogenic abnormalities are not known (Lewis et al., 2000).  The efficacy of dopamine 
 1
 receptor antagonists in controlling the most visible symptoms of schizophrenia has led 
substantial research into the dopamine hyperactivity hypothesis of schizophrenia (Carlsson et al., 
1963; Davis et al., 1991).  More recent evidence suggests that glutamate and GABA 
neurotransmitter systems may also be involved, but a consensus has not been well established 
(Collier et al., 2003; Lewis et al., 1999; Moghaddam, 2003).  Brain imaging studies consistently 
show increased ventricular volume with decreased whole-brain and hippocampal volume (Steen 
et al., 2006).  Recent microarray studies have revealed several genes that appear to be 
differentially expressed in postmortem schizophrenia brains, but inter-study consistency and 
implied causality of differential expression are important issues that have not been fully 
addressed (Mirnics et al., 2006). 
After over a century of schizophrenia epidemiology research, the etiology of 
schizophrenia is still a mystery (Jablensky, 1997).  Schizophrenia prevalence estimates range 
from 1.4-4.6 per 1000, and the disorder has been documented in all ethnic groups investigated to 
date (Jablensky, 1993; Jablensky et al., 1992).  Several general environmental factors such as 
urban birth, winter birth, and immigration have been consistently associated with increased risk 
(Boydell et al., 2003; Davies et al., 2003), but the mechanisms involved in this increased risk are 
uncertain.  Perinatal brain damage and birth complications have also been consistently associated 
with schizophrenia (Jones et al., 1998; Verdoux, 2004), but the population attributable fraction of 
each of these is less than 10% and the exact pathogenic mechanisms are not clear (Jablensky, 
2000). 
Liability to schizophrenia is likely to be due to genetic and environmental factors (see 
section 1.2). The latter include a plausible role for infectious agents (see section 1.3).  Despite 
several promising leads, there is scant consensus on pathogenic etiology at present. 
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 Inconsistencies in etiologic studies involving infectious agents could be explained if interactions 
between pathogens and host genetic variation were to play a role in susceptibility (see section 
1.6), but few studies that have directly investigated interaction have been performed (Clark et al., 
2005). 
 
1. 2. GENETIC EPIDEMIOLOGY OF SCHIZOPHRENIA 
Schizophrenia can cluster in families.  Adoption studies suggest that the familial aggregation is 
unlikely to be due to environmental factors alone (Heston, 1966; Kety et al., 1992). Also, 
concordance for monozygotic twins (39%) is significantly higher than that for dizygotic twins 
(10%) (Gottesman, 1991).  Estimates of heritability have ranged from 60-85% after accounting 
for shared environment (McGue et al., 1983; Rao et al., 1981).  The mode of inheritance is 
controversial.  Autosomal dominant and recessive modes of inheritance have been suggested 
(Hurst, 1972; Slater, 1958) and the possibility of genetic heterogeneity cannot be excluded 
(Baron, 1985).  Nevertheless, complex segregation analyses of published family and twin data 
suggest that multiple genes of small effect are likely (Carter et al., 1980; McGue et al., 1983; 
Rao et al., 1981).  Modeling of risk to relatives of schizophrenia patients suggests that at least 
two or three loci, possibly many more, contribute a moderate to small amount of risk (Risch, 
1990).  
Linkage studies can be a model-free, hypothesis-free method of localizing genes for a 
specific trait, and as such are often the first step in identifying genes that confer disease 
susceptibility (Ott et al., 1999).  Linkage studies investigate the co-segregation of genetic 
polymorphisms with the disease state in families with multiple affected members. Statistically 
significant evidence for co-segregation is termed linkage. If the chromosomal location of the 
 3
 polymorphism is known, it is then possible to localize the region that harbors the disease genes. 
Linkage analysis is attractive because a judiciously chosen set of polymorphisms can enable 
coverage of the entire genome. With adequately sized samples, it is possible to exclude genes 
localized to unlinked regions. On the other hand, the linked regions identified from currently 
available samples are typically quite extensive (millions of base pairs). Initial linkage scans of 
schizophrenia focused on large families with multiple affected individuals were not successful at 
finding genes of major effect, so subsequent linkage scans have incorporated larger samples of 
smaller families, such as affected sibling pairs (Williams et al., 2002).  In the past two decades, 
significant linkage for schizophrenia has been reported at several chromosomal regions, but there 
have been relatively few consistent results (Badner et al., 2002; Lewis et al., 2003). This is likely 
due to inadequate sample size or a multigenic-multifactorial etiology, among other reasons 
(Owen et al., 2000). Because multiply affected families are infrequent it may only be possible to 
recruit sufficiently large samples through collaborative initiatives. Meta-analyses have shown 
that current whole-genome linkage scans are more concordant than expected by chance, but do 
not conclusively identify a loci of major importance  (Lewis et al., 2003; Zintzaras et al., 2005).  
Several genes identified in putative linkage regions have been found to be associated with 
schizophrenia.  There has been recent excitement about several of these positional candidate 
genes including DISC1, RGS4, neuregulin, and dysbindin.  Although multiple groups have found 
associations at each of these genes, no allele has been consistently associated or shown to have a 
functional effect on gene expression or activity (Shirts et al., 2004). Methodological issues that 
could cause discrepancies in these candidate gene studies will be discussed in section 3.1 and 
3.2.  While genetic factors underlie susceptibility to schizophrenia, environmental factors also 
play a role (Murray et al., 2003). 
 4
  
 
1.3. IMMUNE SYSTEM DYSFUNCTION IN SCHIZOPHRENIA 
Findings of immune system imbalance in schizophrenia patients have been reported since the 
early part of the 20th century (Ganguli et al., 1994).  Immune alterations in schizophrenia can be 
seen in several of the distinct but interrelated branches of the immune system (Muller et al., 
1999).  The immune system can be divided into innate and adaptive components (Janeway et al., 
2005).  The innate immune system is phylogenetically older, consists of natural killer (NK) cells, 
monocytes, and granulocytes as well as compliment and acute phase proteins.  The innate 
immune system has evolved to be an early response to a set of general biological triggers, such 
as extracellular and double-stranded RNA or bacterial lipopoplysaccarides.  On the other hand, 
the adaptive immune system is pyhlogenetically younger and more specific; it consists of T and 
B lymphocytes and their molecular products.  It is involved in antigen specific cell-cell 
interactions and specific antibody production.  These antigen specific responses can be 
conditioned and stored in a cellular “memory,” to provide a rapid response to reinfection.  The 
adaptive immune system is sometimes grouped into T-helper 1 (Th1) and T-helper 2 (Th2) 
components.  The Th1 response refers mainly to the activation CD8+ T cells and the cellular 
component of the adaptive immune response, which responds mainly to intracellular pathogens.  
IL-2, IFN-γ, and TNF are often involved in the Th1 response. The Th2 response mainly refers to 
the eventual activation of B-cells, which are responsible for antibody production, targeted mainly 
at extracellular pathogens.  IL-4, IL-10, IL-6, and TGF-β are often associated with the Th2 
response.  This grouping of cytokines can be useful for distinguishing between different immune 
system pathways, but in actuality the pathways are interrelated and infection may simultaneously 
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 elicit cytokines that have overlapping, antagonistic, or synergistic effects in multiple pathways, 
so the balance of conflicting cytokine signals may be important in the final immune response. 
Early studies that showed apparent immune dysfunction in schizophrenia cases have led 
to investigation of autoimmune and infectious disease hypotheses of schizophrenia (Crow, 1983; 
Ganguli et al., 1994; Jones et al., 2005; Kirch, 1993; Wright et al., 2001), (see section 3.2.2 for 
more discussion on genetic studies of these hypotheses).  Recently, there has been renewed 
interest in cytokine abnormalities as markers of immune imbalance in schizophrenia patients 
(Kim et al., 2004c; Riedel et al., 2006).  Studies of schizophrenia immunology have been prone 
to the difficulties of small sample size, varying lab techniques, and confounders such as age and 
medication status (Arolt et al., 2002).  Nevertheless, relatively consistent evidence of decreased 
IL-2 and IFN-γ as well as increased IL10,IL6, and TGF-β suggests Th2 system predominance 
over Th1 system cytokines among patients (Akiyama, 1999; Kim et al., 2004c; Muller et al., 
1999; Rothermundt et al., 2001; Schwarz et al., 2001).  This imbalance may be linked to 
infectious disease exposure, and has recently been invoked in variations of the 
neurodevelopmental, autoimmune, and infectious disease hypotheses of schizophrenia (Brown, 
2006; Eaton et al., 2006; Ganguli et al., 1994; Rapaport et al., 2001).  Genetic variation in the 
immune system may cause cytokine imbalance in schizophrenia.  Findings of altered serum 
cytokine levels have been an important rationale for many association studies of cytokine 
candidate genes in schizophrenia (Muller et al., 1999); several of these will be discussed in more 
detail in section 3.3.2. 
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 1.4. EPIDEMIOLOGIC EVIDENCE OF INFECTIOUS DISEASE RISK 
Early studies investigated the possibility of an infectious etiology for schizophrenia (Kirch, 
1993).  Several infectious agents have received prominent attention (Brown, 2006; Torrey et al., 
2003; Yolken, 2004).  As well as being consistent with immune imbalance, the infectious 
disease hypothesis of schizophrenia is consistent with robust epidemiological findings including 
increased risk caused by urban birth, winter birth, and migration (Boydell et al., 2003).   
Neonatal CNS infection with viruses, such as rubella and Coxsackie virus, is rare but can cause 
a substantial increase in schizophrenia risk (Brown et al., 2001; Koponen et al., 2004; 
Rantakallio et al., 1997).  However, rare viral CNS infection contributes less than 5% to the 
population-attributable risk (Koponen et al., 2004).  Although evidence implicating any specific 
common infection has been inconsistent, recent studies of CMV, herpes viruses, Toxoplasma 
gondii, and influenza have been more promising (Brown et al., 2005a; Brown et al., 2005b; 
Leweke et al., 2004; Pearce, 2003; Wang et al., 2006).  The following section will discuss the 
possible influence of a family of related common viral infections on schizophrenia risk. 
 
1.5.  HERPES VIRUSES AND SCHIZOPHRENIA 
Herpes viruses are enveloped double-stranded DNA viruses.  Eight members of the 
Herpesviridae family are known to infect humans including cytomegalovirus, varicella zoster 
virus, Epstein-Barr virus, and herpes simplex virus 1 and 2 (Cleator et al., 2004).  Each of these 
viruses causes changes in the expression of many immune system genes enabling them to 
establish latent infection in humans. 
A role for some herpes viruses in schizophrenia has been hypothesized because they are 
common and neurotropic (Mettenleiter, 2003; Whitley, 2004).  Herpes encephalitis often 
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 presents with psychiatric symptoms, which can persist for years after the encephalitis resolves 
(McGrath et al., 1997; Wilson, 1976).  CMV infection of the central nervous system is common 
in immunocompromised patients and can lead to apoptosis and glial cell activation, which have 
been noted in postmortem studies of schizophrenia (Cotter et al., 2001; DeBiasi et al., 2002; 
Lokensgard et al., 2002). 
Interest in CMV and schizophrenia began with positive studies of CMV antibodies in the 
CSF and sera of schizophrenia patients (Albrecht et al., 1980; Torrey et al., 1982).  Researchers 
attempting to replicate these results have had mixed results (DeLisi et al., 1986; Fux et al., 1992; 
Rimon et al., 1986; Stevens et al., 1984), as both the quality of design and the results of these 
studies were inconsistent (Pearce, 2003).  PCR-based investigations of CMV and HSV in 
postmortem brains of schizophrenia cases have been largely negative (Sierra-Honigmann et al., 
1995; Taller et al., 1996).  However, recent investigations have shown higher antibody titers 
when examining recent onset schizophrenia cases (Leweke et al., 2004) and specific subtypes of 
schizophrenia (Dickerson et al., 2006).  In addition, schizophrenia patients seropositive for 
HSV1 do worse on cognitive tests and have decreased dorsolateral prefrontal cortex volumes 
when compared with HSV1 seronegative patients and controls (Dickerson et al., 2003a; Prasad 
et al., in press). 
Studies have hinted that other herpes viruses may have an additive effect on 
schizophrenia risk (Yolken, 2004).  It is possible that herpes viruses contribute to the cytokine 
imbalance that has been observed in schizophrenia patients (Almanzar et al., 2005; Kaminska et 
al., 2001; Kim et al., 2004b; Kipnis et al., 2004; Schwarz et al., 2001).  In addition, interactions 
between genes and viruses may account for the variability that has been noted in studies of viral 
risk for schizophrenia.   
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1.6. GENE-VIRUS INTERACTION AND SCHIZOPHRENIA 
Genetic variation in host response to infectious disease has been well documented (Cooke et al., 
2001; Lipoldova et al., 2006; Somech et al., 2003).  For example, the severity of HIV infection is 
dependent on the CCR5 genotype of the host, and hemoglobin variation can be a major factor in 
host response to malaria infection (Hill, 2001; Segal et al., 2003).  Genetic modifiers of 
susceptibility to HSV and CMV have been demonstrated in experimental strains of mice (Beutler 
et al., 2005; Lee et al., 2001; Norose et al., 2002).  Though genetic variation in human 
susceptibility to herpes virus risk has not been extensively studied, candidate genes have been 
associated with human susceptibility to several members of the herpesviridae family (Hurme et 
al., 2003; Hurme et al., 1998).  Genetic differences also modify herpes virus resistance in human 
oligodendrocytes (Kastrukoff et al., 2002). Researchers who have investigated viral risk factors 
for schizophrenia have noted that specific genetic polymorphisms are likely to modulate the 
action of viruses in schizophrenia risk (Pearce, 2003). Consistent with this hypothesis, 
Krabbendam et al. (2005) found that increased schizophrenia risk associated with urban birth 
was conditional on genetic liability.  Furthermore, several cytokine genes have been associated 
with schizophrenia, some of which are involved in controlling HSV1 and CMV infection 
(Chiavetto et al., 2002; Duan et al., 2004; Hurme et al., 2003; Katila et al., 1999b) (see also 
section 1.3, 1.5, and 3.3.2).   
Nevertheless, difficulties in investigating the possibility of gene-environment interaction 
using epidemiological tools have limited formal tests of interaction (Kraft et al., 2005; Wong et 
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 al., 2003).  These difficulties are due to challenges in measuring risk caused by infectious agents 
in schizophrenia, lack of genes of large effect contributing to schizophrenia risk, and difficulties 
inherent in measuring interactions.  The peak incidence of initial schizophrenia onset is in late 
adolescence and early adulthood, and symptoms often persist for months before a definitive 
diagnosis is made (Hafner, 2003).  Environmental insults in utero or in early childhood, while the 
brain is developing, may be more important than proximal events in schizophrenia pathogenesis 
(Cannon et al., 2003).  Thus, measuring the extent and timing of exposures that may precede 
diagnosis by months to decades are a major challenge in schizophrenia epidemiology.  In 
addition, lack of consistency in genetic linkage and association studies of schizophrenia are 
common despite significant heritability (Owen et al., 2000), so there are no clear genetic 
candidates for investigation of interactions.   Difficulties in schizophrenia epidemiology 
compound the limitations inherent in investigations of interaction, specifically a larger space of 
possible tests, smaller cell size due to sample subdivision, and possible additional reductions in 
power due to the necessity of more complex statistical models (Botto et al., 2001; Ottman, 1996). 
Despite these difficulties the nature of herpes viruses, advances in understanding of 
schizophrenia genetics, and more sophisticated statistical techniques have made the investigation 
of possible interactions more tenable. Challenges in the temporal measurement of infection are 
mitigated somewhat in investigations of infections that cause recurrent infection, such as HSV 
and CMV, because serological evidence of infection is attenuated with recrudescence (Yolken, 
2004).  Growing consensus on schizophrenia linkage regions allows selection of candidate genes 
for which there is reasonable combined positional evidence (Lewis et al., 2003).  Larger samples 
with better clinical, genetic, and serological data are becoming available.  In addition, recent 
advances in statistical techniques have demonstrated the feasibility of evaluating of gene-
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 environment interaction in family based samples; these techniques control for the possibility of 
genetic population stratification, but are dependant on assumptions of gene-environment 
independence (Chatterjee et al., 2005)(see section 4.6.2).  Case only analysis of interaction is 
another recently developed method for investigating gene environment interaction (Khoury et al., 
1996a)(see section 4.6.3).  Because HSV1 and CMV are common viruses, stratification by 
exposure divides samples into relatively even segments, so for a common allele only moderately 
sized samples may be necessary to achieve meaningful cell sizes and estimates of risk.  Studying 
common viruses not only mitigates difficulties in study design, it also enhances the potential 
significance of findings. A small increase in risk conferred by common herpes viruses or 
common-gene-common-virus interactions could contribute a relatively large amount to the 
population-attributable risk for schizophrenia, so the potential public health benefits are great.   
 
1.7. SIGNIFICANCE 
Although there is convincing evidence for the presence of environmental and genetic factors, 
pinpointing risk factors for schizophrenia has been difficult.  Exposure to infectious agents is a 
plausible environmental risk factor, but prior studies have not been consistent.  Despite 
excitement about the topic, there is a paucity of studies directly investigating gene-environment 
interaction (Clark et al., 2005).  One reason may be that most research groups investigate 
infectious factors in isolation from genetic variation in the patients.   
The investigation of genes that may interact with HSV1 and CMV infection in 
schizophrenia pathogenesis has several possible outcomes and benefits.  Several candidate genes 
we examine have previously been associated with schizophrenia, but previous studies did not 
take infection into consideration.  Our investigation may clarify whether these genetic 
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 associations are dependent on viral infection as well as acting as and independent replication of 
genetic associations.  Several candidate genes we examine have not been previously investigated.  
Our studies will be the first to investigate candidate genes chosen specifically to test specific 
interaction hypotheses.  Negative findings in well-designed, comprehensive evaluation of 
common polymorphisms in genes of interest will at least demonstrate lack of association strong 
enough to be detect given the power of the study.  Positive findings will have clear utility in the 
understanding of schizophrenia.  Regardless of association with schizophrenia associations with 
CMV or HSV infection will potentially lead to greater understanding of human variation in 
response to viral infection.   
Greater understanding of putative gene-virus interactions in schizophrenia may clarify 
which patients are vulnerable to the deleterious effects of viral infections.  Understanding of 
gene-environment interaction may shed light on studies of decreased cognitive functioning and 
brain volume in HSV1 infected schizophrenia patients (Dickerson et al., 2003a)(Prasad 2006 in 
press).  In light of recent open trials suggesting the benefit of anti-viral therapy among patients 
with prior exposure to CMV (Dickerson et al., 2003b), our genetic analyses may also help 
identify candidates for such treatment.  Indeed, preventive strategies for at risk individuals may 
also be feasible if associations are confirmed in larger studies. Thus, this project may hold one of 
the keys to the molecular etiology of schizophrenia, and lead to new methods for diagnosis, 
therapy, and prevention. 
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2.  SPECIFIC AIMS 
 
 
Hypothesis:  Variations in immune-related positional candidate genes in humans interact with 
common infectious agents to influence schizophrenia risk. 
 
Aim 1 – Select candidate genes and SNPs 
1a. Select positional candidate genes for gene-virus interaction studies based on 
published linkage and association studies and our previous data on chromosome 6p. 
1b.  Using public databases and pooled DNA resequencing , select polymorphic “tag” 
SNPs that represent common polymorphisms at candidate genes identified in Aim 1a. 
 
Aim 2 – Genotype selected SNPs in case and control samples, and compare allele 
frequencies in subgroups of these samples defined by infectious exposure. 
2a.  Genotype selected SNPs using multiplex assay systems. 
2b.  Compare allele and genotype frequencies between subgroups defined by antibody 
titer status for viral antigens while adjusting for differences between groups using various 
statistical methods including genomic control.   
 
Aim 3 – Refine associations and investigate additional samples. 
3a. Use linkage disequilibrium data, association data and pooled sequencing of 
polymorphisms near associated SNPs to identify additional putative risk polymorphisms. 
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 3b.  Investigate associations identified in Aim 2 using additional adequately powered 
samples.  These samples include case-parent trio samples and samples from different ethnic 
populations. 
3c.  Explore statistical methods that may be used to investigate additional hypotheses, 
such as uniparental transmission of risk alleles, likelihood of neonatal transmission of viral 
disease, or gene-gene interaction. 
3d.  Check specificity for schizophrenia by using a sample diagnosed with bipolar 
disorder. 
 
Aim 4 – Synthesis of results from previous aims. 
 
 
2.1.  COMPLETION OF SPECIFIC AIMS FOR INDIVIDUAL CANDIDATE GENES 
All the individual specific aims were addressed.  The selection of candidate genes (Aim 1a) is 
described in chapter 3.  Following a description of general methods used (chapter 4), four 
separate chapters present results for specific candidate genes (chapters 5-8).  Chapter 5 discusses 
studies of TNF.  Chapter 6 discusses evaluation of a region on chromosome 6p and the gene 
MICB.  Chapter 7 discusses studies of IL-10, IL1β, and IL1RN.  And, chapter 8 discusses studies 
of six IL-18 pathway genes.  Each of these chapters describes the selection of candidate genes 
(Aim 1b), evaluation of associations with schizophrenia and interactions in at least one case-
control sample (Aim 2a and 2b), and a discussion and synthesis of findings (Aim 4).  Finally, a 
general discussion and synthesis of all results is presented (chapter 9). 
Aim 3 was completed to varying degrees for each gene, depending on the availability of 
public resources, the results of Aim 2, and the availability of additional samples.  Aim 3a was 
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 redundant for genes covered in chapters 7 and 8 (IL-10, IL1β, IL1RN, and IL-18 pathway genes) 
because comprehensive sequencing data was already available for these genes.  The findings of 
no association in Aim 2 for genes covered in chapters 5 and 7 (TNF, IL-10, IL1β, and IL1RN) 
suggested further investigation of these genes as described in Aim 3 would not be fruitful.  All 
parts of Aim 3 are described in Chapter 6 (MICB) including investigations in multiple additional 
case-control samples, a case-parent trio sample, a bipolar sample, and a mixed outpatient sample.  
Exploratory analysis proposed in Aim 3c is also described in chapter 8 (IL18 pathway genes).  
Genotyping of more samples for associated SNPs reported in chapters 6 and 8 (MICB and 
IL18RAP) is in progress, but technical and bureaucratic difficulties have prevented a more timely 
evaluation of these SNPs. 
 
2.2.  SELECTION OF INFECTIOUS AGENTS TO BE EVALUATED 
Throughout the project there was an open discussion about which infectious agents to evaluate 
for associations with specific genes.  Serum antibody titers for CMV, HSV1, HSV2, and 
Toxoplasma gondii were assayed by Dr. Robert Yolken.  CMV and HSV1 were investigated for 
reasons listed in sections 1.4-1.6; in addition, the relatively high prevalence of these diseases 
gave our samples adequate power to genetic detect associations with these viruses.  The 
prevalence of HSV2 and Toxoplasma gondii is relatively low, so our samples had less power to 
detect genetic associations with these infectious agents.  We decided to include analysis of HSV2 
in this dissertation because, as a herpes virus, it was likely to have similar immune-system 
interactions as HSV1 and CMV, so observed trends could possibly compliment association 
findings with other viruses even in underpowered samples.  Toxoplasma gondii was also of 
interest because of epidemiological evidence supporting association of this parasite with 
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 schizophrenia (see section 1.4).  We decided not to include Toxoplasma gondii in the analysis 
presented in this dissertation because the immune response to protozoan parasites differs from 
the immune response to herpes viruses; however, it was often possible to evaluate genetic 
associations with Toxoplasma gondii with minimal additional effort.  Though not included in the 
formal analysis and discussion, tables generated showing tests of genetic associations with 
Toxoplasma gondii are presented in Appendix C. 
 
2.3.  MANUSCRIPTS 
 Four peer-reviewed articles in various stages have resulted from the work presented in this 
dissertation.  These are listed below: 
1. Shirts BH, Bamne M, Kim JJ, Talkowski M, Wood J, Yolken R, Nimgaonkar VL. “A 
comprehensive genetic association and functional study of TNF in schizophrenia risk” 
Schizophrenia Research 2006 Mar;83(1):7-13.  Chapter 5 of the dissertation is based on 
the work presented in this paper. 
2. Shirts BH, Wood J, Yolken RH, Nimgaonkar VL.  “Association study of IL10, IL1β, 
and IL1RN and schizophrenia using tag SNPs from a comprehensive database:  
suggestive association with rs16944 at IL1β.”   Schizophrenia Research (In press).  
Chapter 7 of the dissertation is based on the work presented in this paper. 
3. Shirts BH, Kim JJ, Reich S, Yolken RH, Devlin B, Nimgaonkar VL. “Polymorphisms in 
MICB are associated with human herpes virus seroposivity and schizophrenia risk.”  
Chapter 6 of the dissertation is based on the work presented in this manuscript, which has 
been submitted to Genes, Brain, and Behavior. 
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 4. Shirts BH, Wood J, Yolken RH, Nimgaonkar VL.  “Systematic association studies with 
IL-18 pathway gene localized to schizophrenia linked regions: Significant associations at 
IL18RAP and possible epistatic and gene-environment interactions.”  .”  Chapter 8 of the 
dissertation is based on the work presented in this manuscript, which will be submitted to 
Molecular Psychiatry. 
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3.  POSITIONAL AND FUNCTIONAL CANDIDATES FOR VIRUS-ENVIRONMENT 
INTERACTION 
 
 
 
3.1. DESIGN OF CANDIDATE GENE ASSOCIATION STUDIES 
Several interrelated issues are germane to genetic association studies. Some of the issues are 
shared with other fields of psychiatric research.  Differences in ascertainment sources such as 
community versus hospital-based or community-based versus screened controls can lead to 
variations in findings (Merikangas et al., 2002).  In addition, the schizophrenia phenotype is not 
easily defined and requires specific clinical skills to diagnose.  There have been several 
diagnostic schedules used in the past three decades; thus, diagnostic criteria are an issue, and 
disease heterogeneity is possible (Jablensky, 2000).  Relatively low incidence has made the cost 
of large-scale and prospective studies of schizophrenia risk prohibitive.  Identification of 
‘prodromal’ symptoms may facilitate future prospective studies (Cannon et al., 2005).  These 
issues have made small sample size a concern for many studies. 
Association studies rely on linkage disequilibrium (LD), the nonrandom segregation of 
alleles at linked loci in physical proximity in the genome. Selected polymorphisms are examined 
among cases and unrelated controls. If differences in the distribution of particular alleles 
(variants) are detected, this suggests that the polymorphism itself confers susceptibility or is 
located very close to the disease locus. LD typically dissipates over short genomic regions (100 
bp–10 kb). Therefore, association studies can only be used to interrogate relatively small 
genomic regions. Often they are employed to investigate genes in regions where linkage has 
been detected.  
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 Frustrated by the lack of consistent evidence from schizophrenia linkage studies, some 
investigators have employed association studies to investigate functional candidate genes, that is, 
genes encoding proteins implicated by biochemical, pharmacologic, or other investigations 
(Nimgaonkar, 1997; O'Donovan et al., 1999). To date, several-hundred candidate gene 
association studies of schizophrenia have been reported. The majority failed to detect significant 
associations. Over 90% of past studies have only investigated one polymorphism per gene, so 
failure to detect a significant association does not ‘rule out’ investigated genes. Most reported 
associations have been modest (odds ratios less than 2.0) (The Chinese National Human Genome 
Center, 2003). For many association studies there are serious design problems. Of prime concern 
is the definition of a functional candidate gene for a disorder with unknown pathogenesis. Hence 
the prior probability of selecting the correct candidate is very low, and corrections for multiple 
comparisons should be applied or multiple samples examined (Weiss et al., 2000). Multiple 
corrections are not usually possible, because most studies comprised samples of 200 individuals 
or less. Replication has been attempted for only a minority of loci, and most of these attempts 
have been inconsistent and underpowered (Baron, 2001). 
Additional study design issues are specific to genetic association studies (Terwilliger et 
al., 2000).  A contested debate relates to the choice of controls: unrelated, population-based 
versus family-based controls. Classical association studies have employed the former design, but 
lately family based analyses have come to the fore. Family studies use hypothetical parental 
genotypes not transmitted to cases as controls (haplotype relative risk) (Falk et al., 1987) or 
examine biased transmission of alleles from heterozygous parents to cases (transmission 
disequilibrium test (TDT)) (Spielman et al., 1993b). Family-based designs are less prone to 
artifacts introduced by differences in ethnic background between the cases and population-based 
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 controls (Lander et al., 1994). On the other hand, methods to estimate and account for ethnic 
admixture are available for case-control studies (Bacanu et al., 2000; Devlin et al., 2004; 
Pritchard et al., 1999). The case-control design is more economical, and in many settings has 
more power than family based designs (Bacanu et al., 2000). Still, the TDT detects association 
only if linkage is present, so is considered more reliable than case-control studies (Spielman et 
al., 1996). 
Another critical issue is the choice of polymorphisms. Short tandem repeat 
polymorphisms (STRPs) have been used extensively for linkage studies, but are less favored for 
association studies than single nucleotide polymorphisms (SNPs) because they are relatively 
sparse in the genome.  SNPs are encountered frequently in the genome and can be assayed more 
accurately than STRPs, however, the allele frequency varies from SNP to SNP.  Allele frequency 
impacts on “informativeness” and hence on the power to detect case-control differences. To 
improve informativeness, investigators use haplotypes, or combinations of SNPs. This benefit is 
offset by uncertainty about assigning haplotypes for heterozygous individuals, the so-called 
phase problem (Sinsheimer et al., 2001). Furthermore, haplotypes may not provide additional 
information if SNPs in tight LD are used. 
The recent completion of the human Hapmap project (HapMap, 2003) has facilitated 
association studies using SNPs by providing an overview of LD structure and haplotype blocks 
throughout the human genome.  The Hapmap project is a database of genotypes for common 
polymorphisms spaced at ~5 kb intervals in a defined set of Caucasian, Asian, and African 
population samples.   With this resource an investigator can select “tag” SNPs: the smallest set of 
SNPs that, based on LD estimates, will represent other common SNPs.  Several applications use 
related algorithms to select tag SNPs (Barrett et al., 2005; Rinaldo et al., 2005).  These usually 
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 group SNPs based on pairwise correlation (r2) and select one SNP per group correlated above a 
preset minimum r2 (often > 0.8). 
Beyond Hapmap, the next phase of understanding variation in the human genome is 
complete sequencing of selected genomic regions in population-based samples.  This has already 
begun for candidate genes in inflammatory pathways by a network of Programs for Genetic 
Applications (PGA) sponsored by the National Heart Lung and Blood Institute (i.e. Seattle SNPs 
PGA and Innate Immunity PGA )(Martinez et al., 2005; Nickerson et al., 2005).  These projects 
provide comprehensive information about common variation in genes sequenced in a defined set 
of 23 individuals of European descent and 25 individuals of African descent.  Previously, limited 
knowledge of genomic variation forced candidate gene association studies to investigate one or 
two polymorphisms within a candidate gene.   This made it impossible to ‘rule out’ candidate 
genes with negative association results.  Now it is possible to perform comprehensive evaluation 
of all common variations within well-characterized genes.  In this project several methods have 
been used for tag SNP selection as the Hapmap project and PGA resources have evolved during 
the course of this project.  More details on specific methods used for SNP selection in this 
project can be found in sections 5.2.4, 6.2.3, 7.3.2, and 8.2.2. 
Factors such as migration, drift, and selection can have significant impact on genetic 
associations. Such factors are difficult to estimate or model for particular populations (Jorde, 
2000); hence, a detected association may not reflect an etiologic process and independent 
replications are crucial. Replications can also mitigate the fact that studies that initially reported 
associations are likely to be uncorrected for multiple comparisons. An ideal replicate examines 
the same markers in a separate, but diagnostically comparable, sample that is large enough to 
statistically replicate the initial finding. Even if replicate samples are not large enough to prove 
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 initial findings, concordant data from several samples lends some credence to putative 
associations.  Several methods of meta-analysis provide well-developed techniques to combine 
and synthesize data from multiple studies with similar or varied study designs (Rosenthal et al., 
2001).  
 
3.2. CONSIDERATIONS FOR SELECTION OF POSITIONAL CANDIDATE GENES 
FOR GENE-ENVIRONMENT INTERACTION 
 
Schizophrenia researchers have begun analyzing genes that are both functional and positional 
candidates (i.e., those that have a plausible pathogenic role and are localized to putative linked 
regions). Predictably, these studies have revealed more consistent associations than previous 
studies (Harrison et al., 2003).  Selecting candidate genes for association studies focuses on 
creating hypotheses from available data.  This method benefits from the ability to assimilate all 
forms of evidence to generate testable hypotheses.  The process is limited by the availability of 
data, and is subject to the possibility that additional data may make current candidate gene 
selections less plausible. 
There is current excitement that whole genome association tests using high density SNPs 
will bring a new wave of genetic discoveries that linkage studies lacked precision to detect 
(Carlson et al., 2004; John et al., 2004).  Even if whole genome association studies are able to 
identify novel risk alleles, it is not clear whether they will be as useful in identifying interactions, 
largely due to the problem of multiple testing (Heidema et al., 2006; Lunetta et al., 2004).  
Hypothesis-free exploration of interactions of multiple polymorphisms with a number of 
environmental variables or other polymorphisms leads to a dramatic increase in statistical tests, 
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 so advanced statistical methods such as multifactor dimensionality reduction or the random 
forests approach will be necessary (Bureau et al., 2005; Hahn et al., 2003).  The debate over how 
to deal with thousands or millions of tests in a whole-genome SNP scan with or without looking 
at interactions has not been resolved (Evans et al., 2006; Ohashi et al., 2005; Wang et al., 2005).  
In the coming years geneticists will find out whether the results of whole genome SNP scans will 
be as fruitful as anticipated.  In the meantime well-designed hypothesis-driven candidate gene 
studies may be the only way to investigate gene-environment interaction. 
Difficulties in evaluating the possibility of gene-environment interaction have already 
been discussed (section 1.6).  Positive results of candidate gene association studies depend on the 
selection of ‘true’ risk genes.  This is not a trivial task.  Extensive lists of positional 
schizophrenia candidates and genes that might influence viral infection can be produced.  In this 
investigation of gene-environment interaction the list of reasonable candidates was shortened by 
searching schizophrenia linkage regions for infection-related candidate genes.  Combined 
evidence from the diverse disciplines of psychiatry, neurology, virology, immunology, and 
genetics were then utilized to investigate plausible common pathways and build hypotheses.  
Clearly genes for which evidence from all of these fields combined supports a biologically 
plausible pathogenic mechanism represent ideal candidate genes.  Selecting ideal candidates 
becomes more challenging when evidence from some fields is lacking and there is conflicting 
evidence from different sources. 
For this project genetic evidence supporting a specific region or gene was taken from 
published linkage and association studies of schizophrenia, particularly the Lewis et al (Lewis et 
al., 2003) meta-analysis.  Our own previous data and previous schizophrenia association studies 
conducted by others were evaluated as well (Williams et al., 2003).  Evidence linking genes with 
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 CMV or HSV was taken from published studies of the molecular mechanisms of virus/host 
interaction.  Recent microarray analysis of gene expression changes caused by latent and active 
viral infection were used (Ray et al., 2004; Song et al., 2002).   
At the end of the search three groups of genes were selected: 1.  Genes in the HLA region of 
chromosome 6p, which were associated with schizophrenia and infection in our previous studies.  
2.  Genes significantly associated with schizophrenia in at least one previous study and known to 
be involved in HSV1 or CMV infection.  3. The IL-18 pathway, which is involved in the innate 
and adaptive immune response to several infections and contains multiple positional candidate 
genes. 
 
3.3.  CANDIDATE GENES INVESTIGATED 
The strengths of different sources of evidence varied for each candidate gene or group of 
candidate genes.  Location, size, and linkage meta-analysis bin rank of selected candidate genes 
are listed in Table 3.1.  Selected publications that link genes with schizophrenia and CMV or 
HSV1 are summarized in Table 3.2.  Detailed gene specific data is also presented in the 
following subsections. 
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Table 3.1. Candidate Genes: Location, Size, and Meta-analyses Rank 
 
Position  Linkage Meta-analyses   
Gene   
  
Name  
  
 Location Mb Size Kb Lewis 
(2003) Rank
Badner (2002) 
p-value range
MICB MHC Class 1 Chain-
Related Gene B 
6p21.3 31.5 12.9 5 p=0.03-0.04 
TNF Tumor Necrosis Factor 6p21.3 31.6 2.8 5 p=0.03-0.04 
IL-10 Interleukin 10 1q31-32 203 4.9 16 - 
IL1RN IL-1 receptor antagonist 2q14.2 113.6 16.1 1 p=0.1-0.008 
IL1-beta Interleukin 1 beta 2q14 113.6 7.0 1 p=0.1-0.008 
IL12A Interleukin 12 alpha 3q25.32 161.2 7.0 117 - 
IL12B Interleukin 12 beta 5q31.1 158.7 15.7 2 - 
IL-18 Interleukin 18 11q22.2 111.5 20.9 4 - 
IL18BP Interleukin 18 Binding 
Protein 
11q13 71 6.8 109 - 
IL18R1 Interleukin 18 Receptor 
1 
2q12 102 36.1 1 p=0.02-0.008 
IL18RAP IL-18 Receptor 
Accessory Protein 
2q12 102 33.7 1 p=0.02-0.008 
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Table 3.2.  Candidate Genes: Summary of Published Supporting Evidence  
 
  Previous Association Studies Involvement in Infection 
Gene   Positive Negative 
Serum or CNS 
levels altered in 
schizophrenia 
Role in 
neurodevelopment 
neurodegeneration
CMV HSV 
MICB (Kim et al., 
2004a) 
 
- - (Azimi et al., 2006) (Cosman et 
al., 2001; Wu 
et al., 2003) 
- 
TNF (Boin et al., 
2001; Meira-
Lima et al., 
2003; Schwab 
et al., 2003b; 
Tan et al., 
2003) 
(Duan et al., 
2004; 
Hashimoto et 
al., 2004; 
Riedel et al., 
2002; Tsai et 
al., 2003) 
(Kowalski et al., 
2001; Urakubo et 
al., 2001) 
(Beattie et al., 2002; 
Stellwagen et al., 
2006) 
(Hurme et al., 
1998), 
(Cheeran et 
al., 2001) 
(Halford et 
al., 1996; Irie 
et al., 2005)
IL-10 (Chiavetto et 
al., 2002; Yu et 
al., 2004) 
(Jun et al., 
2003) 
(Cazzullo et al., 
1998; Rothermundt 
et al., 1996) 
- (Hurme et al., 
2003; Raftery 
et al., 2004) 
(Lokensgard 
et al., 2002; 
Marques et 
al., 2004) 
IL1RN (Katila et al., 
1999a; Kim et 
al., 2004b)] 
(Chowdari et 
al., 2001; 
Papiol et al., 
2004) 
(Akiyama, 1999; 
Maes et al., 1996)
(Allan et al., 2005) (Hurme et al., 
1998; Witkin 
et al., 2002) 
- 
IL1-beta (Papiol et al., 
2004; Zanardini 
et al., 2003) 
(Rosa et al., 
2004; Yang et 
al., 2003) 
(Gilmore et al., 
2004; Marx et al., 
2001) 
(Ashdown et al., 
2006; Hensley et al., 
2000; Viviani et al., 
2004) 
(Randolph-
Habecker et 
al., 2002; 
Wara-
aswapati et 
al., 1999) 
(Lokensgard 
et al., 2001)
IL12A - - 
IL12B - - 
(Kim et al., 2002) (Sitaraman et al., 
2000) 
(Pien et al., 
2000) 
(Kumaraguru 
et al., 2002)
IL-18 - - 
IL18BP - - 
IL18R1 - - 
IL18RAP - - 
(Tanaka et al., 
2000) 
(Felderhoff-Mueser et 
al., 2005a; Hedtjarn 
et al., 2005a; Kanno 
et al., 2004) 
(Andoniou et 
al., 2005; 
Andrews et 
al., 2003; 
Pien et al., 
2000; Vliegen 
et al., 2004) 
(Cui et al., 
2005; Lee et 
al., 2003; 
Malmgaard et 
al., 2003; Zhu 
et al., 2003)
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3.3.1. Regions Associated with Schizophrenia and CMV Infection in Our Previous Studies 
In collaboration with Dr. R H Yolken at the Stanley Laboratory of Developmental Neurovirology 
(Baltimore, MD), we investigated the joint impact of genetic variation and exposure to infectious 
disease (Kim et al., 2004a). We investigated antibody levels and genotyped 151 US Caucasian 
patients with schizophrenia or schizoaffective disorder (DSM IV criteria) and their parents.  A 
sample of 183 neonatal community-based controls were also genotyped, but immunoassays 
could not be conducted.  We simultaneously assessed genetic variation in the HLA region and 
exposure to four infectious agents implicated in schizophrenia: CMV, Toxoplasma gondii, HSV-
1, and HSV-2 (Yolken et al., 1995).  Associations of exposure to infectious agents in simplex 
and multiplex families were evaluated by Dr. Bernie Devlin.  Exposure was increased amongst 
multiplex families (more than one affected child) versus simplex families (one affected child), 
significantly so for CMV, HSV1, and HSV2.  The difference was most consistent for CMV, and 
supported CMV exposure as a risk factor for schizophrenia.  
 Initial genetic analysis was conducted by Dr. Jung Jin Kim, and involved 18 anonymous 
STRPs selected on the basis of known recombination patterns in the HLA region.  Significant 
association was detected with marker D6S2672 in the HLA Class I region among patients with 
elevated levels of antibodies to CMV (CMV seropositive cases, n = 27; total n = 151 cases, p = 
0.0085).  The association was detectable using family-based or unrelated community based 
controls.  A nearby STRP, D6S2676, showed significant differences between HSV seropositive 
cases and controls, and SNPs D6S2676, D6S2694, D6S2707 showed significant differences 
between Toxoplasma gondii seropositive cases and controls, but overtransmissions were not 
apparent in the family-based sample.  To identify specific genes associated with schizophrenia, 
we next examined 59 SNPs in twelve genes selected on the basis of their known involvement in 
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 the pathogenesis of CMV infections or association with schizophrenia.  We genotyped these 
selected SNPs in the initial sample.  When all cases (regardless of CMV status) were analyzed 
using the TDT test no significant associations were detected.  However, among CMV 
seropositive patients, TDT showed statistically significant associations with three 
polymorphisms in the 5’ untranslated region (UTR) of MICB and one in the 5’ UTR of TNF (see 
Table 3.3).  Transmission distortion was also observed at haplotypes incorporating these SNPs.  
The associations were not observed among CMV seronegative cases. 
 
Table 3.3  Associations with Schizophrenia in CMV Seropositive Schizophrenia Cases from 
Our Previous Studies  
 
MICB MICB MICB MICB TNF  
Gene 
SNP rs2244839 rs2596536 rs2904776 rs2242955 rs1799964 
TDT p-value (CMV+ patients only) 0.00369 0.01544 0.30362 0.00647 0.03841 
Trends CMV+/Control p-value 0.01958 0.11013 0.31626 0.00023 0.00041 
Trends CMV+/CMV- p-value 0.00047 0.06193 0.017944 0.00027 0.00247 
 
 
      Consistent with the TDT, comparison of CMV seropositive cases with community-
controls also revealed significant associations with the SNPs at MICB and TNF.  These 
associations were also detectable when CMV seropositive cases were compared with CMV- 
cases.  Notably, D6S2672 is localized only 6kb from MICB and 71kb from TNF raising the 
possibility that linkage disequilibrium between markers may account for these associations. 
The associations at MICB and TNF may reflect an interaction between particular 
genotypes and exposure to CMV, but need not impact on schizophrenia pathogenesis.  If this 
were true, associations with the same SNPs should be present among CMV seropositive parents 
who did not have schizophrenia.  Separate comparison of CMV seropositive fathers and CMV 
seropositive mothers with the unrelated controls did not yield similar genetic associations. The 
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 lack of association among the parents, despite the alleles they share with the probands suggests 
that the genetic associations are germane to schizophrenia pathogenesis, rather than CMV 
infection per se. However, analysis of a separate control group is necessary. 
These findings suggest an association between the schizophrenia and immune response 
genes on chromosome 6p in CMV exposed individuals.  To localize the association further and 
identify and evaluate candidate genes in this region we conducted a multi-staged study using 
individuals of Caucasian ancestry.  This work is described in detail in chapters 5 and 6. 
 
3.3.2.  Immune-Related Genes Previously Associated with Schizophrenia 
Because of the epidemiological evidence suggesting an infectious etiology, geneticists have 
investigated several immune-related genes for association with schizophrenia.  Initially 
researchers focused on the HLA region on chromosome 6, which harbors many immune system 
genes.  Wright et al reviewed multiple association studies of genes in this region and found 
inconsistencies possibly because of differences in study design and genes selected (Wright et al., 
2001).  Recently there has been renewed interest in cytokine genes because of consistent findings 
of Th1 and Th2 cytokine imbalance in schizophrenia (Akiyama, 1999; Kim et al., 2004c; Maes et 
al., 2000; Muller et al., 1999; Schwarz et al., 2001).  Association studies have focused on 
candidate genes in the HLA class III region on chromosome 6p21, the IL-1 cluster on 
chromosome 2q13, and IL-10 on chromosome 1q31.  Each of these regions has been implicated 
in schizophrenia susceptibility by multiple linkage studies (DeLisi et al., 2002; Garver et al., 
2001; Levinson et al., 1998; Lewis et al., 2003; Schwab et al., 2003a; Straub et al., 2002). 
Among genes localized to chromosome 6p, tumor necrosis factor (TNF) has received the 
most attention (Duan et al., 2004; Schwab et al., 2003b; Zhang et al., 2004a).  Several lines of 
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 evidence implicate TNF in the pathogenesis of schizophrenia.  TNF localizes to chromosome 6p 
in a region that has been linked with schizophrenia (Schwab et al., 2000; Straub et al., 2002).  
TNF involvement would fit the infectious hypothesis of schizophrenia genesis: that immune 
disregulation caused by genetic variants, infectious agents, or a combination of both may be 
important (Muller et al., 2000; Torrey et al., 2000; Verdoux, 2004).  During prenatal exposure to 
infection, placental TNF levels are elevated (Buka et al., 2001; Urakubo et al., 2001).  Elevated 
TNF has been shown to reduce neuronal survival and dendrite growth in vitro and in animal 
models (Gilmore et al., 2004) (Marx et al., 2001) providing a mechanism for TNF involvement 
in brain development.  Furthermore, atypical antipsychotic drugs have immunomodulatory 
effects including reduced expression of TNF, which may be responsible for some of their 
therapeutic effects (Kowalski et al., 2001; Kowalski et al., 2003; Monteleone et al., 1997).   
Evidence suggesting elevated levels of TNF in the serum of schizophrenia patients 
(Monteleone et al., 1997; Naudin et al., 1997) motivated Boin and colleagues to examine 
polymorphisms in TNF (Boin et al., 2001).  The -308A allele had been shown to increase TNF 
expression in human B-cell lines (Wilson et al., 1997).  Boin and colleagues found the A allele of 
the -308GÆA polymorphism (rs1800629) to be over-represented among Italian schizophrenia 
patients.  Multiple groups have attempted to replicate this finding with mixed results (Duan et al., 
2004; Handoko et al., 2003; Hanninen et al., 2005; Hashimoto et al., 2004; Kampman et al., 
2004; Meira-Lima et al., 2003; Pae et al., 2003; Riedel et al., 2002; Schwab et al., 2003b; Tan et 
al., 2003; Tsai et al., 2003).  Duan et al (2004) included a meta-analysis of previously published -
308GÆA association studies and concluded that there was evidence for association at this 
polymorphism only among Caucasian populations. 
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 Multiple schizophrenia associations studies have been conducted for three other 
positional candidates genes: interleukin 1-beta (IL1β), interleukin 1 receptor antagonist (IL1RN), 
and interleukin 10 (IL10).  IL1β and IL1RN localize to the 400kb IL1 gene cluster on 
chromosome 2q14; a region that achieved genome wide significance in a recent meta-analysis of 
schizophrenia linkage (Lewis et al., 2003).  IL10 localizes to chromosome 1q32; a region that has 
also been linked with schizophrenia (Garver et al., 2001; Gurling et al., 2001).  Published 
investigations of these candidate genes have focused on one to three polymorphisms, and have 
not explored the extent of common variation or LD at these loci. 
There have been ten published association studies of IL1β and IL1RN and schizophrenia.  
The IL1β promoter and binding sites have been highly conserved through vertebrate evolution 
(Bird et al., 2002).  SNP rs16944, which may be associated with increased IL1β production, has 
been found to be associated with a myriad of apparently unrelated diseases including end-stage 
renal disease, gastric cancer, and febrile seizures (Kira et al., 2005; Manchanda et al., 2006; 
Starzynska et al., 2006).  The diverse associations suggest a key role for this polymorphism in 
biological processes.  The retention of this polymorphism in the population despite its putative 
role in the common diseases listed above suggest some evolutionary mechanism to conserve it, 
such as a balancing selection.  Neither Laurent et al (Laurent et al., 1997) nor Yang et al (Yang et 
al., 2003) found associations at a Taq1 polymorphism (rs1143634) in IL1β.  Katilla et al. (Katila 
et al., 1999b) investigated SNP rs16944 (IL1β –511 C/T) in IL1β, an 86bp tandem nucleotide 
repeat in intron 2 of IL1RN (IL1RN (86bp)n), and a SNP in IL1alpha and found a significant 
haplotype association.  Six additional association studies have investigated rs16944 (IL1β –511 
C/T) (Chowdari et al., 2001; Meisenzahl et al., 2001; Papiol et al., 2004; Rosa et al., 2004; 
Tatsumi et al., 1997; Zanardini et al., 2003).  Of these, only one found a significant association 
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 with schizophrenia (Zanardini et al., 2003).  Four association studies in addition to Katilla el al. 
(Katila et al., 1999b) investigated the IL1RN (86bp)n repeat polymorphism.  Two of these found 
no association (Chowdari et al., 2001; Papiol et al., 2004), and the other two found opposite 
alleles to be associated with schizophrenia (Kim et al., 2004b; Zanardini et al., 2003).   Several 
published studies have investigated IL1β-IL1RN haplotypes, but no single haplotype has been 
consistently associated with schizophrenia.  In addition to genetic associations, other researchers 
have reported that the rs16944 T allele is associated with white and gray matter deficits (Papiol 
et al., 2005), and the IL1RN (86bp)2 allele is associated with ventricular enlargement (Meisenzahl 
et al., 2001). 
 Three independent groups have investigated SNPs in the putative promoter of IL10.  
Chiavetto et al (Chiavetto et al., 2002) found that the G allele of rs1800896 (-1082) was 
associated with schizophrenia.  Jun et al (Jun et al., 2003) found no association at rs1800896 or 
rs1800871 in a Korean sample.  Yu et al (Yu et al., 2004) found the A allele of rs1800872 to be 
associated with schizophrenia, and no significant difference at the rs1800896 allele.  In a case-
parent trio study (He et al., 2006), the same group later found the rs1800896 G allele to be over-
transmitted to cases, but found no preferential transmission of rs1800872 alleles. 
Several explanations for discrepancies between association studies of these cytokine 
candidate genes are possible.  First, study design, recruitment, and sample size issues are 
addressed differently be each study.  Second, most previous studies only examined one or two 
polymorphisms per gene and did not investigate the possibility of linkage disequilibrium with 
other loci. Thus, population differences in haplotype structure could cause different association 
patterns.  Finally, genetic polymorphisms may only increase schizophrenia risk in the presence 
of viral factors.  Because of their known role in the immune system each of these genes is a 
 32
 logical target for gene-environment interaction studies aimed at putative infectious agents.  We 
investigated these genes with each of these issues in mind. 
We chose to investigate TNF because it is localized near D6S2672, and there are 
numerous published association studies of this gene, some of which are positive (Duan et al., 
2004), for review of previous studies).  Our studies of TNF are summarized in chapter 5.  When 
we began investigations of IL10, IL-1β, and IL1RN data for these genes was available in the 
Seattle SNPs database and newer genotyping technology was available.  Our studies of these 
three genes are summarized in chapter 7. 
 
3.3.3.  IL-18 Pathway Positional Candidates Involved in Herpes Virus Infection 
Previous association studies of cytokine genes have acknowledged linkage data, but have not 
used linkage data as the primary criteria in a search for related immune system genes.  In 
evaluating schizophrenia linkage regions for related immune system genes we noted that five IL-
18 related genes localize to regions that have been linked with schizophrenia.  Linkage regions 
were defined primarily by the largest meta-analysis of multiple whole genome linkage scans in 
schizophrenia (Lewis et al., 2003).  The IL-18 gene localizes to chromosome 11q22, in the 4th 
ranked region in this meta-analysis (Lewis et al., 2003).  The IL18R1 and IL18RAP gene both 
localize to chromosome 2q12, the highest ranked region (Lewis et al., 2003) .  IL18BP localizes 
to chromosome 11q13, which is not in a highly ranked region in meta-analyses, but has been 
linked with schizophrenia in a subsequent linkage scan (Yamada et al., 2004).  IL12 can act in 
conjunction with IL-18 to produce inflammatory responses (Robinson et al., 2002).  IL12B 
localizes to chromosome 5q31, the 2nd ranked schizophrenia linkage region  (Lewis et al., 2003). 
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 As well as being a positional candidate, IL-18 is a functional candidate for schizophrenia.   
Serum IL-18 levels are significantly elevated in patients with schizophrenia (Tanaka et al., 
2000).  Furthermore, treatment with clozapine and risperidone both significantly lower serum IL-
18 levels in schizophrenia patients (Lu et al., 2004).   IL-18 interacts with many cytokines 
proteins and their receptors in a myriad of immune functions (Gracie et al., 2003; Reddy, 2004).  
IL-18 has the unique ability to promote either Th1 or Th2 polarization depending on the context 
(Akira, 2000; Nakanishi et al., 2001).  IL-18 was initially categorized as a proinflammatory 
cytokine involved in inducing IFN-γ, but elevated IL-18 can also be consistent with Th2 
predominance (Saiki et al., 2004; Ueda et al., 2006).   
IL-18 has a complex role in cerebral neuroinflammation and neurodegeneration and is 
involved in the brain’s defense against infectious agents (Felderhoff-Mueser et al., 2005a).  Cell 
culture studies have shown that IL-18 is involved in the response to several common CNS 
infections (Felderhoff-Mueser et al., 2005a).  A more specific study found IL-18 activates 
microglia to clear neurons infected with the influenza A virus (Mori et al., 2001).  These 
infectious and hypoxic pathways in which IL-18 is active are similar to pathways being 
investigated in schizophrenia pathogenesis (Babulas et al., 2006; Cannon et al., 2002).  IL-18 is 
constitutively expressed by astrocytes, microglia, neurons, and ependymal cells, and must be 
cleaved by caspase to become active (Conti et al., 1999).  In the rodent brain IL-18 is expressed 
at higher levels in the early postnatal period and then down-regulated (Prinz et al., 1999).  
Furthermore, knockout mice have demonstrated IL-18 is involved in exacerbating hypoxic injury 
in the neonatal brain, and after hypoxia it is detectable on apoptotic, immature neurons 
(Felderhoff-Mueser et al., 2005b; Hedtjarn et al., 2005b).  IL-18 can attenuate the Th1 response 
exacerbating rodent models of CNS autoimmune disease (Shi et al., 2000). 
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 IL-18 is involved in immune-system defense against many infections, including CMV 
and HSV1.  Gracie et al (Gracie et al., 2003) presents an extensive overview of many different 
infectious diseases influenced by IL-18 expression.  Murine CMV infection has been shown to 
greatly induce IL-18 release in experimental strains of mice (Andrews et al., 2003; Pien et al., 
2000).  IL-18 interacts with IL-12 to induce interferon-gamma production during HSV2 infection 
(Malmgaard et al., 2003).  There has also been research into IL-18 as an adjuvant to vaccinations 
against both HSV1 and HSV2 infections (Cui et al., 2005; Lee et al., 2003; Zhu et al., 2003).   
Interestingly, IL-12 and IL-18 have also been shown to be involved in control of Toxoplasma 
gondii, another putative schizophrenia risk factor (Vossenkamper et al., 2004). 
The location of IL-18 pathway genes in regions implicated in schizophrenia linkage 
scans, as well as substantial literature demonstrating a role for IL-18 in infection and brain 
function motivated us to investigate the possibility of genes in this pathway having a role in 
schizophrenia risk by themselves and in conjunction with HSV1 and CMV infections.  These 
studies are presented in chapter 8. 
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4.  GENERAL EXPERIMENTAL METHODS 
 
 
This section has been included to avoid redundancy in subsequent sections.  Some specific 
details about methods used and numbers of individuals assayed can be found in the subsequent 
methods sections for each group of genes (section 5.2, 6.2, 7.2, and 8.2). 
All studies were approved by the University of Pittsburgh Institutional Review Board. 
Written informed consent was obtained from all participants, except the neonatal controls, in 
accordance with IRB guidelines. 
 
4.1.  SAMPLES USED 
4.1.1. Pittsburgh Trios and Singleton Cases 
Unrelated patients were recruited at Western Psychiatric Institute and Clinic, Pittsburgh, 
Pennsylvania and from within a 500-mile radius of Pittsburgh.  Board-certified psychiatrists, 
blind to genotyping results, established a consensus diagnosis of schizophrenia or schizoaffective 
disorder using DSM-IV criteria.  In addition DNA was obtained from parents of patients.  
Serology was available a subset of patients and their parents.  Formal structured diagnostic 
evaluations of the parents were not conducted, but one father received a clinical diagnosis of 
schizoaffective disorder, bipolar type.  
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 4.1.2. Pittsburgh Neonatal Controls 
Control DNA was collected from the cord blood of unscreened Caucasian neonates born at 
Magee-Women’s Hospital, Pittsburgh, PA.  Ancestry was based on maternal report, and no 
demographic details apart from ethnicity and gender were available.   
 
4.1.3.  Baltimore Schizophrenia Cases, Bipolar Cases, and Controls 
Serum was obtained from 272 Caucasian individuals with DSM-IV criteria schizophrenia or 
schizoaffective disorder recruited in and around Baltimore, Maryland.  Diagnosis was made by 
one of two board certified psychiatrists (Dickerson et al., 2004).   The average age was 41.9 (SD 
11.2), and the sample was 64% male. 
Serum was also obtained from 119 Caucasian individuals with DSM-IV criteria bipolar I 
or bipolar II disorder in and around Baltimore, Maryland.   Diagnosis was made by one of two 
board certified psychiatrists (Dickerson et al., 2004).   The average age was 39.5 (SD 12.8), and 
the sample was 30% male. 
For a control sample, serum was also obtained from 108 Caucasian adult individuals 
screened for current and past psychiatric disorder using a structured interview.  The average age 
was 35.7 (SD 12.6), and the sample was 28% male.  None of the patients or control individuals 
had clinically apparent viral infection or was taking antiviral medications.  Detailed descriptive 
and recruitment criteria can be found in Dickerson et al (Dickerson et al., 2006), where 
serological information from the majority of individuals in this sample was previously analyzed.  
DNA for this sample was extracted from serum and amplified using whole genome amplification 
(Quiagen, Valencia, CA).  The study was approved by Sheppard Pratt Institutional Review 
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 Board, and written informed consent was obtained from all participants in accordance with IRB 
guidelines. 
 
4.1.4.  Mental Health Interventional Research Center Samples 
Mental Health Interventional Research Center (MHIRC) samples were obtained as part of a 
study funded through Dr. David Kupfer to optimize the treatment of mood and anxiety disorders.  
DNA and serum samples were obtained from 399 Caucasian patients visiting the outpatient 
clinic of Western Psychiatric Institute and Clinic, Pittsburgh, PA. Diagnoses were taken from 
clinical notes and a limited number of structured examinations.  Table 4.1 contains descriptive 
data about this sample.   
 
Table 4.1 Descriptive statistics for MHIRC sample 
 
Age       
mean stdev Q1 Q3
41.1 11.5 31.6 50.8
  
Sex   
M F 
140 259 
 
Psychiatric diagnoses (not exclusive) 
Bipolar 132 
Depression 177 
Anxiety or Panic disorder 122 
Personality Disorder 55 
Eating Disorder 32 
Substance Abuse 93 
Other 126 
no diagnosis recorded 36 
 
 38
  
4.2.  GENOTYPING AND SEQUENCING 
4.2.1. SNAPshot Assay 
The SNAPSHOT assay is a PCR based single base extension protocol (Applied Biosystems, 
New Jersey, USA).  Genomic DNA flanking the site of interest is amplified using a standard 
PCR reaction (see Appendix B4).  This template is then purified and dNTPs are removed using 
Exonuclease 1 and Shrimp Alkaline Phosphotase. A target oligonucleotide primer is designed so 
that the 5’ end of the target primer anneals to the nucleotide adjacent to the target SNP.  The 
sizes of these target primers can be varied allowing assays to be multiplexed for cost savings.   
The SNAPSHOT reaction is a modified PCR reaction that is run with amplified template, target 
primer, and SNAPSHOT multiplex kit, which contains buffer, polymerase, and fluorescently 
labeled dideoxynucleotides (see Appendix B4). During the SNAPSHOT run the target primer is 
extended by one nucleotide that is complementary to the target SNP. 
For our experiments SNAPSHOT products were electrophoresed using an ABI PRISM 
3100 Genetic Analyzer and the products were analyzed using GeneScan software version 3.7.  
Genescan–120LIZ standard (Applied Biosystems) was used as an internal electrophoresis size 
standard.  Allele calls were made using Genotyper v3.7 Software (Applied Biosystems).  All 
genotypes were assayed blind to clinical and immunological status 
 
4.2.2. Illumina Golden Gate assay 
The Illumina Golden Gate assay is described in detail in Shen et al (Shen et al., 2005).  All 
Illumina reagents and probes were provided by Illumina, Inc. (San Diego, CA).  Assays were 
performed at the University of Pittsburgh Genomics and Proteomics Core Facility.  Briefly, the 
Illumina assay queries genomic DNA with two allele-specific and one locus specific probe.  The 
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 3' ends of the allele specific probes are complementary to universal primers and the 5' end is 
complementary to the 3' end of the locus.  These probes are annealed to the genomic DNA and 
ligated together.  The probe fragments are separated from the genomic DNA and used to 
inoculate a PCR reaction containing specifically coded, fluorescently labeled, biotinylated 
primers.  The PCR product is then hybridized to a Sentrix Bead Array matrix, which contains 
50K fiber optic readers and locus specific beads randomly distributed across the matrix.  
Illumina performs quality control and provides decoding software for each matrix.  Each SNP is 
interrogated at least 6 times on the matrix for each individual sample.  The matrix is decoded 
using an Illumina BeadArray reader, which examines the dye intensity for each specific allele on 
each bead.  Calls are grouped into heterozygote and homozygote clusters using a clustering 
algorithm.  Allele calls are returned with a reliability score for each call. 
 
4.2.3. Pooled DNA Sequencing 
Pooled DNA sequencing assays were validated in our lab by Abigail Northup and Kodavali 
Chowdari.  The technique is described in detail in Sham et al (Sham et al., 2002), and Chowdari 
et al (Chowdari et al., 2006).  Briefly, DNA from individuals was quantified by fluorometry 
using the pico-green method (Molecular Probes, Inc; Eugene, OR) and diluted to 4 ng/ul.  A set 
volume of DNA from pre-specified individuals was combined.  Locus specific primers were then 
used to amplify the sequence of interest in pooled DNA using a standard PCR protocol (see 
Appendix B1).  Amplified products were sequenced using the ABI Prism Big Dye 3.1 
Terminator Kit (Applied Biosystems).  Similar to the SNAPSHOT reaction, genomic DNA 
flanking the site of interest is amplified using a standard PCR reaction.  This template is then 
purified and dNTPs are removed using a Exonuclease 1 and Shrimp Alkaline Phosphotase.  An 
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 oligonucleotide primer, often one of the template amplification primers, is used as a sequencing 
primer.   The sequencing reaction is a modified PCR reaction that is run with amplified template, 
sequencing primer, and Big Dye Terminator Kit multiplex kit, which contains buffer, 
polymerase, and dNTPs combined with fluorescently labeled dideoxynucleotides (see Appendix 
B1). The product of this reaction then precipitated using isopropanol, and analyzed on an ABI 
3700 Genetic Analyzer.  The sequence can then be read using ABI Prism Sequencing Analysis 
software or Sequcencher software (Gene Codes, Ann Arbor, MI). 
For pooled sequencing peak heights obtained from ABI Prism Sequencing Analysis 
software version 3.7 are used to estimate allele frequencies.  In these studies SNP allele 
frequencies were estimated by dividing individual peak heights by the sum of both peak heights.  
Either both forward and reverse primers were used for sequencing allele frequencies were 
averaged or only one primer was used and samples were repeated in triplicate.  We have 
empirically found from our previous studies that this method is sensitive enough to detect 
polymorphisms that are present in >5% of the alleles in a population (Chowdari et al., 2006). 
 
4.3. IMMUNOASSAYS 
Immunoassays were performed in the laboratory of Dr. Robert Yolken of the Stanley Division of 
Neurovirology, Johns Hopkins School of Medicine, Baltimore, USA.  Serum samples were 
obtained from the peripheral venous blood of the subjects, and stored at –80 °C until use.  The 
levels of IgG antibodies to HSV-1, HSV-2, TOX, and CMV were tested with solid phase enzyme 
immunoassay (Ashley et al., 1998),(Buka et al., 2001). Briefly, wells of microtiter plates coated 
with target antigens (obtained from KMI Diagnostics Inc, Minneapolis, USA) were reacted with 
test serum diluted 1:100 in phosphate-buffered saline solution at pH 7.4 containing 0.1 % 
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 polysorbate (Tween) 20.  Following incubation for 2 hours at 37 °C, the plates were washed 5 
times with phosphate-buffered saline solution containing 0.1 % polysorbate 20, and incubated 
with peroxidase-labeled anti–human IgG. Following incubation for 1 hour at 37 °C, the plates 
were washed 5 times and incubated with 2-2'-azino-bis [3-ethylbenzthiazoline-6-sulfonic acid]–
hydrogen peroxide peroxidase substrate.  Following reaction for 30 minutes, the amount of color 
generated by reaction between the antigen-bound enzyme and the soluble substrate was 
quantitated by means of a microplate colorimeter at a wavelength of 450 nm. Assays using 
different microtiter plates were standardized by the use of curves generated from reference 
samples run on each assay plate. Antibody titers were quantified as signal/cutoff (S/C) ratios, 
which were calculated for each sample by dividing the optical density measurements generated 
in the assay by the optical density of cut-off sera that were provided by the manufacturer of the 
assays. S/C values of 2.0 or more were taken as abnormal, based on the frequency distribution 
for S/C values. Immunological analyses were performed only for patients and their parents, as 
sera were unavailable from the cord blood samples. 
 
4.4. STATISTICAL ANALYSES AND QUALITY CONTROL 
4.4.1. Quality Control and Data Management 
When using SNAPSHOT assays, we denoted alleles at each polymorphism as '1' or '2' 
alphabetically for convenience. For Illumina assays alleles are coded ‘A’ and ‘B’ and coding 
documentation was provided by Illumina.  For SNAPSHOT assays 4 to 16 samples were 
sequenced using an ABI 3700 automated DNA sequencer for verification of each SNP. Allele 
calls were re-checked independently, blind to diagnostic status.  SNPs that could not be called 
for over 5% of the sample were not included in further analysis.  Data was formatted for various 
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 analyses using Microsoft Access, Excell, and Word software (Microsoft Corporation, Redmond, 
WA). Genotypes were evaluated for Hardy-Weinberg equilibrium in individual samples using 
GenePOP (Raymond et al., 1995), with cases, controls, mothers, and fathers evaluated 
separately.  SNPs not in Hardy-Weinberg equilibrium in controls (p<0.01) were evaluated for 
potential systematic errors in genotype calling.  Genotypes that could be systematically corrected 
were corrected.   If no systematic error in genotype calling could be found and genotype calls 
were still significantly out of Hardy-Weinberg equilibrium these SNPs were not analyzed 
further.  Family based samples were evaluated for Mendelian consistency using PedCheck 
(O'Connell et al., 1998). Inconsistencies were resolved by repeating the assays or by sequencing 
where possible.  If multiple Mendelian errors could not be resolved, families containing these 
errors were removed from the analysis. 
 
4.4.2. Power calculations, Tag SNPs, and Linkage Disequilibrium 
Power calculations were done using Quanto software, which calculates power for evaluation of 
genetic, environmental, and gene-environment interaction effects using several study designs 
(Gauderman, 2002).   
Haploview software (Barrett et al., 2005) was used to evaluate linkage disequilibrium 
(LD) between polymorphisms in our sample.  LD is the population level correlation of alleles at 
nearby loci.  LD is commonly calculated in two ways r2 and D’.  The correlation of two SNPs 
beyond that expected by chance is represented as r2, which is directly related to Pearson’s 
correlation coefficient ‘r’.  But if two SNPs have different minor allele frequencies then it is 
impossible for them to be perfectly correlated in a population, even though alleles are in tight 
LD.  D’ is a measurement that takes this into account and expresses observed correlation 
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 proportional to the total possible correlation given differences in minor allele frequency.  When 
the LD information about polymorphisms in a region is know, this enables the selection of ‘tag’ 
SNPs.  
Tag SNPs for a gene are SNPs that represent other common variants in order to minimize 
the number of genetic markers evaluated without substantially reducing the amount of 
information obtained (Stram, 2004).   If it is known that two SNPs are highly correlated, than an 
investigator can genotype only one at a substantial cost savings and a relatively small reduction 
in information and power.  An association at an individual tag SNP indicates that all of the 
polymorphisms that the tag SNP represents are very likely to be similarly associated. 
For this project we used Hclust (Rinaldo et al., 2005) and Haploview (Barrett et al., 2005) 
software to select and evaluate tag SNPs.  Each of these software programs calculates correlation 
between polymorphisms and groups them into clusters of correlated polymorphisms.  The user 
specifies the minimum correlation acceptable and the minimum minor allele frequency of 
interest.  For the projects presented here we used minimum correlations (r2) of either 0.8 or 0.9 
and minimum minor allele frequencies of either 10% or 5% depending on the project.  More 
aggressive strategies, which use multiple SNPs to predict ungenotyped polymorphisms, can be 
used to further reduce the number of tag SNPs.  These strategies are analogous to using 
haplotypes to identify associations, and are less straightforward to analyze and interpret than 
tagging strategies that utilize pairwise correlation between individual SNPs. 
 
4.4.3. Association Analysis for Individual SNPs 
We used the χ2-based Armitage trend test (Devlin et al., 1999) to compare allele and genotype 
frequencies in cases and controls as well as subgroups defined by gender and specific diagnosis.  
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 Likewise, we evaluated the possibility of association of tag SNPs with infection status by 
comparing subsets of schizophrenia cases seropositive and seronegative for antibodies to 
infectious agents using the Armitage trend test. 
We used Genehunter software to evaluate the overtransmission of SNPs from parents to 
children in case-parent trios (Kruglyak et al., 1996).  This evaluation of the overtransmission of 
alleles is known as the transmission disequilibrium test TDT (Spielman et al., 1993a), and is 
based on the assumption that a child has an equal chance of inheriting either variant of an 
autosomal polymorphism from a heterozygote parent.  Under this assumption, transmission 
distortion only occurs in the presence of association and linkage. 
 
4.4.4. Genomic Control 
Genomic control is a method used for evaluating and correcting for population stratification in a 
case-control sample (Devlin et al., 1999).  Genomic control uses markers not associated with 
disease to estimate the distribution of allele frequency differences between two populations.  The 
median allele frequency difference can be compared to the expected median difference under the 
assumption of no population stratification.   If the median allele frequency difference is greater 
than that expected under the null hypothesis then an appropriate correction factor can be applied 
to test statistics observed while comparing these populations.  For studies that were performed 
using the Illumina assay we selected thirty-one SNPs for genomic control analysis.  We selected 
one SNP from each of the thirty-one genomic bins least likely to be associated with 
schizophrenia from the Lewis et al (Lewis et al., 2003) meta-analysis.  For each of these thirty-
one bins, we selected one Hapmap validated SNP located in a gene desert with minor allele 
frequency greater than 10%.  The genomic control SNPs are listed in Table 4.2. 
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 Table 4.2.  Genomic Control SNPs 
Bin from Lewis et al dbSNP rs# Chromosome Coordinate
120 rs1556691 1p 4403588 
119 rs1354616 7p 9444325 
118 rs4807030 19p 5340941 
117 rs1512779 3q 145949627
116 rs1443146 11p 25553259
115 rs9319189 13q 85516099
114 rs724291 7p 33572377
113 rs4298967 12p 2278455 
112 rs10737918 1p 14130441
111 rs9298401 8q 84367357
110 rs2418979 10q 109527084
109 rs1531931 11q 41781138
108 rs167053 13p 21802287
107 rs2169724 2q 194341332
106 rs876644 10p 34218433
105 rs12617498 2p 5961180 
104 rs12785159 10q 57584439
103 rs1949514 2p 22031319
102 rs1496180 8q 107043053
101 rs7317328 13q 68971186
100 rs676924 15p 27542278
99 rs1870480 3q 22619924
98 rs2639223 3q 81218291
97 rs7781020 7q 118725121
96 rs2827213 21q 22316388
95 rs924769 8q 134920425
94 rs10851555 15p 52194113
93 rs6464697 7q 144913906
92 rs1471392 19q 23068686
91 rs4900384 14q 97568704
90 rs9459053 6q 164663514
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We used the Armitage trend test to calculate test statistics for each of the thirty-one 
genomic control SNPs.  We compared the median test statistics from the genomic control SNPs 
to the expected median value and assessed the need to correct for population stratification as 
described in Devlin et al (Devlin et al., 1999).  Statistical tests of genomic control SNPs were 
performed by Joel Wood. 
 
4.4.5. Haplotype Analysis 
We estimated haplotype frequencies and tested for haplotype differences between cases and 
controls using ‘Cocaphase’ option of the ‘Unphased’ software (Dudbridge, 2003).  This program 
uses the expectation maximization (EM) algorithm to estimate haplotypes  (Excoffier et al., 
1995). Briefly, this algorithm uses expected haplotype frequencies as a starting parameter to 
estimate observed haplotypes.  Then it iteratively compares expected and observed haplotypes, 
updates the expected parameters based on the comparison, and recompares observed and 
expected haplotypes until they converge.  The software then uses likelihood ratios of log-linear 
models to compare case and control haplotype frequencies estimated using EM (Cordell et al., 
2002).  For calculation of global p-values during haplotype analysis, haplotypes with estimated 
frequency below one percent in cases or controls were excluded. 
For some genes, we also evaluated the possibility that subsets of SNPs may be associated 
with schizophrenia using stepwise logistic regression.  The regression procedure started with all 
the SNPs in each gene and eliminated the least significant predictor of schizophrenia status step-
wise until only SNPs or combinations of SNPs that predicted schizophrenia risk at a p <0.1 
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 remained.  Stepwise logistic regression analysis was performed by Joel Wood and Brian Shirts.  
We could then use the ‘Cocaphase’ to estimate haplotypes comprising subsets of these SNPs 
using EM and compare cases and controls using log-linear models as above. 
 
4.4.6. Analysis of Gene-Environment Interaction 
Several definitions of gene-environment interaction exist.  Both genetic and 
environmental factors may contribute to an outcome of interest, but this does not necessarily 
mean that the factors ‘interact.’  Interaction implies the effect of genetic and environmental 
factors considered together is different from the additive main effects of the two factors.  The 
most common interaction model is one where the effect of both factors combined is greater than 
the additive effects of gene and environment. 
 
4.4.6.1. Standard Methods of Gene-Environment Interaction 
The most uncomplicated method for evaluating gene-environment interaction is using a 
two-by-four table to analyze a case-control sample (Botto et al., 2001).  This allows for separate 
evaluation of genetic, environmental, and interaction factors using simple odds ratios and chi-
square tests (or exact tests if cell size is small).  The 2 x 4 table can be easily expanded to a 3 x 4 
table to allow for all allelic combinations at a SNP (Botto et al., 2001).   
When it is necessary to control for other continuous or dichotomous variables, such as 
gender and age, logistic regression-based modeling can be used, although this can make it more 
difficult to interpret the outcomes (Gauderman, 2002).  Given all the potential study design 
problems that may arise, including genotyping error and gene-environment correlation, the case-
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 control design is most often optimal design for studies of gene-environment interaction (Liu et 
al., 2004). 
4.4.6.2. Case-Only Analysis of Gene-Environment Interaction 
Case-only analysis has been presented as an alternative to case-control analysis of gene-
environment interaction (Khoury et al., 1996b).  The key assumption of this analysis is that 
genetic and environmental factors are independently distributed.  If this assumption is true then 
the presence of association between genetic and environmental factors in the case population is 
evidence for gene-environment interaction.  If genetic and environmental factors are not 
independent misinterpretation is possible, as there may be distortion of interaction factors or 
failure to detect interaction (Albert et al., 2001; Schmidt et al., 1999).  If the correlation between 
genetic and environmental factors is known from previous studies it is possible to adjust for this 
correlation (Gatto et al., 2004). 
4.4.6.3. Family-Based Analysis of Gene-Environment Interaction 
The growing popularity and availability of family-based genetic samples has led to the 
development of several family-based methods of evaluation of gene-environment interaction 
(Cordell et al., 2004; Umbach et al., 2000).  These methods generally use log-linear models to 
perform likelihood ratio tests of the no-interaction null hypothesis.  Like the case-only test of 
gene-environment interaction, a basic assumption of these tests is that genetic and environmental 
factors are independent; likewise, it is often necessary to assume that the environmental factors 
are not correlated between parents and controls (Chatterjee et al., 2005).  Where additional 
family members, affected siblings, and controls samples are all available it may be possible to 
increase the power to find interaction by using all available samples, but in addition to previous 
assumptions independence of environmental exposure between siblings is necessary (Andrieu et 
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 al., 2004; Goldstein et al., 2006).  Besides log-linear model based tests, a multiple dimensionality 
reduction method has recently been proposed for evaluation of gene-gene and gene-environment 
interaction; this method is utilizes the same assumptions of non-independence as the other 
methods (Martin et al., 2006). 
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5. GENETIC ASSOCIATION AND FUNCTIONAL STUDY OF TNF 
 
 
5.1. INTRODUCTION 
We designed our genetic association study of TNF to address three specific possible reasons for 
inconsistencies in previous studies (see section 3.3.1).  1) In order to examine the possibility of 
unidentified polymorphisms in TNF being over-represented in Caucasian schizophrenia cases we 
sequenced the entire TNF gene, including all introns and 4kb of 5’ and 3kb of 3’ UTRs in DNA 
pooled from 125 Caucasian schizophrenia cases and 200 controls.  2) We evaluated the 
possibility that exposure to the infectious agents CMV, HSV1, and HSV2 may cause increased 
risk in combination with TNF polymorphisms by measuring the antibody titers to these agents, 
genotyping selected SNPs, and stratifying our case sample by infectious disease exposure.   3) 
Lastly, we addressed the possibility of risk caused by one or more common haplotypes 
increasing TNF expression using a dual-luciferase reporter system to assay expression in 3.8kb 
of genetic context. 
 
5.2. SPECIFIC METHODS 
5.2.1. Clinical sample 
Cases (n = 244) from the Pittsburgh case sample were used for genetic and immunologic 
analysis.  This subset of the case sample was 65% male and the average age was 38.7 ± 9.7.  
Unscreened Pittsburgh controls (n = 276) were used for genetic analysis, but serum sample were 
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 unavailable for immunologic analysis of this sample.  This subset of the  control sample was 
50.8% male.  Additional details about the recruitment of these samples can be found in sections 
4.1.1 and 4.1.2. 
 
5.2.2. Pooled sequencing 
DNA from individuals was diluted to 4 ng/ul as recommended (Sham et al., 2002), and combined 
into pools of 125 cases and 200 controls. Portions of the region of interest were amplified using a 
standard PCR protocol.  Twenty-three overlapping amplicons were designed to cover 
approximately 10kb including the entire TNF gene, 4kb of 5’ UTR, and 3kb of 3’ UTR. PCR 
primers and conditions are available in Appendix B.  Amplified products were sequenced as 
described in section 4.2.3. 
 
5.2.3. Immunoassays for antibody titers of sera of subjects  
Serum samples were obtained from the peripheral venous blood of the 244 case subjects as 
described in section 4.3. 
 
5.2.4. DNA markers and genotyping  
We selected eight SNPs to genotype individually among cases and controls.  Five of these SNPs 
(rs1799964, rs1800630, rs1799724, rs1800629, rs361525) have been investigated in previous 
studies.  Three additional SNPs were chosen to enable analysis of additional haplotypes 
(rs2844482, rs3093543, rs1800610). Two pairs of these, rs1800610/rs1799724 and 
rs1800630/rs2844482) were in near complete LD in our sample, and thus provided an additional 
check of our genotype assay consistency.  There are only two tag SNPs indicated in phase 2 of 
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 the Hapmap project indicating the 6 independent SNPs cover TNF reasonably well (HapMap, 
2003).  We used Haploview software (Barrett et al., 2005) to evaluate LD and haplotype block 
structure in this region (Appendix A, Table A1 and Figure A1).  SNPs were analyzed using the 
multiplexed SNAPSHOT method as described in section 4.2.1. 
 
5.2.5. Generation of reporter constructs and transfection studies 
Transfection experiments were preformed by Dr. Mikhil Bamne, Ph.D. An extended 5’TNF-
alpha promoter region (-3858 to –1) was amplified using sequence specific tagged primers Kpn1 
(sense) and Nhe1 (antisense).  DNA fragments were taken from 5 different cases homozygous 
for 5 of the 6 commonly found haplotypes (see Table 5.7).  Amplified products were cloned into 
pGL3 basic promoter-less luciferase vector at Kpn1 and Nhe1 sites.  The integrity of each 
construct was checked by restriction enzyme digestion and sequencing.  We were unable to 
identify an individual homozygous for the remaining common haplotype so site-specific 
mutation of SNP -308GÆA was performed on the haplotype 4 clone, using QuickChange XL 
Site-Directed Mutagenesis Kit (Stratagene), according to manufacturer’s protocol.  Transfections 
into SHSY-5Y (ATCC-CRL-2266) cells were performed in 24-well plates (1X105 cells/well) 
using lipofectAMINE (Life Technologies, Inc.) according to manufacturer’s instructions. Cells 
were harvested after 36hrs, and luciferase assays performed using dual luciferase reagents 
(Promega).  Luciferase values were normalized for transfection efficiency using cotransfected 
promoterless pGL3 (Promega).  Each clone was tested in triplicate. 
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 5.2.6  Statistical analysis 
We used the Armitage trend test for analysis of case-control allele-wise and genotype-wise 
differences for individual SNPs (Devlin et al., 1999).  We separated cases groups defined by 
gender, HSV1, HSV2, and CMV seropositivity and compared subgroups of cases with the 
control sample using the Armitage trends test.  Using Quanto Software (Gauderman, 2002) 
known rs1800629 allele frequencies (minor allele frequency = 0.2) and schizophrenia population 
prevalence (0.008), we calculated our sample had >95% power to replicate the findings of Boin 
et al or Meira-Lima et al (relative risk > 2.0) using a log-additive or dominant model .  We used 
the ‘Cocaphase’ option of UNPHASED software (Dudbridge, 2003) to calculate case and control 
haplotype frequencies and compare case and control haplotype frequencies for statistical 
significance.  Significance of expression differences was calculated using the unpaired two-tailed 
students t-test.  Statistical methods are described in more detail in  section 4.4. 
 
5.3. RESULTS 
5.3.1 Pooled sequencing 
The primary purpose of our pooled sequencing was SNP discovery in a schizophrenia sample 
(Sham et al., 2002).  We identified 18 SNPs with minor allele frequencies > 5% in patients, all of 
which were listed in public databases.  Estimated allele frequencies for and dbSNP rs numbers 
for SNPs identified are listed in Appendix B, Table B2.  Case and control allele frequencies as 
estimated by pooled sequencing were correlated with allele frequencies reported in dbSNP (case 
r = 0.76, p = 0.2 x 10-4; control r = 0.83, p = 2 x 10-5) 
(National_Center_for_Biotechnology_Information, 2005). 
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 5.3.2 Genotype analysis of individual samples 
None of the 8 individual SNPs we analyzed were associated with schizophrenia (Table 5.1).  All 
of the 8 SNPs genotyped were in Hardy-Weinberg equilibrium in the case and control 
population.  Furthermore, individual SNPs were not associated with subgroups of schizophrenia 
patients defined by sex or CMV, HSV1, or HSV2 exposure as compared to controls (Table 5.2 – 
5.6). 
 
Table 5.1:  Association Analysis of SNPs in TNF and Its Promoter. 
 
   Case (n=244)
Control 
(n= 276) 
Genotype-
wise 
Minor allele 
frequency 
Allele-
wise 
ID#  Marker 1/1 1/2 2/2 1/1 1/2 2/2 p-value case control p-value
1  rs2844482 (C/T) 169 69 6 189 74 7 0.896 0.182 0.163 0.896 
2  rs3093543 (A/C) 205 38 1 228 44 1 0.892 0.097 0.084 0.894 
3  rs1799964 (C/T) 11 82 151 11 93 170 0.897 0.227 0.210 0.898 
4  rs1800630 (A/C) 6 67 171 8 84 174 0.268 0.176 0.188 0.274 
5  rs1799724 (A/G) 5 39 200 3 55 213 0.538 0.091 0.113 0.529 
6  rs1800629 (A/G) (-308) 7 64 173 8 73 195 0.952 0.142 0.161 0.951 
7  rs361525 (A/G) 1 22 221 3 24 249 0.721 0.051 0.054 0.708 
8  rs1800610 (C/T) 201 38 5 214 55 3 0.482 0.909 0.112 0.472 
 
1/1, 2/2, 1/2: Individuals homozygous for allele1, allele2 and heterozygous, respectively.  
Nucleotides were labeled 1 or 2 in alphabetical order, nucleotide identity is indicated in the 
second column. 
 
 
Table 5.2: Association Analysis of SNPs in TNF and Its Promoter Comparing HSV1 
Seropositive Schizophrenia Cases with Community Controls. 
 
    
  
HSV1+ Case
 (n = 88) 
  
  
Control 
(n =276) 
  
Minor allele 
frequency 
  
ID# Marker 11 12 22 11 12 22
 
Genotype-
wise 
p-value 
 case control 
Allele-wise
p-value 
 
1rs2844482 (C/T) 59 26 3 189 74 7 0.561 0.182 0.163 0.561 
2rs3093543 (A/C) 71 17 0 228 44 1 0.603 0.097 0.084 0.614 
3rs1799964 (C/T) 4 32 52 11 93 170 0.619 0.227 0.210 0.624 
4rs1800630 (A/C) 3 25 60 8 84 174 0.723 0.176 0.188 0.726 
5rs1799724 (A/G) 3 10 75 3 55 213 0.432 0.091 0.113 0.420 
6rs1800629(-G308A) (A/G) 1 23 64 8 73 195 0.542 0.142 0.161 0.542 
7rs361525 (A/G) 0 9 79 3 24 249 0.876 0.051 0.054 0.869 
8rs1800610 (C/T) 75 10 3 214 55 3 0.441 0.909 0.112 0.428 
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1/1, 2/2, 1/2: Individuals homozygous for allele1, allele2 and heterozygous, respectively.  
Nucleotides were labeled 1 or 2 in alphabetical order, nucleotide identity is indicated in the 
second column.  Serum was not available for controls, so HSV1 seropositive cases were 
compared to all controls. 
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 Table 5.3: Association Analysis of SNPs in TNF and Its Promoter Comparing HSV2 
Seropositive Schizophrenia Cases with Community Controls. 
 
    
  
HSV2+ Case
(n = 29) 
  
  
Control 
(n = 276) 
  
Minor allele 
frequency 
  
ID# Marker 11 12 22 11 12 22
Genotype-
wise 
p-value 
 case control 
Allele-wise
p-value 
 
1 rs2844482 (C/T) 24 5 0 189 74 7 0.124 0.182 0.163 0.125 
2 rs3093543 (A/C) 26 3 0 228 44 1 0.378 0.097 0.084 0.388 
3 rs1799964 (C/T) 0 10 19 11 93 170 0.494 0.227 0.210 0.503 
4 rs1800630 (A/C) 0 5 24 8 84 174 0.051 0.176 0.188 0.054 
5 rs1799724 (A/G) 1 5 23 3 55 213 0.853 0.091 0.113 0.852 
6 rs1800629(-G308A) (A/G) 1 5 23 8 73 195 0.428 0.142 0.161 0.420 
7 rs361525 (A/G) 0 5 24 3 24 249 0.349 0.051 0.054 0.321 
8 rs1800610 (C/T) 23 5 1 214 55 3 0.845 0.909 0.112 0.845 
 
1/1, 2/2, 1/2: Individuals homozygous for allele1, allele2 and heterozygous, respectively.  
Nucleotides were labeled 1 or 2 in alphabetical order, nucleotide identity is indicated in the 
second column.  Serum was not available for controls, so HSV2 seropositive cases were 
compared to all controls. 
 
 
Table 5.4: Association Analysis of SNPs in TNF and Its Promoter Comparing CMV 
Seropositive Schizophrenia Cases with Community Controls. 
 
    
  
CMV+ case
(n = 58) 
  
  
Control 
(n = 276) 
  
Minor allele 
frequency 
  
ID# Marker 11 12 22 11 12 22
Genotype-
wise 
p-value 
 case control 
Allele-wise
p-value 
 
1 rs2844482 (C/T) 43 15 0 189 74 7 0.360 0.182 0.163 0.366 
2 rs3093543 (A/C) 50 8 0 228 44 1 0.576 0.097 0.084 0.585 
3 rs1799964 (C/T) 2 21 35 11 93 170 0.890 0.227 0.210 0.892 
4 rs1800630 (A/C) 0 15 43 8 84 174 0.125 0.176 0.188 0.134 
5 rs1799724 (A/G) 1 8 49 3 55 213 0.408 0.091 0.113 0.407 
6 rs1800629(-G308A) (A/G) 0 17 41 8 73 195 0.693 0.142 0.161 0.694 
7 rs361525 (A/G) 1 8 49 3 24 249 0.220 0.051 0.054 0.189 
8 rs1800610 (C/T) 49 8 1 214 55 3 0.415 0.909 0.112 0.413 
 
1/1, 2/2, 1/2: Individuals homozygous for allele1, allele2 and heterozygous, respectively.  
Nucleotides were labeled 1 or 2 in alphabetical order, nucleotide identity is indicated in the 
second column.  Serum was not available for controls, so CMV seropositive cases were 
compared to all controls. 
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Table 5.5: Association Analysis of SNPs in TNF and Its Promoter Comparing Male 
Schizophrenia Cases with Male Community Controls. 
 
    
  
Male Case 
(n = 172) 
  
  
Male Control
(n = 127) 
  
Minor allele 
frequency 
  
ID# Marker 11 12 22 11 12 22
Genotype-
wise 
p-value 
 case control 
Allelewise
p-value 
 
1 rs2844482 (C/T) 117 51 4 85 39 4 0.697 0.172 0.184 0.701 
2 rs3093543 (A/C) 144 28 0 111 19 0 0.693 0.081 0.073 0.706 
3 rs1799964 (C/T) 7 59 106 7 43 77 0.720 0.212 0.224 0.721 
4 rs1800630 (A/C) 4 50 119 4 41 83 0.443 0.168 0.191 0.451 
5 rs1799724 (A/G) 3 31 138 1 23 102 0.745 0.108 0.099 0.741 
6 rs1800629(-G308A) (A/G) 4 48 120 2 37 88 0.963 0.163 0.161 0.964 
7 rs361525 (A/G) 1 12 159 2 10 115 0.447 0.041 0.055 0.409 
8 rs1800610 (C/T) 138 31 3 100 24 1 0.891 0.108 0.104 0.889 
 
1/1, 2/2, 1/2: Individuals homozygous for allele1, allele2 and heterozygous, respectively.  
Nucleotides were labeled 1 or 2 in alphabetical order, nucleotide identity is indicated in the 
second column. 
 
 
Table 5.6: Association Analysis of SNPs in TNF and Its Promoter Comparing Female 
Schizophrenia Cases with Male Community Controls. 
 
    
Female 
Case 
(n = 101) 
  
Female 
Control 
(n = 130) 
Minor allele 
frequency 
  
ID# Marker 11 12 22 11 12 22
Genotype-
wise 
p-value 
 case control 
Allelewise
p-value 
 
1 rs2844482 (C/T) 73 25 3 93 30 2 0.601 0.153 0.136 0.599 
2 rs3093543 (A/C) 88 12 1 106 19 1 0.585 0.069 0.083 0.578 
3 rs1799964 (C/T) 5 33 63 6 37 84 0.606 0.213 0.193 0.598 
4 rs1800630 (A/C) 3 24 74 4 35 85 0.484 0.149 0.173 0.477 
5 rs1799724 (A/G) 2 14 85 2 29 96 0.180 0.089 0.130 0.170 
6 rs1800629(-G308A) (A/G) 3 24 74 3 32 95 0.944 0.149 0.146 0.943 
7 rs361525 (A/G) 0 13 88 1 9 115 0.345 0.064 0.044 0.337 
8 rs1800610 (C/T) 86 13 2 94 30 3 0.067 0.084 0.142 0.057 
 
1/1, 2/2, 1/2: Individuals homozygous for allele1, allele2 and heterozygous, respectively.  
Nucleotides were labeled 1 or 2 in alphabetical order, nucleotide identity is indicated in the 
second column. 
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5.3.3. Haplotype analysis 
None of the common haplotypes were associated with schizophrenia (Table 5.7).  ‘Cocaphase’ 
predicted 28 total haplotypes, with 22 rare haplotypes estimated to be present in ≤ 1% of 
Caucasian schizophrenia cases.  Six haplotypes were present at frequencies > 1% in cases.  The 
global p-value for these six haplotypes was not significant (p = 0.414).  LD and haplotype block 
structure for our samples is shown in Appendix A1. 
 
5.3.4. Expression analysis of common promoter haplotypes 
We identified 6 common haplotypes (frequency > 1%) in our Caucasian case population (Table 
5.7).  The most common TNF promoter haplotype drove the highest levels of luciferase 
expression (Haplotype IV in Table 5.7).  Three haplotypes drove significantly lower levels of 
expression (p < 0.05) in comparison with the most common haplotype (Haplotypes III, V, and VI 
in Table 5.7).  These included the only haplotype that had the -308A allele at SNP rs1800629 
(Haplotype III), which showed the lowest expression of any common haplotype. 
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Table 5.7:  Association and Expression Analysis of Common TNF Promoter Haplotypes. 
 
  Haplotype Case Control frequency p-value Expression % maximal
ID#  1-2-3-4-5-6-7-8 frequency frequency difference  level Expression
I  C-A-C-C-G-G-A-C 0.047 0.047 -0.001 0.97 5.7+/-1.4 95 
II  C-A-T-C-A-G-G-T 0.107 0.134 -0.027 0.20 5.4+/-0.4 90 
III  C-A-T-C-G-A-G-C 0.156 0.161 -0.005 0.83 4.1 +/-0.4 68* 
IV  C-A-T-C-G-G-G-C 0.533 0.503 0.031 0.35 6.0+/-0.2 100 
V  T-A-C-A-G-G-G-C 0.080 0.093 -0.013 0.50 4.7+/-0.6 78* 
VI  T-C-C-A-G-G-G-C 0.077 0.051 0.026 0.12 4.5+/-0.2 75* 
SNPs nomenclature (#1 – 8) reflects that used in Table 5.1.  Expression level is relative to the 
promoterless pGL3 vector.  Percent maximal expression was calculated relative to the most 
common and most efficient promoter haplotype. 
* Significantly lower expression than most common haplotype (IV) (p < 0.05). 
 
 
5.4. DISCUSSION 
We evaluated five previously investigated SNPs in the TNF gene in an adequately powered 
sample and found no significant association with schizophrenia.  Several explanations have been 
proposed to explain inconsistencies in previous association studies of TNF and schizophrenia.  
Some groups have suggested that observed associations may be due to rare variants within the 
TNF gene that are novel in schizophrenia (Schwab et al., 2003a) (Handoko et al., 2003) (Tsai et 
al., 2003).  We found no novel polymorphisms that were present in the schizophrenia population 
at a frequency greater than 5%.   Thus, it seems unlikely that the prior associations reflect 
hitherto undetected SNPs. 
Boin et al (2001) postulated that elevated TNF expression might only contribute to risk in 
the presence of an infectious exposure at a critical stage of neural development; this would cause 
more significant associations when exposure to infectious agents is taken into account.  We 
quantified antibody titers for four agents that cause latent neural infections and which have been 
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 implicated in schizophrenia.  Our assays were not designed to address the precise timing of 
infection, however, as markers of exposure and latent infection they would increase the power to 
detect associations if the infectious agents acted in conjunction with TNF polymorphisms to 
increase schizophrenia risk.  We find no significant associations with schizophrenia in any of the 
four subgroups of schizophrenia patients defined by infectious disease exposure. 
We have evaluated differential expression at the haplotype level by performing a 
functional evaluation of all common TNF promoter haplotypes in our sample of Caucasian cases. 
In SHSY-5Y neuroblastoma cells, presence of the A allele at the -308GÆA polymorphism in a 
haplotype is associated with reduced expression.  This contrasts a previous report by Wilson et al 
(1997), who found the –308A allele caused increased expression in a lymphocyte derived B-cell 
line.  These differences are important, as the increased expression due to the –308A allele was 
invoked as added evidence for a pathogenic role for this variant.  Wilson et al (1997) evaluated 
TNF promoter activity using a construct that contained a 691 bp sequence in a human Raji B-cell 
line.  We used a 3.8kb sequence to evaluate promoter activity in a neuroblastoma cell line.  One 
explanation for observed differences between our results may be translation repressor sequences 
that are contained in the additional 3kb of sequence we included in our assays.  Others have 
found TNF expression to be cell type specific (Barthel et al., 2003).  Varying transcriptional 
activator profiles in B-cell and neuroblastoma cell lines may explain the difference in TNF 
expression.  It is not clear which in vitro findings are most applicable to in vivo TNF expression 
in schizophrenia.
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6. LOCALIZATION OF CHROMOSOME 6P ASSOCIATIONS AND MICB 
 
6.1.  INTRODUCTION 
Association and linkage with polymorphisms in the MHC region have been reported (Lewis et 
al., 2003; Wright et al., 2001).  We previously found the marker D6S2672 to be associated with 
schizophrenia in CMV seropositive individuals and other nearby markers may be associated with 
schizophrenia HSV1 seropositive individuals (Kim et al., 2004a).  Here we present a staged 
study using individuals of Caucasian ancestry designed to localize this association further, to 
evaluate possible main genetic effects on schizophrenia and viral infection separately, and to 
investigate possible interactions of the two in schizophrenia risk.  Initially, we selected 
representative or “tag” SNPs spanning a 100kb region flanking D6S2672.  We genotyped these 
polymorphisms in a preliminary sample of schizophrenia cases and unscreened controls.  We 
then selected five SNPs to investigate further.  We assayed these SNPs in two additional 
Caucasian case-control and case-parent trio samples for which serological data on CMV and 
HSV1 infection were available.  The case-control sample was used to confirm previous 
associations, evaluate genetic associations with viral antibody titers, and investigate the 
possibility of gene-virus interaction in schizophrenia.  We used a family based sample as an 
additional replicate to evaluate genetic associations while controlling for population 
stratification.  If genetic polymorphisms and environmental exposures are independent, such a 
sample enables further evaluation of interactions.  Simultaneously investigating two independent 
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 samples not only provided replication, but also allowed us to utilize the strengths of both case-
control and family based study designs.   
 
6.2.  METHODS 
6.2.1. Clinical Samples 
6.2.1.1. Pittsburgh cases and community controls. 
Unrelated patients (n=236) were recruited as described in  section 4.4.1.  This patient 
sample had an average age of 38.7 (SD 9.8), and was 64% male.  DNA from neonatal cord blood 
(n=240) was used as a control sample as described in section 4.4.2; the sample was 52% male. 
6.2.1.2 Baltimore schizophrenia, cases bipolar cases, and controls  
Schizophrenia cases n=272, Bipolar cases n=119, and controls n=108 recruited in 
Baltimore were used as a replicate case-control sample. These samples are described in section 
4.1.3.  
6.2.1.3 Pittsburgh cases-parent trios 
A sample of 221 unrelated patients diagnosed with schizophrenia and their 442 parents 
was used for a family based replicate sample.  The average age of schizophrenia cases in this 
sample was 36.1 (SD 9.3), and the cases were 67% male.  Serologic information was available 
for 195 of these cases, and 338 parents.  Forty-nine unselected patients included in the trio 
sample had also been included in the preliminary Pittsburgh case-control sample.  This sample is 
described in more detail in section 4.1.1. 
6.2.1.4 MHIRC sample 
The MHIRC sample described in section 4.1.4. was used to test the generalizability of 
associations with antibody titer status and diagnostic specificity of schizophrenia associations. 
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6.2.2. Immunoassays 
Immunoassays were performed on serum samples as described in section 4.3. 
 
6.2.3. Selection of SNPs and genotyping 
We used information from dbSNP (National_Center_for_Biotechnology_Information, 2005), 
phase 1 of the Hapmap project (HapMap, 2003), and our own in-house sequencing using pooled 
DNA samples (Chowdari 2006 in press) to select SNPs covering a 100kb region centered on 
D6S2672.  This region spans chromosome 6p position 31534000-31634000 (NCBI genome build 
36.1), and includes 6 known transcripts: HLA complex P5 (HCP5), MHC class I polypeptide-
related sequence B (MICB), mitochondrial coiled-coil domain 1 (MCCD1), HLA-B associated 
transcript 1 (BAT), ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G2 (ATP6V1), and 
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 1 
(NFKBIL1)(see Appendix A, Figure A2 for line diagram of region).  In order to estimate how 
well public databases represented the region and identify SNPs with possible association we 
sequenced over 20kb (20%) of the region in pools of DNA from 125 cases and 200 controls as 
described in Chowdari et al (2006 in press).  From our sequencing we selected 10 SNPs that 
showed preliminary evidence for case-control differences (p < 0.05).  We genotyped these SNPs 
in the Hapmap CEPH trios (Coriell, New Jersey, USA) to determine linkage disequilibrium 
(LD), the population-level correlation of alleles at nearby loci, between SNPs selected by 
exploratory analysis and Hapmap phase 1 SNPs.  We then used Hclust software (Rinaldo et al., 
2005) to select 26 common SNPs (minor allele frequency > 0.1) that tagged Hapmap phase 1 
SNPs in this region at a correlation (r2) of 0.8.  This set of SNPs represent over half of Hapmap 
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 phase 2 SNPs in this 100kb region at an r2 above 0.8 and over 70% of these SNPs at an r2 above 
0.7.  SNPs were assayed using the multiplexed SNAPSHOT method as described in section 
4.2.1. 
 
6.2.4. Statistical Analyses 
We used the chi-square based Armitage trend test (Devlin et al., 1999) or Fisher’s exact test to 
evaluate allele and genotype frequency differences between schizophrenia case and controls and 
between seropositive and seronegative individuals.  In the trio sample we evaluated the 
overtransmission of alleles from parents to children using the TDT test with Genehunter software 
(Kruglyak et al., 1996).  In addition we used the SAS software ‘proc catmod’ to evaluate 
differences in CMV and HSV1 seropositivity while correcting for age and gender.  We used SAS 
‘proc catmod’ to test models of gene-environment interaction.  Due to the number of tests 
necessary to investigate genetic effects on schizophrenia, CMV, and HSV1 antibody titer status 
as well as gene-virus interactions at five loci we chose not to correct for multiple comparisons.  
Instead, we chose to evaluate independent samples and interpret the significance of our findings 
in light of consistency between these samples.  Statistical methods are described in more detail in 
section 4.4. 
 
6.3. RESULTS 
Several separate samples were evaluated: a Pittsburgh case-control sample; Baltimore 
schizophrenia case, bipolar case, and control samples; a Pittsburgh case-parent trio sample; and 
the MHIRC sample.  Results from the Pittsburgh case-control sample was analyzed first, as it 
was used to identify the SNPs analyzed in the other samples.  Subsequently, Baltimore 
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 schizophrenia case-control and Pittsburgh trio samples were analyzed side-by-side to evaluate 
associations of antibody titer status with schizophrenia, genetic associations with antibody titer 
status, genetic associations with schizophrenia, and interaction between genes and antibody titer 
status in schizophrenia.  Finally, Baltimore Bipolar case-control and MHIRC were analyzed to 
evaluate the generalizability of associations with antibody titer status and the specificity of 
associations with schizophrenia. 
 
6.3.1. Genetic Associations with Schizophrenia in Pittsburgh Case-Control Sample 
In the initial sample (Pittsburgh case-control sample, n = 236 cases, 240 controls) we genotyped 
twenty-six SNPs and evaluated evidence for association with schizophrenia.  Five SNPs 
(rs2523666, rs2523650, rs2516500, rs2855812, and rs2844494) had a failure rate over 5% or 
were not in Hardy-Weinberg equilibrium (p<0.01, see Appendix A, Figure A2 and Table A2 for 
location and LD estimates).  These SNPs were not included in the association analysis.  Four of 
21 SNPs analyzed were nominally associated with schizophrenia (rs2596453, p =0.026; 
rs2596536, p = 0.025; rs2523651, p = 0.022, rs2904776, p = 0.021, Table 6.1).  Each localized to 
a 15kb region between the genes MICB and HCP5 (Appendix A, Figure A2).  Several of the 
SNPs were in tight LD and showed similar associations (see rs2523651, rs2904776, and 
rs2395038 on Table 6.1 and Appendix A, Table A2, for example). 
The following SNPs were associated with schizophrenia and were selected for further 
analysis: rs2596453, rs2596536, and rs2523651.  SNPs rs2904776 and rs2395038 were not 
included because they were in LD with rs2523651, which could be reliably multiplexed for 
genotype assays with the other SNPs.  In addition, we added SNP rs1051788, which causes a 
non-synonymous change in MICB and is in substantial LD with rs2596536 (r2 = 0.67) and 
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 rs1055569, which showed a trend towards association and was easily assayed with the other 
SNPs.  We evaluated these five SNPs for associations with schizophrenia, HSV1, CMV, and 
gene-environment interaction in two other samples (Baltimore case-control sample n= 272 cases, 
108 controls and Pittsburgh trio sample, n=221 cases, 442 parents).  
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 Table 6.1.  Association Analysis of Chromosome 6p SNPs in Pittsburgh Case-Control 
Sample. 
Code Case  (n = 236) 
Control  
(n = 240) case controlMarker 
1 
Position 
11 12 22 11 12 22
Success 
Rate p-value 
Allele-
wise 
p-value freq_1
rs2523685 C G 31534235 138 74 19 84 22 0.966 0.224 0.201 0.758 0.721
C T 31539799 155 60 18 163 60 0.985 0.396 0.357 0.794 0.818
rs2523674 A 31544768 36 96 103 27 108 90 0.966 0.936 0.357 0.360
rs2596453 A G 31544881 91 22 148 72 16 0.992 0.026 0.020 
 
Genotype-
wise 
2 freq_1
123
rs2243621 13
G 0.937 
123 0.714 0.780
rs2244839 C T 31546347 127 94 14 109 18 0.996 0.123 0.134 0.740 0.697
rs14597 G T 31547993 84 111 36 130 34 0.989 0.597 0.608 0.604 0.588
rs1055569 C T 31548061 113 100 21
112
76
98 109 28 0.985 0.118 0.120 0.697 0.649
rs2248372 A G 31554445 97 105 24 112 99 0.987 0.838 0.837 0.340
rs2248462 C T 31554775 146 84 152 80 5 0.994 0.582 0.601 0.797 0.810
rs2596536 C T 31555827 106 110 18 85 29 0.977 0.025 0.032 0.688 0.621
rs2523651 G 31556133 43 114 79 28 105 97 0.022 0.021 0.424 0.350
rs2904776 C G 43 112 81 27 111 100 0.996 0.021 0.419 0.347
rs3094009 C T 31565157 144 4 139 90 6 0.985 0.513 0.543 0.799
33 0.347
6 
117
A 0.979 
31557060 0.021 
86 0.783
rs2395038 A C 31568430 39 113 78 29 107 97 0.973 0.055 0.056 0.415 0.354
rs2242955 A G 31582259 2 57 177 5 53 180 0.996 0.886 0.887 0.129
rs3131635 A G 31584113 18 81 134 13 89 137 0.992 0.712 0.708 0.251 0.241
rs3130637 C T 31596124 135 80 18 139 73 20 0.977 0.856 0.849 0.751 0.756
rs3130055 A G 31605378 135 87 10 149 75 15 0.989 0.690 0.688 0.769 0.780
rs2071594 C G 31620699 25 114 97 29 103 104 0.992 0.836 0.837 0.347 0.341
rs2255798 C G 31629281 1 62 169 2 57 170 0.968 0.824 0.833 0.138 0.133
rs3130062 C T 31633891 1 36 196 2 23 214 0.992 0.133 0.128 0.082 0.056
0.132
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6.3.2.  Associations of Antibody Titer Status with Schizophrenia in Baltimore Case-Control 
and Pittsburgh Trio Samples 
Based on established cutoff values the samples were classified as “seropositive” or 
“seronegative” with respect to HSV1 and CMV antibodies.  Detailed serologic analyses of the 
Baltimore schizophrenia and bipolar case-control sample have been published (Dickerson et al., 
2004), Torrey et al 2006(submitted)).  In brief, there was no significant difference between either 
schizophrenia or bipolar cases and controls from Baltimore in regard to HSV1 status, but there 
was a significant association with cognitive deficits in HSV1 seropositive individuals (Dickerson 
et al., 2004).  CMV seropositivity was significantly associated with schizophrenia and 
specifically deficit schizophrenia (Torrey et al 2006(submitted)(Dickerson et al., 2006). 
Among cases from Pittsburgh and their parents, 34.9 % and 61.8% were HSV1 
seropositive respectively and 22.2 % and 43.1% were CMV seropositive respectively (see Tables 
6.2 and 6.3).  These rates are similar to other studies, with the prevalence of HSV1 and CMV 
infection correlated with age (Marshall et al., 2005; Yolken, 2004).  Associations of antibody 
status with schizophrenia were not investigated in the Pittsburgh trio sample because suitable 
control samples were not available.  
 
6.3.3.  Associations of SNPs with CMV and HSV1 Antibody Titer Status 
In the Baltimore control sample the rs1051788 ‘G’ allele was associated with HSV1 
seropositivity even after adjusting for age and gender (p = 0.006, OR=2.7, 95% CI = 0.7-4.7, see 
Table 6.2).  The rs2523651 ‘A’ allele was significantly associated with CMV antibody 
seropositivity after adjusting for age and gender (p=0.001, OR = 3.6, 95% CI 1.5-5.8, Table 6.3).  
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 Neither of the SNPs was significantly associated with infection in the Baltimore schizophrenia 
case sample or bipolar case sample (Tables 6.2 and 6.3). 
In parents of Pittsburgh trios the same allele of SNP rs1051788 was also associated with 
HSV1 antibody titer after adjusting for age and gender (p = 0.024, OR = 1.6, 95% CI 0.1-3.1 
Table 6.2.  No SNPs were associated with HSV1 antibody titer status in the Pittsburgh case 
sample. In the Pittsburgh trio sample SNP rs2523651 was not significantly associated with CMV 
antibody titer status in either parents or cases (Table 6.3). 
 
Table 6.2: Association of rs1051788 with HSV1. 
 
 HSV1+  HSV1- HSV1+ HSV1- ORa rs1051788 
AA AG GG AA AG GG freq A Freq G freq A freq G G vs A 
95% CIa pvala 
Baltimore control 2 13 34 6 27 26 0.173 0.827 0.331 0.669 2.7 [1.3,5.5] 0.006
Baltimore case 10 41 43 13 65 61 0.324 0.676 0.327 0.673 1.0 [0.7,1.5] 0.991
Pitt trio case 7 28 45 14 42 59 0.263 0.738 0.304 0.696 1.0 [0.6,1.6] 0.981
Pitt parent 11 76 120 11 57 60 0.237 0.763 0.309 0.691 1.6 [1.1,2.4] 0.024
Baltimore Bipolar 3 23 21 7 28 35 0.309 0.691 0.300 0.700 0.9 [1.3,5.5] 0.817
MHIRC Caucasian 18 72 75 22 107 104 0.327 0.673 0.324 0.676 1.3 [0.7,1.5] 0.201
 
a- Odds ratios, 95% confidence intervals, and p-values calculated using SAS proc genmod to 
correct for age and gender. 
 
 
 
Table 6.3: Association of rs2523651 with CMV 
 
CMV+ CMV- CMV+ CMV- ORa rs2523651 
AA AG GG AA AG GG freq A freq G freq A freq G A vs G 
95% CIa pvala
Baltimore control 5 13 1 11 29 49 0.605 0.395 0.287 0.713 3.6 [1.7,7.8] 0.001
Baltimore case 14 37 39 26 82 68 0.361 0.639 0.381 0.619 0.9 [0.6,1.4] 0.791
Pitt trio case 7 15 17 24 55 58 0.372 0.628 0.376 0.624 1.1 [0.6,2.0] 0.798
Pitt Parent 21 52 56 50 137 126 0.418 0.582 0.378 0.622 1.2 [0.8,1.7] 0.425
Baltimore Bipolar 2 21 9 14 66 35 0.391 0.609 0.409 0.591 1.1 [1.7,7.8] 0.766
MHIRC Caucasian 16 72 55 29 123 103 0.364 0.636 0.355 0.645 1.1 [0.6,1.4] 0.703
 
a- Odds ratios, 95% confidence intervals, and p-values calculated using SAS proc genmod to 
correct for age and gender. 
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Neither rs1051788 nor rs2523651 was associated with HSV2 status in Baltimore 
schizophrenia case or control samples, but the number of HSV2 seropositive control individuals 
was small (Table 6.4).  SNPs rs2596453, rs1055569 and rs2596536 were not significantly 
associated with HSV1 or CMV antibody titer status in any of the Pittsburgh or Baltimore 
samples.  None of the five SNPs evaluated was significantly associated with HSV1 or CMV in 
Caucasians from the Baltimore bipolar case or Caucasian MHIRC samples (data not shown). 
 
Table 6.4.  Evaluation of rs2523651 and rs1051788 and HSV2 Status in Baltimore Controls 
and Schizophrenia Cases. 
 
HSV2 Baltimore Control HSV2+ (N=15) HSV2 - (N=86)     
Marker allele 1 frequency Allele 1 frequency Χ2 p-value 
rs2523651 a 0.46667 0.31977 2.14706 0.14284 
rs1051788 a 0.16667 0.27326 1.42196 0.23308 
     
HSV2 Baltimore Case HSV2+ (N=51) HSV2 - (N=210)     
Marker allele 1 frequency Allele 1 frequency Χ2 p-value 
rs2523651 a 0.37255 0.37799 0.01 0.92035 
rs1051788 a 0.26471 0.33333 1.86568 0.17197 
 
a- At rs2523651 and rs1051788 allele 1 = A and allele 2 = G.   
 
 
6.3.4. Genetic Associations with Schizophrenia in Baltimore Case-Control and Pittsburgh 
Trio Samples 
In the Baltimore schizophrenia case-control sample, none of the SNPs was associated with 
schizophrenia.  Likewise, when comparing Baltimore bipolar cases with controls, none of the 
SNPs showed significant associations.  The rs1051788 ‘A’ allele frequency was elevated in 
schizophrenia cases compared to controls, consistent with the Pittsburgh trio sample (see 
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 following paragraph), but the difference was not quite significant (p = 0.101, OR = 1.357, CI 
0.943-1.955, Table 6.5).  
In the Pittsburgh trio sample there were overtransmissions of the rs1051788 ‘A’ allele 
(Transmitted (T)= 107, not transmitted (NT) = 74, p = 0.014) and the rs1055569 ‘C’ allele (T = 
90, NT = 64, p = 0.036) in the entire trio sample (Table 6.5).  The association at 1055569 was 
consistent with the association at this SNP in the Pittsburgh case-control sample.  No other allele 
was significantly overtransmitted to schizophrenia cases. 
 
Table 6.5: Associations with Schizophrenia in Pittsburgh Trio Sample and Baltimore Case-
Control Sample. 
 
Pittsburgh Trios (n = 221 trios) Transmitted Allele   
Marker 1 2 Χ2 p-value 
rs2596453 69 68 0.01 0.932 
rs1055569 90 64 4.39 0.036 
rs2596536 92 107 1.13 0.287 
rs2523651 116 103 0.77 0.380 
rs1051788 a 107 74 6.02 0.014 
     
Baltimore case-control Allele Count   
(n = 272 cases, 108 controls) case Control   
Marker 
allele 1 
frequency 
allele 1 
frequency Χ2 p-value 
rs2596453 0.718 0.728 0.063 0.802 
rs1055569 0.638 0.673 0.809 0.367 
rs2596536 0.653 0.693 1.045 0.307 
rs2523651 0.377 0.342 0.782 0.377 
rs1051788 a 0.320 0.257 2.696 0.101 
 
a- At rs1051788 allele 1 = A and allele 2 = G.  The coding system for all other SNPs is given in 
Table 6.1. 
 
 
6.3.5.  Interaction Between Antibody Titer Status and Genotype in Schizophrenia Risk in 
Baltimore Case-Control and Pittsburgh Trio Samples 
We used logistic regression analyses to assess possible interactions of rs1051788 with HSV1 and 
rs2523651 with CMV in schizophrenia pathogenesis in the Baltimore case-control sample while 
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 adjusting for gender, age, and main effects.  When modeling main effects and interaction neither 
HSV1, rs1051788, nor the interaction of HSV1 and rs1051788 was a significant predictor of 
schizophrenia, but there was suggestive evidence for separate interaction (p=0.06) and genetic 
main effects (p = 0.08, Table 6.6 Model B).  Using a similar model for CMV, rs2523651, and 
CMV-rs2523651 interaction, the interaction was the only significant factor (p = 0.003, Table 6.6 
Model D).  Age and gender were significantly associated with case status, but controlling for age 
and gender made little impact in estimates of main effects or interaction effects for either model 
(Compare Table 6.6 Models A and C with Table 6.6 Model B and C). 
 
 
Table 6.6:  Interaction Analysis: Maximum Likelihood Estimates Using SAS "proc 
catmod" for Models of Associations. 
 
Model A: Diagnosis = HSV1 + rs1051788 + 
rs1051788*HSV1 
Model B: Diagnosis = HSV1 + rs1051788 + 
rs1051788*HSV1 + age + gender 
Parameter Estimate 
Std 
Error 
Chi- 
Square p-value Parameter Estimate
Std 
Error 
Chi- 
Square p-value
Intercept -1.45 0.32 21.21 <.0001 Intercept 0.91 0.56 2.67 0.10 
Hsv1 0.51 0.32 2.57 0.11 hsv1 0.48 0.35 1.91 0.17 
r1051788 0.37 0.20 3.65 0.06 r1051788 0.38 0.22 2.99 0.08 
r1051788*hsv1 -0.42 0.20 4.62 0.03 r1051788*hsv1 -0.41 0.22 3.45 0.06 
age -0.06 0.01 26.44 <.0001
gender -0.90 0.14 40.80 <.0001
  
Model C: Diagnosis = CMV + rs2523651 + 
rs2523651*CMV 
Model D: Diagnosis = CMV + rs2523651 + 
rs2523651*CMV + age + gender 
Parameter Estimate 
Std 
Error 
Chi- 
Square p-value Parameter Estimate
Std 
Error 
Chi- 
Square p-value
Intercept -0.87 0.26 11.40 0.0007 Intercept 1.47 0.53 7.61 0.006
Cmv -0.34 0.26 1.71 0.19 cmv -0.28 0.30 0.85 0.36 
r2523651 -0.29 0.21 1.92 0.17 r2523651 -0.32 0.25 1.65 0.20 
r2523651*cmv 0.69 0.21 10.65 0.001 r2523651*cmv 0.75 0.25 8.84 0.003
age -0.06 0.01 24.96 <.0001
  gender -0.94 0.15 41.52 <.0001
 
Formal evaluation of interaction in the case-parent trio are complicated by the constraints 
of family based tests of gene-environment interaction (Chatterjee et al., 2005); however, the 
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 association of rs1051788 in parents, but not in cases, is consistent with an interaction (See Table 
6.2).  Antibody titers were unavailable for the Pittsburgh controls. 
 
6.4.  DISCUSSION AND CONCLUSIONS 
Although our staged design targeted localization of associations with schizophrenia on 
chromosome 6p in CMV and HSV1 exposed patients, we were also able to query the genetic 
basis of risk for HSV1 and CMV seroposivity.  We identified separate polymorphisms in and 
near the MICB gene that appear to modulate risk for HSV1 and CMV seropositivity.  
Interestingly, these polymorphisms could also contribute to schizophrenia risk. 
The evidence for association with HSV1 is strongest in MICB at the non-synonymous 
polymorphism, rs1051788, as this association is seen in more than one non-schizophrenia sample 
(see Table 6.2).  This association was not seen in either schizophrenia case sample, MHIRC 
sample, or the bipolar case sample.  This could be interpreted as sample heterogeneity, or it 
could suggest that this SNP is involved in both schizophrenia and bipolar disorder.  This 
possibility is discussed below.  Though the MHIRC sample is diagnostically variable, after 
adjusting for age and gender there is a trend similar to that seen in controls and parents although 
it is not significant, possibly because of a large number of bipolar cases in the sample. The ‘G’ to 
‘A’ change in rs1051788 causes an aspartic acid to asparagine change in the MICB protein on 
one of the alpha-helical folds presented to the NKG2D receptor on NK cells or gamma/delta T 
cells, so this polymorphism seems likely to have functional effects. 
We also find some evidence for association of rs2523651 with CMV seropositivity.  This 
association is very significant in one control sample, but the sample is small (only 19 CMV 
seropositive individuals), and the other samples are not as consistent (see Table 6.3).  There are 
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 no known functional changes caused by rs2523651, and there is extensive linkage disequilibrium 
in this region, so rs2523651 may be a genetic marker for a nearby functional polymorphism. 
One of the difficulties in interpreting these studies is the inconsistency between samples.  
Some inconsistencies could be due to stochastic variation and differences in power across 
samples.  It is likely that the true relative risk is smaller than the risk estimated by the most 
significant sample, so it would not be unusual for other small samples to fail to detect significant 
associations.  Another possibility is that associations of these SNPs with schizophrenia are 
obscuring associations with HSV1 and CMV in schizophrenia samples. 
Intriguingly, the two SNPs that show associations with HSV1 and CMV are also the 
SNPs most consistently associated with schizophrenia.  The ‘A’ allele of SNP rs1051788 is 
associated with schizophrenia in the Pittsburgh Trio sample and shows a similar trend in the 
Baltimore case-control sample that is consistent with the association in the trio sample (see Table 
6.5).  The association of rs2523651 is only significant in the initial Pittsburgh case-control 
sample (see Table 6.1, but both additional samples do show a similar trend consistent with a 
small effect (OR~1.2, see Table 6.5).  The association of these SNPs with both viral infection 
and schizophrenia could indicate pleiotropic effects (unrelated phenotypes produced by a single 
gene) or an interaction between viruses and MICB in schizophrenia. 
Interactions between genetic polymorphisms and viral infection in schizophrenia 
pathogenesis have long been hypothesized (Kirch, 1993), and could account for variability in 
previous studies of HSV1 and CMV in schizophrenia (Pearce, 2003; Rapoport et al., 2005).  We 
formally evaluated the possibility of interaction for rs1051788 with HSV1 and rs2523651 with 
CMV.  We found significant evidence for interaction of rs2523651 and CMV in schizophrenia in 
the Baltimore case-control sample, but as noted above, these associations are based on one 
 75
 relatively small case-control sample and are not consistent with the trio sample.  We also found 
suggestive evidence for interaction of HSV1 with rs1051788 in schizophrenia pathogenesis in 
the Baltimore case-control sample.  Though not statistically significant, evidence for this 
interaction is more consistent with the Pittsburgh trio sample.  One interpretation of the statistical 
interaction between HSV1, rs1051788, and schizophrenia is that the genetic variant has an 
impact on risk for HSV1 and schizophrenia; however, other models are also consistent with these 
data, and only future studies will be able to draw compelling conclusions. 
Further studies of associated polymorphisms are necessary to confirm functional effects 
of genetic variants.  While these functional studies are forthcoming, hypotheses of likely 
outcomes can be built from previous studies of MICB and the related protein MICA.  MICA and 
MICB are highly polymorphic MHC-class-1-related proteins (Elsner et al., 2001).  Both MIC 
proteins interact with and activate NKG2D receptor on NK cells and gamma/delta T cells (Groh 
et al., 2001).  Although constitutively expressed only in the gut, MICB expression can be 
induced in many other cell types including CD4+ and CD8+ T cells and glial cells in the brain 
(Azimi et al., 2006; Friese et al., 2003).  MICA and MICB are thought to be involved in the 
activation of the innate immune system to control viral infection and recognize tumor cells 
(Collins, 2004; Groh et al., 2001).  A common polymorphism in MICA has been shown to 
modify NK cell mediated apoptosis in CMV infected cells (Zou et al., 2005), and MICB 
translocation to the cell surface is inhibited by CMV infection (Dunn et al., 2003).  MICB alleles 
associated with lower antibody titers could cause more efficient activation of NK cells in 
response to HSV1 resulting in fewer latently infected cells or less frequent viral reactivation.  
This in turn would allow viral antibody titers to decrease below the seropositivity-threshold over 
time.  Given that cytokines released by NK cells have known effects in neurodevelopment and 
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 neuromodulation (Alsharifi et al., 2006; Ashdown et al., 2006; Stellwagen et al., 2006; Stoll et 
al., 2002), it is conceivable that MICB activation of the innate immune system could also impair 
neurodevelopment through neuromodulatory cytokine release. 
The association of MICB polymorphisms with HSV1 and possibly CMV seropositivity 
reported here suggest the need for functional studies to explore the exact mechanism of MICB 
action in HSV1 infection.  Additional genetic associations studies will be necessary to confirm 
intriguing findings of associations of MICB with viral immune response, and to evaluate the 
possible interaction of herpes viruses and MICB in schizophrenia pathogenesis. 
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7. ASSOCIATION STUDY OF IL10, IL1Β, AND IL1RN. 
 
7.1.  INTRODUCTION 
In our investigation of the genes IL1β, IL1RN, and IL10 we have attempted to address some of 
the concerns about discrepancies in previous association studies that were discussed in section 
3.3.2.  We used a publicly accessible database of sequenced genes to evaluate LD between 
common polymorphisms of IL1β, IL1RN, and IL10 among individuals reporting Caucasian 
ancestry.  We then genotyped representative ‘tag SNPs’ in a moderately sized sample.  In 
addition, we typed genomic control SNPs in both case and control samples to evaluate and 
control for population stratification.  We also examined associations in subgroups of our 
population defined by gender, diagnosis (schizophrenia / schizoaffective disorder), and infectious 
disease exposure as these variables might impact on the associations.  Finally, we conducted a 
meta-analysis of rs16944, which is localized to IL1β, because findings at this SNP appeared 
remarkably consistent between studies. 
 
7.2. MATERIALS AND METHODS 
7.2.1. Sample 
Unrelated patients from the Pittsburgh case sample were used for this study (n = 478).  This case 
sample was 64.9% male, with a mean age of 38.2 years (standard deviation 9.6). Antibody titers 
for cytomegalovirus, herpes simplex virus 1 and 2, and Toxoplasma gondii were available for 
352 cases.  Unscreened Pittsburgh controls (n = 501) were used as a comparison group.  This 
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 control sample was 51.9% male.  Additional details about the recruitment of these samples can 
be found in sections 4.1.1 and 4.4.2. 
 
7.2.2. SNP Selection 
The Seattle SNPs Program for Genetic Applications (Nickerson et al., 2005) has made 
information available from completely sequenced IL10, IL1β, and IL1RN genes in a set of 23 
individuals of European descent.   LD estimates based on D’ and r2 are available for these SNPs 
(Devlin et al., 1995). We used the hierarchical clustering procedure ‘Hclust’ (Rinaldo et al., 
2005) to select representative “tag” SNPs using a minor allele frequency cutoff of five percent 
and a minimum correlation (r2) of 0.9.  This criterion was intended to ensure that the selected 
SNPs would have over 90% relative power to detect associations at the SNPs they tag, based on 
LD estimates from the Seattle SNPs database.  Small insertion/deletion polymorphisms were 
included in Hclust analysis, and where possible tag SNPs were chosen to represent such 
polymorphisms.  The IL1RN (86bp)n variable tandem repeat polymorphism was not included in 
the Seattle SNPs database.  To determine LD between this polymorphism and other SNPs, we 
genotyped it among 47 Caucasian cases; historically studies label IL1RN (86bp)4 as allele 1 and 
IL1RN (86bp)2 as allele 2 (Tarlow et al., 1993).  The analyzed tag SNPs are listed in Table 7.1 
and LD between the tag SNPs in our sample is shown in Appendix A, Figures A3-A4 and Tables 
A3-A4. We selected a total of thirty-four polymorphisms: eleven polymorphisms from 17.4kb at 
IL1β including 1.5 kb 5’ and 9kb 3’ flanking sequence, fifteen SNPs from 19.7kb at IL1RN 
including 2kb of 5’ and 3’ flanking sequence, and eight SNPs from 7.9kb at IL10 including 1kb 
5’ and 2kb 3’ flanking sequence (Appendix A, Figure A3-A4 for location of individual SNPs).  
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 The average coverage was one SNP per 1.3kb.  We used genomic control as described in section 
4.4.4 to correct for population stratification. 
 
7.2.3. Genotyping 
Polymorphisms were genotyped using highly accurate, multiplexed, hybridization based Illumina 
Golden Gate assays (Shen et al., 2005) as described in section 4.2.2.  Candidate polymorphisms 
are first evaluated for assay designability with a primer design algorithm.  Four tag 
polymorphisms were not included in Illumina assays: two because the assays were not feasible 
(rs1143625, rs3917354), and two were excluded due to errors (rs1143640, rs3021094).  These 
SNPs were not re-genotyped using other techniques resulting in some gaps in coverage as noted 
in the results section.  Nevertheless, all common SNPs except one were represented at r2 greater 
than 0.6. 
 
7.2.4 Statistical Analysis 
7.2.4.1. SNP and haplotype analysis 
We used the χ2-based Armitage trend test (Devlin et al., 1999) to compare allele and 
genotype frequencies in cases and controls and subgroups defined by gender and specific 
diagnosis.  We evaluated the possibility of association of tag SNPs with infection status by 
comparing subsets of schizophrenia cases seropositive and seronegative for antibodies to CMV, 
HSV1, and HSV2 using the Armitage trend test.  We controlled for multiple testing using 
Bonferroni correction.  We did not statistically control for genotyping error-rate.  We estimated 
haplotype frequencies for haplotypes comprising all SNPs in each gene and haplotypes identified 
from stepwise logistic regression using ‘Cocaphase’ software as described in section 4.4.5.  We 
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 also used ‘Cocaphase’ to estimate frequencies of the IL1β-IL1RN haplotype reported in 
published studies.  Statistical methods are described in more detail in section 4.4. 
7.2.4.2. Meta-analysis 
We performed a meta-analysis of published case-control studies at rs16944 (IL1β -511) 
(Table 7.9).  We considered meta-analyses of IL1RN (86bp)n and rs1800896 (IL10 –1081), but 
three or fewer studies have been published among the same ethnic group for each polymorphism, 
making meta-analysis less meaningful for these polymorphisms. 
We used χ2 tests and descriptive statistics to evaluate heterogeneity between samples 
(Munafo et al., 2004).  Genotype information was available for all case-control studies, so we 
initially summed, unweighted case and control genotype counts separately for Caucasian and 
Asian samples (Caucasian sample: n = 819 cases, 1292 controls; Asian sample: n = 235 cases 
239 controls).   Differences in proportion of cases and controls between studies could inflate 
artifacts due to population stratification when analyzing genotype counts.  Therefore, as a second 
method of analysis average unweighted effect sizes were calculated.  Averaging effect sizes is 
less powerful than summing genotypes counts, but it is independent of sample size and does not 
risk introducing stratification (Rosenthal et al., 2001). 
 
7.3. RESULTS 
7.3.1 LD Between Selected SNPs 
We selected thirty-four tag polymorphisms in IL10, IL1β, and IL1RN that represent all 120 
common polymorphisms present in the Caucasian sample from the Seattle SNPs database.  We 
genotyped 478 cases and 501 unscreened controls for 30 SNPs.  Of these SNPs, rs3024494 and 
rs3087269 were later excluded from analysis due to quality control considerations (cluster 
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 scoring below cutoff values).  In view of these exclusions, LD was re-evaluated in our sample.  
The analyzed SNPs represented all common polymorphisms satisfactorily (mean r2 = 0.961, n = 
28 selected SNPs, total reported SNPs, n=120, see Appendix A, Table A3-A4).  Of these, 87% 
(n=104) polymorphisms were represented at r2 greater than 0.9 by the analyzed tag SNPs, and 
99% (n=119) were represented at r2 greater than 0.6.  Most tag SNPs were in relatively low LD 
with each other, as would be expected.  We found the common alleles (86bp)2 and (86bp)4 of 
IL1RN (86bp)n  were perfectly correlated with rs1794068 A and G alleles respectively.  Hence 
this SNP was investigated in lieu of IL1RN (86bp)n.   
 
7.3.2 Associations at Individual SNPs 
No significant case-control differences were detected at any individual SNP in the entire sample 
(Table 7.1).  For twenty-one SNPs with minor allele frequency greater than 20%, including tags 
for all SNPs reported in previous schizophrenia association studies, our sample had greater than 
80% power at α=0.05 to detect a relative risk of 1.35 using a log-additive model and 1.45 using a 
dominant model.  For the remaining seven SNPs our sample had over 80% power to detect a 
relative risk greater than 1.8 using either dominant or log-additive models.   
Furthermore, we found no significant associations among sub-groups based on gender 
(Table 7.2).  When patients were divided into schizophrenia and schizoaffective subgroups, the 
“A” allele of rs4252041 was associated with schizophrenia (p = 0.024, χ2 =5.1, 1df, Table 7.2).  
This association did not remain significant after correcting for multiple comparisons.  Sub-
groups of cases seropositive and seronegative for CMV, HSV1, or HSV2 did not differ 
significantly from each other except at rs3917356 for HSV1 (p = 0.037, χ2 =4.4, 1df), and 
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 rs2853550 and rs3917365 for CMV (p=0.018, χ2 =5.6, 1df for each SNP)(Table 7.3).  These 
associations did not remain significant after correcting for twenty-eight comparisons. 
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 Table 7.1.  Distribution of Genotypes for Tag SNPs Among Cases and Controls. 
 
Allele 
code
Case  
(n = 478a) 
Control  
(n = 501a) 
allele 1 
frequency Chr Genomic Location Gene SNP 1 2 11 12 22 11 12 22 case control 
Genotype
-wise 
p-value 
Allele-
wise 
p-value
1 203330808 IL10 rs3024495 T C 11 131 336 12 114 375 0.160 0.138 0.168 0.165
1 203332507 IL10 rs3024492 T A 21 176 280 39 167 295 0.229 0.245 0.412 0.405
1 203333256 IL10 rs1518110 T G 30 151 294 18 198 285 0.222 0.234 0.544 0.547
1 203333441 IL10 rs3024491b A C 110 222 146 101 238 162 0.462 0.439 0.314 0.302
1 203334802 IL10 rs1800872b A C 41 157 279 23 208 269 0.251 0.254 0.860 0.860
1 203335061 IL10 rs1800894 T C 1 33 444 2 31 468 0.037 0.035 0.845 0.841
2 113302700 IL1β rs3917365 T C 3 72 403 3 75 423 0.082 0.081 0.951 0.951
2 113303352 IL1β rs2853550 A G 4 72 402 4 83 414 0.084 0.091 0.577 0.576
2 113306621 IL1β rs1143634b A G 17 175 286 28 179 294 0.219 0.235 0.393 0.401
2 113306698 IL1β rs1143633 T C 74 203 199 68 220 212 0.369 0.356 0.571 0.560
2 113307506 IL1β rs3136558 T C 298 162 17 303 172 26 0.795 0.776 0.327 0.330
2 113308594 IL1β rs3917356 A G 112 222 144 95 250 156 0.467 0.439 0.229 0.223
2 113310618 IL1β rs1143627 A G 204 220 53 205 233 63 0.658 0.642 0.439 0.443
2 113311098 IL1β rs16944b T C 53 220 205 63 231 207 0.341 0.356 0.475 0.478
2 113590698 IL1RN rs4251961 A G 194 215 68 204 233 64 0.632 0.640 0.727 0.725
2 113592309 IL1RN rs4251974 C G 256 183 39 279 184 38 0.727 0.741 0.507 0.498
2 113593010 IL1RN rs2637988 T C 180 221 77 188 238 75 0.608 0.613 0.821 0.819
2 113599937 IL1RN rs315934 A G 300 158 20 312 163 26 0.793 0.785 0.688 0.686
2 113600433 IL1RN rs3087262 G C 3 108 367 5 115 379 0.119 0.125 0.676 0.686
2 113601999 IL1RN rs3087263 T C 6 86 384 3 80 418 0.103 0.086 0.196 0.195
2 113602581 IL1RN rs1794066 T C 176 225 77 186 236 79 0.604 0.607 0.885 0.884
2 113602734 IL1RN rs1794068b T C 40 187 250 40 185 276 0.280 0.264 0.453 0.444
2 113603566 IL1RN rs2232354 T G 291 160 25 331 151 19 0.779 0.811 0.083 0.080
2 113604788 IL1RN rs451578 T C 46 190 242 44 194 263 0.295 0.281 0.517 0.508
2 113605131 IL1RN rs380092 A T 40 218 220 55 226 220 0.312 0.335 0.256 0.264
2 113606535 IL1RN rs315952 A G 232 209 37 250 204 47 0.704 0.703 0.946 0.947
2 113606841 IL1RN rs4252041 A G 0 51 427 1 37 463 0.053 0.039 0.123 0.128
2 113609005 IL1RN rs315949 T C 83 222 173 75 237 189 0.406 0.386 0.379 0.375
a – Missing genotype counts for less than three individuals for some SNPs due to uncertain 
genotype calls. 
b- Represents a polymorphism investigated in a published study: rs3024491 (A/C) represents 
IL10 –1082 (G/A), r2 = .965; rs1800872 is IL10 –592;  rs1143634 is IL1β 105 Taq1; rs16944 is 
IL1β –511 C/T; rs1794068 (T/C) represents IL1RN (86bp)n or IL1RA(VNTR), r2 = 1.00, 
rs1794068 T = IL1RN (86bp)2 = IL1RA allele 2, rs1794068 C = IL1RN (86bp)4 = IL1RA allele 
1. 
 84
 Table 7.2  Association Analysis by Gender and Diagnostic Category, IL-10, IL1β, and 
IL1RN. 
 
    
Female case vs 
Female control 
Male case vs 
Male control 
Schizophrenia vs 
Control 
Chr Coordinate Gene SNP casea controla pvalb casea controla pvalb casea controla pvalb
1 203330808 IL-10 rs3024495 0.161 0.145 0.549 0.160 0.131 0.168 0.145 0.138 0.693
1 203332507 IL-10 rs3024492 0.250 0.255 0.871 0.217 0.235 0.475 0.218 0.245 0.243
1 203333256 IL-10 rs1518110 0.223 0.239 0.606 0.222 0.229 0.766 0.234 0.234 0.976
1 203333441 IL-10 rs3024491 0.491 0.444 0.187 0.447 0.435 0.692 0.434 0.439 0.844
1 203334802 IL-10 rs1800872 0.256 0.260 0.886 0.248 0.248 0.985 0.267 0.254 0.589
1 203335061 IL-10 rs1800894 0.048 0.029 0.185 0.031 0.040 0.377 0.031 0.035 0.708
2 113302700 IL1β rs3917365 0.065 0.075 0.599 0.090 0.087 0.826 0.097 0.081 0.265
2 113303352 IL1β rs2853550 0.065 0.083 0.331 0.094 0.098 0.801 0.101 0.091 0.509
2 113304897 IL1β rs1143641 0.000 0.000 0.000 0.000 0.002 0.275 0.000 0.001 0.462
2 113306621 IL1β rs1143634 0.211 0.222 0.715 0.223 0.246 0.336 0.232 0.235 0.896
2 113306698 IL1β rs1143633 0.377 0.353 0.492 0.364 0.359 0.864 0.382 0.356 0.330
2 113307506 IL1β rs3136558 0.793 0.780 0.649 0.795 0.773 0.360 0.788 0.776 0.606
2 113308594 IL1β rs3917356 0.464 0.429 0.339 0.468 0.448 0.507 0.480 0.439 0.132
2 113310618 IL1β rs1143627 0.652 0.629 0.497 0.662 0.654 0.775 0.683 0.642 0.107
2 113311098 IL1β rs16944 0.345 0.369 0.481 0.339 0.344 0.843 0.318 0.356 0.131
2 113590698 IL1RN rs4251961 0.628 0.631 0.937 0.634 0.648 0.632 0.609 0.640 0.230
2 113592309 IL1RN rs4251974 0.711 0.730 0.564 0.735 0.750 0.580 0.761 0.741 0.385
2 113593010 IL1RN rs2637988 0.604 0.589 0.679 0.610 0.635 0.380 0.651 0.613 0.138
2 113599937 IL1RN rs315934 0.783 0.813 0.292 0.798 0.760 0.114 0.787 0.785 0.952
2 113600433 IL1RN rs3087262 0.107 0.135 0.226 0.126 0.116 0.587 0.108 0.125 0.316
2 113601999 IL1RN rs3087263 0.126 0.100 0.247 0.091 0.073 0.279 0.089 0.086 0.839
2 113602581 IL1RN rs1794066 0.610 0.587 0.521 0.600 0.625 0.385 0.645 0.607 0.138
2 113602734 IL1RN rs1794068 0.290 0.272 0.571 0.274 0.258 0.535 0.245 0.264 0.427
2 113604788 IL1RN rs451578 0.301 0.282 0.578 0.292 0.281 0.683 0.259 0.281 0.361
2 113605131 IL1RN rs380092 0.295 0.322 0.398 0.321 0.348 0.329 0.329 0.335 0.800
2 113606535 IL1RN rs315952 0.711 0.718 0.838 0.700 0.688 0.671 0.706 0.703 0.893
2 113606841 IL1RN rs4252041 0.048 0.041 0.676 0.056 0.037 0.106 0.064 0.039 0.024c
2 113609005 IL1RN rs315949 0.411 0.398 0.723 0.403 0.375 0.338 0.417 0.386 0.239
 
a- See Table 7.1 for Allele coding.  Case and control frequencies for Allele 1 are shown. 
b- Genotypewise p-values. 
c-  The “A” allele of rs4252041 was associated with schizophrenia (p = 0.024, χ2 =5.1, 1 d.f.).  
This association did not remain significant after correcting for multiple comparisons.   
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Table 7.3 Associations with Infections Agents, IL-10, IL1β, and IL1RN 
 
Gene SNP HSV1+ a HSV1- a pval b CMV+ a CMV- a pvalb HSV2+ a HSV2- a pvalb 
IL-10   rs3024495 0.171 0.147 0.391 0.176 0.152 0.399 0.143 0.163 0.593 
IL-10   rs3024492 0.259 0.225 0.264 0.252 0.235 0.590 0.286 0.232 0.196 
IL-10   rs1518110 0.213 0.203 0.752 0.199 0.214 0.665 0.173 0.216 0.332 
IL-10   rs3024491 0.500 0.451 0.206 0.513 0.457 0.170 0.491 0.473 0.728 
IL-10   rs1800872 0.256 0.222 0.315 0.223 0.247 0.508 0.214 0.243 0.538 
IL-10   rs1800894 0.035 0.039 0.792 0.042 0.035 0.632 0.027 0.039 0.535 
IL1β rs3917365 0.098 0.067 0.138 0.118 0.065 0.018c 0.071 0.085 0.636 
IL1β rs2853550 0.098 0.067 0.138 0.118 0.065 0.018c 0.071 0.085 0.636 
IL1β rs1143634 0.228 0.216 0.706 0.202 0.234 0.311 0.205 0.226 0.611 
IL1β rs1143633 0.345 0.399 0.152 0.387 0.372 0.722 0.393 0.374 0.718 
IL1β rs3136558 0.799 0.781 0.535 0.797 0.786 0.728 0.786 0.790 0.913 
IL1β rs3917356 0.424 0.505 0.037c 0.466 0.470 0.936 0.438 0.474 0.485 
IL1β rs1143627 0.639 0.694 0.110 0.660 0.674 0.696 0.634 0.676 0.375 
IL1β rs16944 0.361 0.304 0.100 0.340 0.325 0.668 0.357 0.325 0.493 
IL1RN rs4251961 0.627 0.624 0.921 0.627 0.626 0.968 0.625 0.626 0.980 
IL1RN rs4251974 0.728 0.735 0.845 0.752 0.721 0.388 0.714 0.735 0.664 
IL1RN rs2637988 0.604 0.613 0.811 0.609 0.608 0.980 0.554 0.619 0.202 
IL1RN rs315934 0.794 0.789 0.853 0.782 0.799 0.592 0.848 0.782 0.112 
IL1RN rs3087262 0.130 0.121 0.719 0.151 0.113 0.125 0.161 0.119 0.201 
IL1RN rs3087263 0.111 0.080 0.153 0.081 0.102 0.372 0.107 0.092 0.624 
IL1RN rs1794066 0.601 0.611 0.798 0.613 0.602 0.767 0.554 0.616 0.225 
IL1RN rs1794068 0.275 0.268 0.832 0.240 0.288 0.183 0.286 0.269 0.717 
IL1RN rs2232354 0.775 0.772 0.917 0.769 0.776 0.830 0.750 0.778 0.515 
IL1RN rs451578 0.291 0.281 0.772 0.248 0.305 0.125 0.304 0.282 0.660 
IL1RN rs380092 0.329 0.312 0.614 0.345 0.307 0.305 0.321 0.320 0.971 
IL1RN rs315952 0.668 0.696 0.424 0.660 0.699 0.288 0.652 0.692 0.400 
IL1RN rs4252041 0.066 0.041 0.125 0.046 0.056 0.562 0.063 0.051 0.609 
IL1RN rs315949 0.386 0.412 0.490 0.403 0.400 0.942 0.357 0.410 0.310 
 
a-  See Table 7.1 for Allele coding.  Frequencies for Allele 1 are shown. 
b-  Genotypewise p-values. 
c-  For HSV1 rs3917356, p = 0.037, χ2 =4.4, 1df; for CMV rs2853550 and rs3917365, p=0.018, 
χ2 =5.6, 1df. These association did not remain significant after correcting for multiple 
comparisons.   
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7.3.3 Genomic control analysis  
In addition to tag SNPs, thirty-one genomic control SNPs were assayed (see Table 4.2).  The 
median χ2 for the genomic control SNPs was 0.336 when comparing cases and controls.  This 
value is below the expected median χ2 of 0.456 under the null hypothesis, indicating insufficient 
evidence for population stratification between cases and controls due.  Hence corrections for 
population sub-structure were not applied. 
 
7.3.4 Haplotype associations 
We used ‘Cocaphase’ to estimate haplotype frequency differences and compare common 
haplotype distributions in cases and controls.  When all tag SNPs were used to determine 
haplotypes for each gene, there were seven common (frequency > 1%) haplotypes at IL10 (n = 7 
SNPs), seven common haplotypes in IL1β (9 SNPs), and thirteen common haplotypes at IL1RN 
(14 SNPs).  No individual haplotypes were associated with schizophrenia; the respective gene-
based global p-values were 0.196 for IL10, 0.819 for IL1β, and 0.627 for IL1RN (Tables 7.4-7.6).  
We next used stepwise logistic regression to evaluate the possibility that smaller subsets of SNPs 
might be associated with schizophrenia.  Logistic regression showed no individual SNPs or sets 
of SNPs in IL1β or IL10 predicted schizophrenia status.  Logistic regression of IL1RN SNPs 
revealed three SNPs (rs1794068, rs315952, and rs315949) that remained significant at < 0.05 
level after the last iteration of the logistic regression.  Notably, the A allele of rs1794068 was 
completely correlated with IL1RN (86bp)4.  ‘Cocaphase’ was used to estimate haplotypes 
spanning these three SNPs.  Case-control comparisons suggested that the A-A-C haplotype was 
over-represented among the controls (case frequency 4.8%, control frequency 7.2%, p = 0.011), 
and there was a trend for case-control differences in the overall distribution of all haplotypes 
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 (global p-value = 0.058, Table 7.7).  Since we conducted statistical comparisons for 36 common 
haplotypes this is likely to be a chance finding.  Published studies reported associations with 
haplotypes comprising the rs16944 (IL1β –511)-IL1RN(86bp)n haplotype (Katila et al., 1999b; 
Papiol et al., 2004; Zanardini et al., 2003), so we evaluated the rs16944-rs1794088 haplotype, 
which corresponds to this haplotype in our sample. None of the four haplotypes defined by these 
markers were associated with schizophrenia (global p-value = 0.62, Table 7.8). 
 
 
Table 7.4.  IL10 Haplotype Analysis Using ‘Cocaphase’. 
 
Markers  
1 2 3 4 5 6 7  
3024495 3024494 3024492 1518110 302449118008721800894  
        
Haplotype Casea Freq Controla Freq ORb chisq P 
1-2-2-2-1-2-2 151 0.158 136.8 0.137 1.24 1.77 0.18
2-2-1-2-1-2-2 218 0.228 245 0.245 1.00 0.74 0.39
2-2-2-1-2-1-2 213.7 0.224 234 0.234 1.02 0.27 0.60
2-2-2-2-1-2-1 35 0.037 35 0.035 1.12 0.04 0.84
2-2-2-2-1-2-2 36 0.038 22 0.022 1.83 4.23 0.04
2-2-2-2-2-1-2 25.27 0.026 19.75 0.020 1.43 0.90 0.34
2-2-2-2-2-2-2 275 0.288 308.2 0.308 1.00 0.92 0.34
Likelihood ratio test: null = -2684.62 alternative = -2678.46 
LRS = 12.3239 DF = 9 p = 0.195658 
 
a- Estimated case and control haplotype counts. 
b- Odds Ratio compared to most common haplotype. 
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 Table 7.5.  IL1β Haplotype Analysis Using ‘Cocaphase’. 
 
Markers 
1 2 3 4 5 6 7 8 
rs3917365 rs2853550 rs1143634 Rs1143633 rs3136558 rs1143627 rs16944
      
Haplotype Case  a freq Control  a freq OR  b chisq p 
1-1-2-2-1-1-1-2 23.94 0.02504 16.75 0.01672 1.435521 1.326 0.2496
1-1-2-2-1-2-2-1 52.26 62.1 0.06198 0.84556 0.3233 0.5696
2-2-1-2-1-2-2-1 26.69 0.02792 29.16 0.0291 0.03739 0.8467
2-2-1-2-2-2-1-2 160.6 0.168 182.1 0.1818 0.885714 0.6636 0.4153
2-2-2-1-1-1-1-2 323.3 0.3381 324.7 0.3241 1 0.4279 0.513 
2-2-2-2-1-1-1-2 73 70.27 0.07013 1.043243 0.418 0.518 
2-2-2-2-1-2-2-1 227.9 0.2384 227.9 0.2275 0.2595 0.6104
Likelihood ratio test: null = -3244.83 alternative = -3243.37 
LRS = 2.92081 DF = 6 p = 0.818719 
 
a- Estimated case and control haplotype counts. 
b- Odds Ratio compared to most common haplotype 
 
Table 7.6.  IL1RN Haplotype Analysis Using ‘Cocaphase’. 
 
1 2 3 4 5 6 7 
rs4251961 rs4251974 rs315934 rs3087262 rs3087263 rs1794066
8 9 10 11 12 13 
rs1794068 rs2232354 rs451578 rs380092 rs315952 rs4252041 rs315949
 
Haplotype a freq Controla freq OR  b chisq P 
1-1-1-1-2-2-1-2-1-2-1-1-2-2 0.01873 18.99 0.01896 1.03533 0.001682 0.9673 
1-1-1-2-2-2-1-2-1-1-1-2-2-2 13 0.01359 18 0.793395 0.6028 0.4375 
1-1-1-2-2-2-1-2-1-2-1-1-2-1 13.65 0.01428 14.64 0.01461 1.02381 0.002137 
1-1-1-2-2-2-1-2-1-2-1-2-2-2 129 0.1349 130.1 0.1298 1.089094 0.1111 0.7389 
1-1-1-2-2-2-1-2-1-2-2-1-2-1 0.03929 34.86 0.03479 1.183564 0.2556 0.6131 
1-1-2-1-1-2-2-2-1-2-1-2-2-2 105.5 0.1103 116.5 
rs3917356
  
0.05467 
0.918919
0.07636 
1.004633
Markers 
rs2637988 
14 
Case  
17.91 
0.01796
0.9631 
37.56 
0.1162 0.994624 0.1733 0.6772 
1-2-2-1-2-1-2-1-1-1-2-1-2-2 80.96 0.08469 73.97 0.07382 1.201997 0.7812 0.3768 
1-2-2-1-2-2-2-1-1-1-2-1-2-2 147.9 0.1547 162.4 0.1621 1 0.1824 0.6694 
1-2-2-1-2-2-2-1-1-1-2-2-2-2 19.1 0.01998 11.58 0.01156 1.811828 2.203 0.1377 
2-1-1-1-2-2-1-2-1-2-2-1-2-1 137.5 0.1439 164.8 0.1645 0.917051 1.57 0.2102 
2-1-1-1-2-2-1-2-2-2-2-1-1-1 48 0.05021 35.99 0.03592 1.465438 2.438 0.1184 
2-1-1-1-2-2-1-2-2-2-2-1-2-1 141.2 0.1477 127.4 0.1271 1.218126 1.722 0.1894 
2-1-1-1-2-2-1-2-2-2-2-1-2-2 13.03 0.01363 18.88 0.01885 0.758065 0.865 0.3524 
Likelihood ratio test: null = -4342.59 alternative = -4337.67 
LRS = 9.84425 DF = 12  p = 0.629622 
 
a- Estimated case and control haplotype counts. 
b- Odds Ratio compared to most common haplotype 
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 Table 7.7. Analysis of IL1RN Associated Haplotype Using ‘Cocaphase’. 
 
Markers 
1 2 3 
rs1794068 rs315952 rs315949 
   
Haplotype Casea Freq Controla Freq ORb chisq p 
1-1-2 240.7 0.2504 243.7 0.2444 0.976514 0.1934 0.6601 
1-2-2 25.88 0.02806 19.87 0.01888 1.416873 1.215 0.2704 
2-1-1 386.5 0.404 385.5 0.3851 1 0.7821 0.3765 
2-1-2 44.35 0.0477 73.33 0.07194 0.631953 6.446 0.01112 
2-2-2 257.1 0.268 278.1 0.2785 0.917027 0.1845 0.6675 
Likelihood ratio test: null = -2122.35 alternative = -2118.61 
LRS = 7.4818 DF = 3 p = 0.0580279 
 
a- Estimated case and control haplotype counts. 
b- Odds Ratio compared to most common haplotype. 
 
 
 
Table 7.8.  Analysis of IL1β-IL1RN Previously Reported Haplotype Using ‘Cocaphase’. 
 
Markers 
1c 2c 
rs16944 rs1794068 
  
Haplotype Casea Freq Controla freq ORb chisq p 
1-1 158 0.1652 158.3 0.1579 1.033378 0.1318 0.7165 
1-2 168 0.1758 198.7 0.1983 0.875168 1.581 0.2087 
2-1 110.1 0.1151 106.7 0.1065 1.06748 0.6242 0.4295 
2-2 519.9 0.5439 538.3 0.5372 1 0.05334 0.8173 
Likelihood ratio test: null = -1788.51 alternative = -1787.62 
LRS = 1.783 DF = 3 p = 0.618642 
 
a- Estimated case and control haplotype counts. 
b- Odds Ratio compared to most common haplotype. 
c- Alleles in tables are opposite those reported in published literature for rs16944:  rs16944 1 
represents the T allele in this table and C in published literature, likewise rs1794068 allele 1 
represents the IL1RN(86bp)2 variant in this table, which is the IL1RN 2 allele in published 
literature. 
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 7.3.5 Meta-Analysis of Association Studies at rs16944 
We found evidence for heterogeneity between studies of Asian and Caucasian samples with 
respect to allele frequency differences (χ2 = 6.16, 1df, p = 0.013). Among samples of Caucasian 
ancestry, heterogeneity was apparent with regard to the ratio of cases to controls in each sample 
(range = 0.125-1).  In view of these sources of heterogeneity, we used two methods to analyze 
the published case-control studies (Table 7.9).  First, we summed allele counts for Caucasian and 
Asian sub-samples separately.  The C allele was significantly associated with schizophrenia in 
the Caucasian samples (n = 819 cases, 1292 controls, p = 0.0013, OR = 1.24, 95% CI 1.09,1.41), 
but not in the Asian samples (n = 235 cases, 239 controls, p = 0.828, OR = 1.03, 95% CI 
0.80,1.33).  We then averaged unadjusted effect sizes for Caucasian and Asian studies separately 
and together.  This method is more robust to sample size and allele frequency heterogeneity 
(Rosenthal et al., 2001).  We found similar results using this method; the C allele was 
significantly associated with schizophrenia in the Caucasian samples (effect size = 0.056, 95% 
CI 0.014, 0.098), but not in the Asian samples.  An effect size of 0.056 corresponds to an odds 
ratio of 1.25, which is very similar to the odds ratio estimate from the summed samples.  
Assuming an odds ratio of 1.24 and log additive risk, a replicate sample of 1,350 Caucasian 
cases and controls would be needed to attain 80% power to detect this association (α = 0.05). In 
retrospect it is likely that even this study, which is the largest association study of this marker 
conducted to date, was underpowered. 
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Table 7.9.  Meta-Analysis of IL1β -511 (rs16944) Association Studies in Schizophrenia. 
 
case control  Study population DC c CC d 
C T C T 
pval e OR 95% CI r f 
 
Tatsumi 
1997a Japanese 1 + 64 44 64 44 1 1.00 0.58,1.72 0.000  
Katilla 
1999b Finnish 2 + 71 29 472 328 0.021 1.70 1.08,2.68 0.077  
Chowdari 
2001a Chinese 2 +/- 198 164 198 172 0.809 1.05 0.78,1.40 0.009  
Meisenzhal 
2001b American 2 ++ 60 28 60 36 0.419 1.29 0.70,2.37 0.060  
Zanardini 
2003b Italy 3 ++ 227 111 212 142 0.047 1.37 1.00,1.87 0.075  
Papiol 
2004b Spanish 2 + 111 45 219 113 0.253 1.27 0.84,1.93 0.052  
Shirts 
2006b American 4 - 630 326 645 357 0.478 1.07 0.89,1.29 0.016  
             
Totals           mean r 95% CI 
Sub-
samples Asian   262 208 262 216 0.828 1.04 0.80,1.33 0.004 -0.006,0.096
 Caucasian   1099 539 1608 976 0.001 1.24 1.09,1.41 0.056 0.014,0.098
Total           0.041 -0.013,0.096
 
a- Included in Asian subsample. 
b- Included in Caucasian subsample. 
c- Diagnostic Criteria: 1= DSM-III-R schizophrenia, 2 = DSM-IV or ICD10 schizophrenia, 3 
= DSM-IV schizophrenia or schizophrenia spectrum, 4 = DSM-IV schizophrenia or 
schizoaffective.   
d- Control Criteria: ++ = controls screened for personal and family psychiatric illness, + = 
controls screened for general health, +/- = reports two control samples one screened for 
general health and another portion unscreened, - = unscreened controls. 
e- p-values calculated from χ2 test of allele counts.   
f- phi calculated from case and control allele counts. 
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 7.4. DISCUSSION 
 Previous genetic association studies of schizophrenia and IL10, IL1β, and IL1RN 
generally focused on single polymorphisms.  We used a tag SNP approach to comprehensively 
evaluate common polymorphisms at these genes in a moderately sized Caucasian sample.  We 
did not find significant associations at twenty-eight tag SNPs when we evaluated the entire 
sample.  Following corrections for multiple comparisons, significant associations with 
haplotypes were also not detected.  We did find one suggestive association at rs4252041 in 
IL1RN among the sub-group of patients with schizophrenia.  We also found suggestive 
associations with certain sub-groups at SNPs in IL1β.  The G allele of rs3917356 was over-
represented in herpes simplex virus 1 seropositive cases (p = 0.037).  The A and T alleles of 
rs2853550 and rs3917365, which are in tight LD, were over-represented in cytomegalovirus 
seropositive patients (p=0.018 for both SNPs).  More focused investigations of these 
polymorphisms in unscreened populations will be necessary to determine if they are associated 
with the immune response to viral infection. 
Our meta-analysis suggests that the C allele of rs16944 (IL1β –511) is associated with a 
modest increase in schizophrenia risk in Caucasian populations.  Consistent with our results, 
several investigators reported that haplotypes comprising the C allele at rs16944 was 
significantly associated with increased risk (Katila et al., 1999b; Papiol et al., 2004).  In support 
of the association, other investigators reported that haplotypes comprising the T allele at this 
SNP were less frequent among cases (Zanardini et al., 2003).  Interestingly, the C allele at 
rs16844 has also been associated with psychosis in Alzheimer’s disease (Craig et al., 2004).  In 
contrast, significant association with schizophrenia was not detected in papers reporting on 
samples with Asian participants.  This may reflect a difference in risk etiology among Asian 
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 populations.  It may also be attributable to the smaller number of Asian participants analyzed 
(Table 7.9). 
Publication bias was not evaluated in our meta-analysis as six of the seven association 
studies included in the meta-analyses report no association at the individual SNP level.  We 
observed three common features among the studies with larger effect sizes (see Table 7.9).  First, 
these studies involved Caucasian individuals.  Second, control individuals had been screened for 
physical health. Two studies reported that the control individuals were also screened for personal 
and family history of psychiatric illness.  Finally, these studies investigated patients with 
schizophrenia, but not those with schizoaffective disorder.  Due to the small numbers of studies 
and the qualitative nature of inclusion criterion we did not calculate the magnitude or 
significance of these factors.  For reference, if our study had been limited to cases with 
schizophrenia the odds ratio at rs16944 in our sample would have been 1.19 instead of 1.07 (see 
Table 7.2). The schizophrenia-schizoaffective disorder dichotomy in this context, is supported by 
a family based association study of IL1β (Rosa et al., 2004).   
As they are located in the putative promoter of IL1β, variations at rs16944 or rs1143627, 
which is also located in the promoter of IL1β and is in LD with rs16944, may impact on IL1β 
expression.  In support, Barak et al (Barak et al., 1995) report decreased IL1β levels in CSF from 
patients with schizophrenia, and the rs16944-rs1143627 C-T promoter haplotype causes 2-3 fold 
lower IL1β secretion in LPS stimulated blood (Hall et al., 2004).  On the other hand, other 
investigators have found evidence for an increase in IL1β expression in monocytes and serum 
from schizophrenia cases (Katila et al., 1994a; Kowalski et al., 2001).  The majority of studies of 
IL1β expression in schizophrenia have found no significant change (Baker et al., 1996; Bessler et 
al., 1995; Erbagci et al., 2001; Katila et al., 1994b; Kim et al., 1998).  The relationship of these 
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 results to brain function is uncertain, though it has been suggested that exposure to elevated IL1β 
levels leads to a dose dependent reduction in neuronal survival (Marx et al., 2001).   
In conclusion, comprehensive evaluation of common polymorphisms of three positional 
candidate genes did not reveal convincing evidence for association in a moderately large case-
control sample.  Meta analysis suggests modest genetic risk due to polymorphisms in the 
promoter region of IL1β.  Future replicate studies are needed to confirm this modest risk, and 
additional cytokine expression studies may benefit from evaluation of genetic effects. 
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8. IL-18 PATHWAY POSITIONAL CANDIDATE GENES 
 
 
8.1. INTRODUCTION 
In light of localization of many IL-18 related genes to schizophrenia linkage regions and recent 
literature on the role of IL-18 in the CNS we investigated polymorphisms in four IL-18 pathway 
genes (IL-18, IL18BP, IL18R1, and IL18RAP) as well as two IL12 genes (IL12A and IL12B), 
which can act synergistically with IL-18, for associations with schizophrenia.  Our primary 
experiments were designed to evaluate all common polymorphisms in these genes using a tag 
SNP approach.  We utilized permutation testing to evaluate the significance level of associations 
while adjusting for multiple comparisons and we used genomic control (Bacanu et al., 2000) to 
control for population stratification.  Subsequently we performed exploratory analysis to 
investigate the possibility of gene-gene interaction among these six genes.  Additionally we used 
a case-only design to explore potential interactions of associated SNPs with three infections 
agents thought to be involved in schizophrenia HSV1, HSV2 , and CMV. 
  
8.2. MATERIALS AND METHODS 
8.2.1. Sample 
The sample used for evaluation of IL-18 pathway genes was identical to the sample used to 
evaluate IL1β, IL1RN, and IL10 (see section 7.2.1, 4.1.1, and 4.1.2). 
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8.2.2. SNP Selection 
The Innate Immunity Program for Genetic Applications (PGA) (Martinez et al., 2005) has made 
information available from IL-18, IL18BP, IL18R1, and IL18RAP genes, and the Seattle SNPs 
PGA (Nickerson et al., 2005) has made information available from IL12A and IL12B genes.  The 
PGA initiatives have sequenced exons, introns, UTRs and several kb flanking sequence for these 
genes in a set of twenty-three individuals of European descent and twenty-four individuals of 
African descent.   Linkage disequilibrium (LD) estimates based on D’ and r2 were available for 
these SNPs. We used the hierarchical clustering procedure ‘Hclust’ (Rinaldo et al., 2005) to 
select representative “tag” SNPs using a minor allele frequency (MAF) cutoff of five percent and 
a minimum correlation (r2) of 0.9.  This criterion was intended to ensure that the selected SNPs 
would have over 90% relative power to detect associations at the SNPs they tag, based on LD 
estimates from the Program for Genetic Applications databases.  All small sequenced 
insertion/deletion polymorphisms were included in Hclust analysis, and where possible tag SNPs 
were chosen to represent such polymorphisms.  In addition, several non-synonymous 
polymorphisms with MAF slightly below five percent were included.  The analyzed tag SNPs 
are listed in Table 8.1 and LD between the tag SNPs in our sample is shown in AppendixA, 
Tables A5-8 and Figures A5-A8. We selected a total of sixty-five tag SNPs: twelve at IL-18, two 
at IL18BP, seventeen at IL18R1, sixteen at IL18RAP, seven at IL12A, and eleven at IL12B.  The 
average coverage was one SNP per 1.85 kb.  We also utilized genomic control SNPs described in 
section 4.4.4. 
 97
  
8.2.3. Genotyping and Immunology 
Polymorphisms were genotyped using highly accurate, multiplexed, hybridization based Illumina 
Golden Gate assays (Shen et al., 2005)(see section 4.2.2).  Candidate polymorphisms are first 
evaluated for assay designability with a primer design algorithm.  Five polymorphisms were not 
included in Illumina assays because the assays were not feasible and no alternative tag SNPs 
were available (rs3771167, rs582054, rs5744237, rs5744241, rs675614).  This resulted in some 
decrease in coverage (see results, section 8.3). 
 Specific enzyme based immunoassays for HSV1, HSV2, and CMV were performed on 
serum samples from 352 cases as described in section 4.3.  Serological analysis was not feasible 
for the controls as IgG antibodies are not produced in the neonatal period. 
 
8.2.4. Statistical Analysis 
8.2.4.1. Evaluation of associations at SNPs 
We used the Armitage trend test (Devlin et al., 1999) to compare allele and genotype 
frequencies in cases and controls.  We ran 20,000 random permutations of case and controls 
status using the ‘Cocaphase’ option of ‘Unphased’ software to generate empiric p-values 
(Dudbridge, 2003).  Genomic control was used to correct for population stratification as 
described in section 4.4.4. 
8.2.4.2. Exploratory Analysis.   
We evaluated the possibility that combinations of SNPs within genes may be associated 
with schizophrenia using backwards stepwise logistic regression.  We then used the ‘Cocaphase’ 
option of  ‘Unphased’ software (Dudbridge, 2003) to estimate haplotype frequencies as 
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 described in section 4.4.5. 
We used Multifactor Dimensionality Reduction (MDR) (Hahn et al., 2003) to explore the 
possibility of gene-gene interaction.   We ran 1000 permutations of MDR to estimate 
significance.  To better assess the nature, magnitude, and significance of main effects and 
interaction effects we performed chi-square analysis comparing expected frequencies compared 
to observed marker combinations calculated by ‘Cocaphase’. 
 We used the Armitage trend test to compare allele and genotype frequencies in the subset 
of 352 cases classified as seropositive and seronegative for three infectious agents, CMV, HSV1, 
and HSV2.   This test is similar in theory to standard case-only analysis of gene-environment 
interaction, and assumes independence of genetic and environmental factors for correct 
interpretation of interaction effects (Gatto et al., 2004).   
 
8.3. RESULTS 
8.3.1. Analysis of associations at individual SNPs 
8.3.1.1. LD between selected SNPs 
A total of sixty tag SNPs were genotyped among 478 schizophrenia cases and 501 
unscreened controls.  Of these SNPs five (rs11465672, rs11465648, rs2058623, rs5744257, and 
rs2243131) were later excluded from analysis due to quality control considerations (cluster 
scoring on Illumina assays below cutoff values).  For most marker pairs the LD in our sample 
was similar to that reported in the PGA databases, but for some marker pairs the LD was 
different.  This resulted in some markers being in greater LD than expected and greater 
redundancy in genotyping results (see Appendix A, Figures A5-A8).  In view of exclusions and 
redundancies, gene coverage was re-evaluated comparing our sample with the PGA samples.  
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 The fifty-five analyzed tag SNPs captured 230 of 263 polymorphisms with MAF over 5% in the 
PGA databases at r2 greater than 0.9, and 215 of 231 polymorphisms with MAF over 10% at r2 
greater than 0.8. 
8.3.1.2. Individual SNP associations 
Nominally significant case-control differences (p<0.05) were detected at seven individual 
SNPs (Table 8.1): four including the most significant in IL18RAP (rs2272127, rs1146702, 
rs1146723, and rs6543135), one in IL18R1 (rs7558013), one in IL-18 (rs5744247), and one in 
IL12B (rs2853694).  Only one association remained significant after empirically adjusting for 
multiple comparisons (rs2272127, p = 0.028).  All other associated SNPs in IL18R1 and 
IL18RAP, which are contiguous on chromosome 2p, were in LD with rs2272127. 
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 Table 8.1.  Associations of SNPs in IL-18 Pathway Candidate Genes with Schizophrenia. 
 
    
Allele 
code Case Control 
Geno 
type-
wise 
Allele 1 
frequency 
Allele
-wise
Gene Chr Coordinate SNP 1 2 11 12 22 11 12 22 pval case control pval
IL-18 11 111519971 rs3882891 T G 161 233 84 168 240 93 0.799 0.581 0.575 0.800
IL-18 11 111521724 rs5744280 T C 50 212 216 57 212 232 0.962 0.326 0.325 0.962
IL-18 11 111526126 rs549908 T G 231 206 41 262 193 45 0.375 0.699 0.717 0.378
IL-18 11 111529037 rs1834481 C G 32 177 269 37 173 291 0.775 0.252 0.247 0.780
IL-18 11 111531366 rs5744247 C G 5 81 0.124 392 8 108 385 0.043 0.095 0.045
IL-18 11 111531913 rs360722 T A 8 96 374 11 122 368 0.081 0.117 0.144 0.085
IL-18 11 111536834 rs2043055 A G 193 224 61 214 219 68 0.725 0.638 0.646 0.727
11 111540198 rs187238 G C 259 184 35 284 183 34 0.442 0.734 0.750 0.447
IL-18 11 111540717 rs1946519 A C 79 234 165 87 239 175 0.924 0.410 0.412 0.924
IL18BP 11 71386920 rs3814721 T 424C 52 2 441 58 2 0.759 0.941 0.938 0.760
IL18R1 2 102436918 rs11465567 A G 395 79 4 391 103 6 0.081 0.909 0.885 0.081
IL18R1 2 102438142 rs9308857 T C 74 207 197 73 238 190 0.587 0.371 0.383 0.593
IL18R1 2 102438741 rs11465572 T G 4 79 394 6 104 391 0.075 0.091 0.116 0.074
IL18R1 2 102439495 rs11465576 T C 420 0.939 56 2 442 57 2 0.863 0.937 0.863
IL18R1 2 102443202 rs1558627 A G 276 165 37 293 183 25 0.366 0.750 0.767 0.373
IL18R1 2 102445731 rs11465597 T C 389 85 4 394 100 7 0.235 0.903 0.886 0.236
IL18R1 2 102445879 rs7579737 A G 239 192 47 253 203 45 0.744 0.701 0.708 0.747
IL18R1 2 102445977 rs6543124 A T 72 204 201 67 244 189 0.546 0.365 0.378 0.549
2 102448203 rs11465608 G C 476 2 0 498 3 0 0.693 0.998 0.997 0.692
IL18R1 2 102451324 rs7558013 T G 22 169 287 18 143 340 0.015 0.223 0.179 0.015
IL18R1 2 102461783 rs2241116 T G 32 139 306 21 156 324 0.406 0.213 0.198 0.423
IL18R1 2 102464905 rs4851570 T C 257 167 54 268 195 38 0.396 0.712 0.730 0.415
IL18R1 2 102471420 rs1420095 A G 396 80 2 427 73 1 0.292 0.912 0.925 0.280
IL18RAP 2 102493267 rs4851581 A G 389 86 2 426 73 2 0.166 0.906 0.923 0.158
IL18RAP 2 102493637 rs1420105 A G 153 209 116 127 253 121 0.147 0.539 0.506 0.158
IL18RAP 2 102493893 rs11465673 T C 403 72 3 406 90 5 0.161 0.918 0.900 0.161
IL18RAP 2 102494407 rs2293225 A G 32 139 306 21 156 324 0.406 0.213 0.198 0.423
IL18RAP 2 102495520 rs1420100 A C 116 209 153 121 253 127 0.147 0.461 0.494 0.158
IL18RAP 2 102497045 rs3755268 C G 275 166 37 290 185 26 0.454 0.749 0.763 0.460
IL18RAP 2 102498391 rs2272127 G C 18 114 346 26 165 310 0.0007 0.157 0.217 0.001
IL18RAP 2 102499463 rs887972 A G 59 182 236 45 199 257 0.209 0.314 0.288 0.226
IL18RAP 2 102512967 rs2058660 A G 268 172 36 292 183 26 0.263 0.744 0.765 0.268
IL18RAP 2 102516410 rs11465702 A G 367 99 11 346 138 17 0.005 0.873 0.828 0.007
IL18RAP 2 102520693 rs6748390 T C 236 194 48 263 196 42 0.244 0.697 0.721 0.253
IL18RAP 2 102520924 rs6543135 A G 22 169 286 19 142 340 0.016 0.223 0.180 0.017
IL18RAP 2 102522038 rs11465723 T C 11 99 367 17 138 346 0.005 0.127 0.172 0.007
IL18RAP 2 102522373 rs11465724 A G 0 31 447 0 28 473 0.562 0.032 0.028 0.556
IL18RAP 2 102526341 rs11465732 A G 5 61 412 5 61 435 0.771 0.074 0.071 0.779
IL-18 
IL18R1 
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 Table 8.1 (continued) 
 
    
Allele 
code Case Control 
Geno
type-
wise 
Allele 1 
Frequency 
Allele
-wise
Gene Chr Coordinate SNP 1 2 11 12 22 11 12 22 pval case control pval
IL12A 3 161192353 rs2243123 T C 232 217 29 255 211 35 0.723 0.712 0.720 0.713
IL12A 3 161193092 rs583911 T C 146 245 87 151 258 92 0.900 0.562 0.559 0.897
IL12A 3 161196548 rs640039 A G 364 107 7 359 129 13 0.074 0.873 0.845 0.075
IL12A 3 161198088 rs2243147 A G 167 240 71 189 235 77 0.607 0.600 0.612 0.604
IL12A 3 161198944 rs2243154 A G 7 81 390 5 78 418 0.380 0.099 0.088 0.390
IL12B 5 158674592 rs1368439 A C 330 130 18 358 128 15 0.342 0.826 0.842 0.353
IL12B 5 158675981 rs2853697 T G 329 134 14 347 136 18 0.914 0.830 0.828 0.915
IL12B 5 158676366 rs3213119 A C 0 24 454 0 28 473 0.696 0.025 0.028 0.692
IL12B 5 158680142 rs919766 T G 381 90 7 388 102 11 0.302 0.891 0.876 0.313
IL12B 5 158681666 rs2853694 A C 113 248 117 144 258 99 0.030 0.496 0.545 0.027
IL12B 5 158682907 rs3213096 T C 0 6 472 0 9 492 0.492 0.006 0.009 0.491
IL12B 5 158683347 rs3213094 T C 22 162 294 29 188 284 0.115 0.215 0.246 0.114
IL12B 5 158683571 rs2569253 A G 121 237 119 152 233 116 0.134 0.502 0.536 0.142
IL12B 5 158684724 rs3181218 T C 22 162 294 29 187 284 0.121 0.215 0.245 0.120
IL12B 5 158685556 rs3181216 A T 44 228 206 41 209 250 0.059 0.331 0.291 0.053
IL12B 5 158687708 rs3212217 G C 294 161 22 284 188 29 0.108 0.785 0.754 0.107
 
 
 
8.3.1.3. Genomic control analysis 
The results of genomic control analysis are describe in section 7.3.3. 
8.3.2.  Exploratory Analysis 
8.3.2.1. Haplotype analysis 
Several related haplotypes in a large haplotype block are associated with schizophrenia 
(see Table 8.2 for extended haplotype). The rs7558013-rs1420100 haplotype was the best 
predictor of schizophrenia (global p-value = 0.0003, Table 8.3).  Of these, rs7558013 was 
significantly associated with schizophrenia; rs1420100 was in tight LD, but was not highly 
correlated with rs7558013 (D’ = 1.0, r2 = 0.27, see Table 8.1 and Appendix A, Figures A5-A8).  
All other associated SNPs in L18R1-IL18RAP region are in tight LD with the rs7558013-
rs1420100 haplotype and do not significantly predict schizophrenia when controlling for these 
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 markers.  At the rs7558013 –rs1420100 haplotype the frequency of the (T-A) haplotype is 4.4% 
higher in cases where the (T-C) haplotype is 7.7% higher in controls.  The third (G-C) haplotype 
is 3.2 % higher in cases (see Table 8.3).  Stepwise logistic regression identified a combination of 
three markers in IL12A that was associated with schizophrenia (rs583911, rs640039, and 
rs2243147).  From ‘Cocaphase’, the global p-value associated with this haplotype was 0.015 
(Table 8.4).  There were no haplotypes in IL-18, IL12B, or IL18BP that were significantly 
associated with schizophrenia.    
 
Table 8.2 Extended Haplotypes associated with schizophrenia in IL18R1-IL18RAP. 
 
rs11465567 rs9308857 rs7558013 rs1420105 rs2293225 rs1420100 
1 2 3 4 5 6 
rs2272127 rs2058660 rs11465702 rs22465723 rs6543135 
7 8 9 10 11 
 
Haplotype Case freq Control freq OR chisq p 
1-1-1-2-2-1-2-1-1-2-1 208.4 0.218 170.9 0.171 1.28 6.98 0.008 
1-1-2-2-2-1-1-1-2-1-2 118.4 0.124 168.5 0.168 0.74 7.69 0.006 
1-1-2-2-2-1-2-1-1-2-2 18.6 0.019 29.6 0.029 0.66 1.93 0.165 
1-2-2-1-1-2-2-1-1-2-2 196.8 0.206 194.5 0.194 1.06 0.41 0.520 
1-2-2-1-2-2-2-1-1-2-2 72.5 0.076 73.8 0.074 1.03 0.03 0.853 
1-2-2-1-2-2-2-2-1-2-2 237.5 0.248 230.4 0.230 1.08 0.91 0.341 
2-2-2-2-2-1-1-1-1-2-2 19.4 0.020 34.7 0.035 0.59 3.74 0.053 
2-2-2-2-2-1-2-1-1-2-2 61.4 0.064 67.7 0.068 0.95 0.11 0.742 
 
Likelihood ratio test: null = -3335.44, alternative = -3326.03,  
LRS = 18.82, DF = 7, p = 0.0088         
 
Table 8.3:  Most Significantly Associated Two-Marker Haplotype in IL18R1-IL18RAP. 
 
1 2 
7558013 1420100 
 
Haplotype Case freq Control freq OR chisq p 
1-1 213 0.223 179 0.179 1.25 5.96 0.0146 
2-1 228 0.239 316 0.315 0.76 14.46 0.0001 
2-2 515 0.539 507 0.506 1.06 2.10 0.1474 
 
Likelihood ratio test: null = -1591.74 alternative = -1583.62,  
LRS = 16.23 DF = 2 p = 0.0003 
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Table 8.4: Three Marker Associated Haplotype in IL12A 
 
583911 640039 2243147 
1 2 3 
 
Haplotype Case freq Control freq OR chisq p 
1-1-1 34 0.036 16 0.016 2.23 7.694 0.006 
1-2-1 121 0.127 155 0.155 0.82 3.204 0.073 
2-1-1 419 0.438 442 0.441 0.99 0.016 0.900 
1-1-2 382 0.400 389 0.388 1.03 0.264 0.607 
 
Likelihood ratio test: null = -1713.41, alternative = -1708.2,  
LRS = 10.4241, DF =  3, p = 0.0152849 
 
 
8.3.2.2.  Interaction analysis 
MDR was used as a hypothesis free test of gene-gene interactions.  MDR analysis 
confirmed that the rs7558013-rs1420100 haplotype is the best two-marker predictor of 
schizophrenia risk (p=0.005 after 1000 permutations).  MDR also suggests that rs360722 in IL-
18 may interact with the rs7558013-rs142100 haplotype (p=0.04 after 1000 permutations)(Figure 
8.1).  Chi-square analysis of expected frequencies compared to observed three-marker 
combinations estimated by ‘Cocaphase’ confirms that the rs7558013-rs142100 haplotype and 
rs360722 do not segregate independently in cases or controls (p=0.04, Table 8.5). The model of 
interaction is not simple; the rs360722 (2) allele preferentially segregates to cases in the presence 
of the rs7558013-rs1420100 (G-C) or (T-C) haplotype, but it distributes as expected in 
combination with the risk (T-A) haplotype (Table 8.5). 
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IL18R1-RAP genotypes at rs7558013 and rs1420100 are indicated by column headings 
and IL18 rs360722 genotypes are indicated by row headings.  In each cell case counts are 
represented in the left bar and control counts in the right bar.  Cells where the case count is equal 
or greater than the control count are highlighted in dark gray.  The empiric p-value for model 
from 1000 MDR permutations is 0.04. 
 
Figure 8.1:  MDR Analysis of rs7558013-rs1420100-rs360722 interaction. 
 
 
 
Table 8.5:  Chi-test for IL18R1-IL18RAP, IL-18 gene-gene interaction . 
 
  rs7558013-rs1420100 haplotype 
  observed TA TC GC 
Case 360722-T 24.8 37.1 50.1 
 360722-C 188.2 190.9 464.9 
Control 360722-T 17.2 41.1 85.7 
 360722-C 161.8 274.9 421.3 
     
 expected 11 12 22 
Case 360722-T 24.9 26.7 60.3 
 360722-C 188.1 201.2 454.7 
Control 360722-T 25.8 45.5 73.0 
 360722-C 153.2 270.5 434.0 
 
Chi-square analysis was performed to evaluate the significance of interaction after taking into 
account main effects of the IL18R1-IL18RAP haplotype and rs360722.  The ‘observed’ table 
shows frequencies of observed 3 marker haplotypes estimated by ‘Cocaphase’.  The ‘expected’ 
table shows expected frequencies given genotype and haplotype frequency differences between 
cases and controls.  Chi-square for interaction = 13.4, 6 DF, p = 0.04.
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8.3.2.3. Evaluation of gene-environment interaction 
Among cases with serological data we compared allele frequencies SNPs in subsets 
defined by infectious disease serum antibody titer.  Significant associations with HSV1 antibody 
titer and putative gene-environment interaction were seen at three correlated SNPs in IL18RAP 
(rs11465702, p = 0.006; rs11465723, p = 0.006; rs2272127 p = 0.04), each of which were also 
associated with schizophrenia (see Table 8.6).  HSV2 antibody titer status was associated with 
rs2043055 in IL-18, rs3814721 in IL18BP, and rs9308857, rs11465597, and 6543124 in 
IL18RAP.  There are similar trends for HSV2 and HSV1 antibody status at rs11465702, 
rs11465723, rs2272127, rs6543124, and rs9308857 suggesting that effects may not be specific 
(Table 8.6).  CMV antibody titer status was associated with rs11465576 in IL18R1.
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Table 8.6.  Associaitons of IL-18 Pathway Genes with Viral Antibody Status in 
Schizophrenia Cases. 
 
Gene SNP HSV1+ a HSV1- a pval b CMV+ a CMV- a pvalb HSV2+ a HSV2- a pvalb 
IL-18 rs3882891 0.589 0.585 0.924 0.580 0.589 0.821 0.625 0.578 0.357 
IL-18 rs5744280 0.332 0.330 0.945 0.315 0.342 0.461 0.393 0.321 0.129 
IL-18 rs549908 0.703 0.696 0.847 0.702 0.699 0.944 0.714 0.697 0.718 
IL-18 rs1834481 0.256 0.250 0.849 0.256 0.247 0.786 0.223 0.255 0.482 
IL-18 rs5744247 0.089 0.103 0.516 0.109 0.093 0.494 0.080 0.102 0.478 
IL-18 rs360722 0.114 0.111 0.898 0.122 0.110 0.654 0.089 0.119 0.367 
IL-18 rs2043055 0.623 0.629 0.877 0.634 0.619 0.680 0.545 0.639 0.049 
IL-18 rs187238 0.753 0.735 0.579 0.752 0.740 0.738 0.777 0.738 0.397 
IL-18 rs1946519 0.383 0.415 0.381 0.399 0.403 0.929 0.348 0.412 0.206 
IL18BP rs3814721 0.934 0.943 0.597 0.954 0.931 0.237 0.982 0.930 0.039 
IL18R1 rs11465567 0.902 0.918 0.471 0.916 0.905 0.627 0.946 0.901 0.130 
IL18R1 rs9308857 0.396 0.345 0.181 0.353 0.381 0.477 0.455 0.355 0.050 
IL18R1 rs11465572 0.099 0.082 0.455 0.085 0.095 0.650 0.054 0.099 0.128 
IL18R1 rs11465576 0.924 0.938 0.464 0.903 0.948 0.027 0.938 0.932 0.832 
IL18R1 rs1558627 0.769 0.753 0.619 0.735 0.777 0.227 0.750 0.765 0.732 
IL18R1 rs11465597 0.899 0.907 0.703 0.903 0.900 0.901 0.955 0.891 0.036 
IL18R1 rs7579737 0.693 0.711 0.607 0.718 0.690 0.454 0.723 0.696 0.568 
IL18R1 rs6543124 0.392 0.337 0.137 0.349 0.374 0.521 0.464 0.346 0.020 
IL18R1 rs11465608 0.997 0.997 0.884 0.996 0.998 0.632 1.000 0.997 0.536 
IL18R1 rs7558013 0.228 0.219 0.776 0.214 0.232 0.595 0.277 0.216 0.149 
IL18R1 rs2241116 0.191 0.250 0.083 0.185 0.241 0.112 0.179 0.230 0.259 
IL18R1 rs4851570 0.725 0.673 0.165 0.702 0.697 0.905 0.759 0.687 0.157 
IL18R1 rs1420095 0.934 0.907 0.191 0.941 0.905 0.089 0.884 0.923 0.153 
IL18RAP rs4851581 0.921 0.904 0.422 0.936 0.896 0.069 0.873 0.917 0.127 
IL18RAP rs1420105 0.506 0.575 0.084 0.563 0.526 0.374 0.491 0.548 0.294 
IL18RAP rs11465673 0.918 0.920 0.909 0.916 0.918 0.936 0.955 0.910 0.113 
IL18RAP rs2293225 0.193 0.249 0.101 0.185 0.241 0.112 0.179 0.230 0.259 
IL18RAP rs1420100 0.494 0.425 0.084 0.437 0.474 0.374 0.509 0.452 0.294 
IL18RAP rs3755268 0.769 0.753 0.619 0.735 0.777 0.227 0.750 0.765 0.732 
IL18RAP rs2272127 0.185 0.126 0.041 0.139 0.158 0.521 0.188 0.145 0.270 
IL18RAP rs887972 0.291 0.352 0.103 0.319 0.324 0.907 0.268 0.333 0.202 
IL18RAP rs2058660 0.766 0.740 0.422 0.727 0.769 0.222 0.750 0.755 0.907 
IL18RAP rs11465702 0.832 0.904 0.006 0.874 0.870 0.875 0.821 0.881 0.100 
IL18RAP rs6748390 0.690 0.704 0.700 0.702 0.688 0.723 0.679 0.696 0.728 
IL18RAP rs6543135 0.231 0.218 0.665 0.218 0.230 0.714 0.277 0.217 0.154 
IL18RAP rs11465723 0.168 0.096 0.006 0.126 0.130 0.875 0.179 0.119 0.100 
IL18RAP rs11465724 0.041 0.034 0.586 0.038 0.039 0.939 0.027 0.041 0.471 
IL18RAP rs11465732 0.082 0.077 0.818 0.113 0.061 0.020 0.063 0.082 0.513 
 
a-  See Table 8.1 for Allele coding.  Frequencies for Allele 1 are shown. 
b-  Genotypewise p-values. 
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 Table 8.6 (continued) 
 
Gene SNP HSV1+ a HSV1- a pval b CMV+ a CMV- a pvalb HSV2+ a HSV2- a pvalb
IL12A rs2243123 0.706 0.704 0.949 0.702 0.712 0.761 0.723 0.706 0.694
IL12A rs583911 0.547 0.580 0.372 0.571 0.554 0.651 0.554 0.561 0.877
IL12A rs640039 0.886 0.874 0.616 0.891 0.872 0.478 0.911 0.872 0.255
IL12A rs2243147 0.611 0.582 0.442 0.567 0.617 0.201 0.598 0.600 0.966
IL12A rs2243154 0.098 0.103 0.835 0.122 0.093 0.258 0.089 0.105 0.623
IL12B rs1368439 0.845 0.827 0.545 0.811 0.848 0.220 0.875 0.828 0.237
IL12B rs2853697 0.816 0.830 0.642 0.861 0.805 0.065 0.786 0.832 0.243
IL12B rs3213119 0.032 0.021 0.350 0.017 0.030 0.279 0.009 0.029 0.215
IL12B rs919766 0.880 0.894 0.551 0.887 0.885 0.961 0.902 0.883 0.567
IL12B rs2853694 0.500 0.497 0.945 0.466 0.522 0.157 0.500 0.503 0.946
0.003 0.008 0.421 0.013 0.004 0.216 0.000 0.009 0.326
IL12B rs3213094 0.196 0.216 0.489 0.206 0.212 0.840 0.188 0.214 0.503
IL12B rs2569253 0.472 0.505 0.379 0.517 0.483 0.396 0.411 0.510 0.056
IL12B rs3181218 0.196 0.216 0.489 0.206 0.212 0.840 0.188 0.214 0.503
0.345 0.330 0.669 0.345 0.327 0.632 0.375 0.325 0.293
IL12B rs3212217 0.804 0.785 0.521 0.794 0.789 0.872 0.813 0.787 0.519
IL12B rs3213096 
IL12B rs3181216 
a-  See Table 8.1 for Allele coding.  Frequencies for Allele 1 are shown. 
b-  Genotypewise p-values. 
 
 
 
 
8.4  DISCUSSION 
Many previous studies of candidate genes for immune dysfunction in schizophrenia have focused 
on candidate genes derived from serological studies.  Prompted by more successful positional 
candidate gene studies we investigated schizophrenia linkage regions for candidate genes that 
could contribute to immune dysfunction (Norton et al., 2006).  We found it remarkable that many 
of the genes most closely related to IL-18 function localized to prominent schizophrenia linkage 
regions.  Our analysis of six IL-18 pathway genes in schizophrenia revealed rs2272127 allele ‘C’ 
in IL18RAP to be significantly associated with schizophrenia after empirically correcting for 
multiple comparisons and population stratification. 
Further analysis revealed that several haplotypes in the same haplotype block as 
rs2272127 were associated with schizophrenia.  The association was clearest in this sample when 
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 evaluating the rs7558013-rs1420100 haplotype, which spans IL18R1 and IL18RAP.  Hapmap 
data indicates that in Caucasian populations there is extensive LD in this region that extends well 
beyond the IL18R1 and IL18RAP genes.  Other genes in the region of extensive LD include 
several interleukin 1 receptor-like genes and sodium/hydrogen solute carrier family genes.  Due 
to the extensive LD, we cannot rule out the possibility of other risk polymorphisms in these 
genes. 
Exploratory analysis suggests the rs7558013-rs1420100 haplotype may interact with 
rs360722 in intron 1 of IL-18.  We were unable to identify alleles with known functional 
relevance of any of these SNPs, so the biological implication of both single SNP and gene-gene 
interaction effects is not clear.  Further investigation of this interaction in additional samples 
would be advisable. 
We found that rs22721217 allele ‘T’ and other SNPs in the same haplotype block were 
associated with HSV1 seropositivity.  Case-only analysis of gene-environment interaction shows 
a significant interaction between HSV1 and rs2272127 in schizophrenia, but this assumes that 
there is no association between these alleles and HSV1 serology in controls.  Prior studies 
indicate that IL-18 is involved in the immune response to HSV1 (Fujioka et al., 1999; Lee et al., 
2003; Zhu et al., 2003), so it is possible that the assumption of gene-environment independence 
is false.  However, the association of a schizophrenia risk allele with HSV1 is important 
regardless of the presence of association in control individuals.  If the same allele is associated 
with HSV1 seroposivity in controls and in cases there may not be a significant statistical 
interaction effect, but the main effects of IL18R1-IL18RAP alleles on HSV1 would be an 
important factor in modeling schizophrenia risk. 
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 It is intriguing that the allele associated with lower HSV1 antibody titers, with a similar 
trend for HSV2 antibody titers, is also associated with schizophrenia.  Could an immune 
response responsible for controlling primary HSV infection or reactivation from latency also 
play a role in schizophrenia pathogenesis?  If serum HSV antibody titer is associated with 
genetic variations, how good of a measure is it of HSV exposure?  We are currently investigating 
additional case and control groups to evaluate these possibilities. 
Our findings should be investigated in other samples.  Haplotype patterns may not be 
identical in additional populations of different ethnicities; therefore, replicate studies in non-
Caucasian populations may need to investigate multiple SNPs to identify associated haplotypes.  
If replicated, these findings could lead to greater understanding of the immune imbalance that is 
observed in schizophrenia patients, and may establish a link between genetic and environmental 
factors influencing schizophrenia risk. 
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9. SUMMARY AND CONCLUSIONS: MODELS OF GENE-ENVIRONMENT 
INTERACTION IN SCHIZOPHRENIA 
 
Our studies were designed to address the hypothesis that immune-related positional candidate 
genes interact with common infectious agents to influence schizophrenia risk.  We evaluated the 
possibility of gene-virus interaction at 11 loci, namely:  TNF, MICB and contiguous genes, IL10, 
IL1β, IL1RN, IL-18, IL-18BP, IL-18R1, IL-18RAP, IL12A, and IL12B.  We also evaluated these 
genes for associations with schizophrenia.  We found evidence for associations of individual 
SNPs with schizophrenia at MICB and IL-181-IL18RAP.   We also identified a significant 
association with schizophrenia at IL1β upon meta-analysis of our data with other published 
studies.  We found some evidence for interaction of SNPs in MICB with HSV1 and CMV and 
SNPs in IL-18RAP with HSV1 and possibly HSV2.  Detailed discussion of these specific 
findings is available in chapters 5-8. 
This section will address difficulties and concerns about the implementation of this study 
as well as unique strengths of this project.  This will be followed by a discussion of models of 
gene-infection interaction and future experiments suggested by our results that may help to 
clarify these models 
 
9.1.  DIFFICULTIES AND CONCERNS 
Despite widespread acknowledgement of the potential importance of gene-environment 
interaction, there is a paucity of genetic association studies that incorporate evaluation of 
environmental interactions (Clark et al., 2005).  Some of the reasons that similar studies have not 
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 previously been performed are challenges inherent in investigating gene-infection interactions 
identified in section 1.6.  Though we have attempted to address these concerns, our studies have 
not been free from difficulties.  Our studies have highlighted several expected and unexpected 
difficulties; these include:  1) Difficulties evaluating exposure to infectious agents of interest, 2) 
Difficulties obtaining appropriate control samples, and 3) non-independence of genetic and 
environmental factors. 
 
9.1.1. Difficulties in Measuring Infection 
Common difficulties in measuring infectious disease involvement in schizophrenia were 
addressed in section 3.1.  In the study of schizophrenia these concerns revolve around the 
possible delay between infectious disease exposure and onset of psychiatric symptoms.  One 
reason our studies focused on herpes viruses, which cause latent infections, is that periodic 
reactivation of latent viruses can cause long term elevation in antibody titers. 
Our studies revealed another potential concern about antibody measurements as markers 
of infectious disease exposure.  We found several genetic variants were associated with viral 
antibody status.  Significant genetic variability in measures of infectious status indicates a 
potential form of bias in the categorization of exposed and unexposed individuals if these genetic 
markers are unevenly distributed between compared groups.  To further complicate matters, 
several of the alleles we found to be associated with viral antibody status were also associated 
with schizophrenia.  Our findings at MICB and IL18R1-IL18RAP suggest that schizophrenia 
samples may be enriched for variants that are associated with lower herpes virus antibody titers.  
If this is the case, previous studies investigating the association of herpes viruses with 
schizophrenia using antibody titers as markers of infection could be skewed.  Observed infection 
 112
 rates as measured by antibody titer may be underestimated in schizophrenia samples.  This 
concern about antibody titer as a marker of exposure to CMV, HSV1, and HSV2 may not be 
resolved until genetic variability in virus specific antibody production is understood, and 
researchers can correct for these biases in their investigations of potential viral risk factors. 
 
9.1.2. Difficulties Obtaining Control Samples 
Another issue that has repeatedly come up in our studies is the difficulty in obtaining appropriate 
control samples for the investigation of gene-virus interactions in schizophrenia.  An ideal 
control sample would be one that has been recruited in a similar manner from a similar area and 
characterized in similar manner as the case sample.  This would hopefully yield a sample that is 
well matched in terms of age, ethnicity, sex, socioeconomic status, and genetic background.  
Avoiding both genetic and environmental bias, the non-random assortment of a trait, other than 
the trait of interest, in case and control samples, is a major concern.  Population stratification is a 
form of genetic bias.  Concerns about population stratification have lead our group and many 
others analyze populations with separate ethnic ancestry separately, as it has been documented 
that disparate proportions of case and control samples from varying ethnic groups can lead to 
spurious associations due to population stratification (Devlin et al., 2001).  Similar issues arise in 
case-control studies of infectious agents. A number of factors, including age, gender, location of 
residence, and socio-economic status are known to be associated with infectious disease 
exposure.  These could lead to segregation artifacts in case-control studies.  Since the 
development of the transmission disequilibrium test (TDT)(Spielman et al., 1993a) family based 
tests of genetic linkage and association in case-parent trios have become popular, as they are 
robust to population stratification (Cardon et al., 2003).  We used a Caucasian case-parent trio 
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 sample to identify and confirm schizophrenia risk at MICB.  Although trio samples are useful for 
genetic association studies, they are not ideal for studies of gene-environment interaction 
because of familial correlation of many environmental factors.  New methods are being 
developed to evaluate gene-environment interaction in family samples, but these often require 
assumptions of gene-environment independence (Cordell et al., 2004; Umbach et al., 2000)(See 
section 4.4.6.2).  So, trio samples cannot replace case-control samples for analysis interaction 
between genes and viral infection. 
The only matched case-control sample with both DNA and serum available that we have 
had access to is the Baltimore schizophrenia case-control sample used in the study of MICB.  
This contains a well-categorized sample of 108 Caucasian control individuals.  Despite the 
quality of this sample the small size leads to concerns about power (Only 19 Baltimore controls 
are CMV seropositive).  For several genetic studies we have used DNA from the cord blood of 
unscreened neonates as a control sample.  The genetic background of neonatal control samples 
collected in a specific region will theoretically be the similar to that of the general population in 
that region if there is not substantial immigration, selection, or selective breeding.  Genomic 
control analysis of the Pittsburgh case-control sample confirms that the neonatal control sample 
is similar in genetic background to the cases at non-disease loci 
For a period of time we had considered using the MHIRC samples discussed in section 
5.2 as ‘non-schizophrenia controls.’  The MHIRC samples are a collection of samples from 
patients gathered at the outpatient clinics of Western Psychiatric Institute and Clinic.  Some 
patients with psychosis and those with a diagnosis of schizophrenia were generally excluded 
from the sample, but the sample still has a substantial portion of individuals diagnosed with 
major depression or bipolar disorder that have a history of psychosis.  Furthermore, about one 
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 third of the sample has a diagnosis of bipolar disorder (see Table 4.1), which may have 
overlapping genetic etiology with schizophrenia (Cardno et al., 2002).  Major depression, is the 
other major diagnostic group represented in the MHIRC sample.  Unfortunately, putative 
infectious risk factors for both bipolar disorder and depression are similar to those for 
schizophrenia (Hinze-Selch, 2002; Marques-Deak et al., 2005).  The MHIRC sample may 
eventually be an ideal sample to identify risk factors that are specific to schizophrenia and not 
related with other psychiatric diseases.  But, until greater understanding of general schizophrenia 
risk factors is achieved, this sample has less utility.  For these reasons we decided against large-
scale genotyping of the MHIRC sample at most loci. 
 
9.1.3. Non-Independence of Genetic and Environmental Factors 
Related to concerns about control selection are concerns about non-independence of 
genetic and environmental factors.  Owing to the lack of availability of a large, matched control 
sample we have resorted to using case-only analysis of gene-environment interaction for all 
genes except MICB.  Similarly, we considered using family based analysis of gene-environment 
interaction.  Both case-only and family based analyses of gene-environment interaction depend 
on the assumption that genetic and environmental risk factors are acquired independently (see 
section 4.4.6). 
It seems intuitive that inheritance of genes and infection with viruses are likely to be 
independent, because they happen through unrelated mechanisms.  However, evidence that 
serum antibody titer levels are correlated with genetic variants indicates that measures of 
infection and the presence genetic variants are certainly not independent, even if exposure to 
infection may be independent of genetic risk.  Moreover, genes involved in infectious disease 
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 response could modify transmission of disease from parents to offspring.  Correlation of 
infectious disease measures and genes is especially likely in this project because we used 
evidence that a gene is involved in controlling HSV and CMV as a selection criterion for 
candidate genes.   
The consequences of using case-only estimates of gene-environment interaction can be 
illustrated by comparing our findings at rs2272127 in IL-18RAP and rs1051788 in MICB.  As 
noted in the discussion of the IL-18 pathway chapter (section 5.5), case-only analysis limits the 
interpretation of the interaction noted at rs2272127 because gene-environment independence has 
not been established at this locus.  It is impossible to tell if the association we see represents 
interaction of HSV1 and rs2272127 in schizophrenia risk or separate genetic effects on HSV1 
and schizophrenia.  On the other hand, SNP rs1051788 is associated with HSV1 status in two 
non-schizophrenia samples, but it is not associated with HSV1 in two schizophrenia samples.  
This apparent interaction would not have been detected by case-only analysis because there is no 
association of rs1051788 with HSV1 in schizophrenia cases.  It is impossible to determine if 
other potential interactions were missed due to case-only analysis of correlated genetic and 
environmental factors. 
 
9.1.4.  A More Positive View: Unique Strengths 
These studies have attempted to overcome the difficulties inherent in studies of gene-
environment interaction.  Despite difficulties, we found preliminary evidence of gene-
environment interaction that appears to be consistent across multiple independent samples.  The 
importance of investigations of gene-environment interaction in schizophrenia has been 
reiterated for decades (Clark et al., 2005; Murray et al., 1986). Several reasons for the shortage 
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 of gene-environment investigations are listed in section 1.6.  Our studies were made possible by 
unique well-characterized samples collected with the foresight to obtain both serological and 
genetic data.  Our results highlight the need to design future studies of schizophrenia with the 
analysis of both serological and genetic data in mind.   
Our studies address a reasonable, testable hypothesis of schizophrenia pathogenesis.  In 
light of the controversy that surrounds previously reported genetic associations with 
schizophrenia (Shirts et al., 2004), our results should be considered preliminary.  Though these 
data are preliminary, they can be used to refine current models of schizophrenia.  A discussion 
gene-virus interaction models is presented in the next section. 
 
9.2.   DEVELOPING EVIDENCE BASED MODELS OF GENE-VIRUS INTERACTION 
IN SCHIZOPHRENIA 
The hypothesis investigated in this dissertation was that immune-related positional candidate 
genes interact with common infectious agents to influence schizophrenia risk.  We have found 
evidence that polymorphisms in two genes could interact with herpes viruses in schizophrenia 
risk.  Additional studies will be necessary to confirm these findings and explore the exact 
mechanism of interactions. 
For the remainder of this general discussion I will discuss how information from this 
project combined with published literature can be used to evaluate models of gene-virus 
interaction in schizophrenia pathogenesis.   The goal of this discussion is not to comprehensively 
evaluate the vast space of possible schizophrenia models, but to evaluate a few general models 
with the intention of suggesting a model that will facilitate future hypothesis driven research.  
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 Other models may also be consistent with this data, and other interpretations of these results may 
prove to be more consistent with future data. 
 
9.2.1.  A Statistical Model of Gene-Infection Interaction 
A simple model of general interaction is presented in Figure 9.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.1: General Model of Gene-Infection Interaction. 
 
 
Pathway 
Genes Infection
Schizophrenia
Immune 
 
In this figure, solid arrows represent interaction effects.  Dashed arrow lines represent 
marginal effects apparent because of the interaction effects. 
 
 
This general model represents statistical relationships.  There may also be main genetic 
and environmental effects in addition to interaction effects.  Marginal effects may only be 
apparent if the interaction is not modeled.  As we have seen there may also be associations 
between immune pathway genes and infection (not diagrammed in Figure 9.1).  This model does 
not represent biological mechanisms of infection and genes interacting or how this interaction 
may cause schizophrenia.   
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9.2.2. Evaluating models of gene-infection interaction 
Several biological models of interaction are shown in Figure 9.2. 
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Figure 9.2: Several Biological Models Explaining Gene-Infection Interaction in 
Schizophrenia Pathogenesis. 
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Models presented in Figure 9.2 show a feedback loop between infection and the immune 
response; infection stimulates immune responses, which act to control infection.  The 
relationship between infection, the immune response, and schizophrenia varies from model to 
model.  The first model is a model where immune imbalance and infection are not causal, but are 
secondary effects of schizophrenia or schizophrenia treatment.  Next, in the infections disease 
model infection is the main factor that contributes directly to schizophrenia risk and immune 
genes modify this risk by controlling the infection.  In the immune imbalance model imbalance 
of the immune system is the main factor that contributes directly to schizophrenia risk and 
infection modifies risk by activating immune pathways and triggering imbalance.  Finally, the 
autoimmune pathway is a specific case of the immune imbalance pathway where immune cells 
are activated to attack ‘self’ cells instead of infection; this response can be, but is not necessarily, 
triggered by infection.  The developmental timing of infection and genetic susceptibility in other 
non-related pathways could influence all of these models.  Evidence from published literature 
and from our studies supporting each model is presented below. 
 
9.2.2.1 The Secondary Immune Consequences Model 
In this model immune and infectious observations are secondary to schizophrenia.  For 
example: psychiatric hospitalization could cause increased infection rates, and observed immune 
system changes could be due to antipsychotic medications. 
Our studies and published literature do not support this model.  Recent onset 
schizophrenia patients have antibody titers to CMV that are significantly higher than controls 
and also higher than patients with chronic schizophrenia (Leweke et al., 2004).  Several studies 
cytokine studies have found imbalance in medicated schizophrenia patients (O'Donnell et al., 
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 1996; Sperner-Unterweger et al., 1999; Theodoropoulou et al., 2001), and others have found 
cytokine levels normalize with antipsychotic treatment (Kowalski et al., 2001; McAllister et al., 
1995; Zhang et al., 2004b). 
  Furthermore, our findings of gene-virus interaction are not consistent with this model, 
because specific genetic polymorphisms necessarily precede the onset of schizophrenia.  
Similarly, findings of immune gene associations with schizophrenia are not consistent with this 
model.  We found several instances of immune gene associations with schizophrenia and 
possible gene-virus interaction.  If our associations are replicated they will present a strong 
argument against the secondary immune consequences model. 
 
9.2.2.2. The infectious disease model 
Initially, proponents of the infectious disease hypothesis suggested specific infections are 
likely to be associated with schizophrenia, but newer versions of this hypothesis are consistent 
with multiple infections (Crow, 1983; Kirch, 1993).  The presence of general immune 
dysfunction does not rule out the infectious disease model, as immune dysfunction may be 
induced by viral infection (Schwarz et al., 2006).  Decades of schizophrenia investigations have 
failed to identify a specific infectious agent or groups of infectious agents that contribute a large 
portion to schizophrenia attributable risk (Koponen et al., 2004; Rantakallio et al., 1997).  
However, the inability to find evidence of an infection does not rule out this model if the timing 
or methods of detecting the infections agents are not ideal; there is also the possibility that the 
putative risk infection has yet to be discovered.  In support of this hypothesis, several infectious 
agents have been shown to be associated with schizophrenia risk especially if infection happens 
in the prenatal-neonatal time period (Brown, 2006).  
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  The infectious disease model is consistent with alleles that confer schizophrenia risk also 
being associated with an immune response that is more permissive to infection; if infection 
causes schizophrenia, then an immune response that allows the infection to propagate should be 
associated with schizophrenia as well.  On the other hand, the infectious disease model is not 
consistent with schizophrenia risk alleles being associated with a strong protective immune 
response to infection.  The schizophrenia associated alleles we see at MICB and IL-18 are also 
associated with lower HSV1 antibody levels, or HSV1 seronegativity.  These findings would be 
consistent with the infectious model of schizophrenia if these alleles are markers for a weaker 
antibody and more permissive immune response to HSV1. 
 
9.2.2.3. The immune imbalance model 
In the immune imbalance model dysfunction in the immune system causes schizophrenia 
risk.  These immune processes could be initiated or exacerbated by infectious disease.  The 
immune pathways are often stimulated by various infections, but this hypothesis could also be 
consistent with one or a few specific infections if the pathway is only activated in response to a 
few types of infection.  The immune imbalance pathway is consistent with findings of general 
immune dysfunction and little evidence of active infection.  Studies of immune dysfunction in 
schizophrenia routinely use active infection as an exclusion criterion, but few of have evaluated 
antibody titers to specific infections agents.  The presence of immune imbalance with no 
evidence of concurrent infection, as well as the recent identification of genetic polymorphisms 
that may contribute to this imbalance suggests that immune-imbalance in itself may be the main 
cause of schizophrenia (Schwarz et al., 2006).  There is growing evidence for cytokine 
imbalance in schizophrenia, which is the primary evidence for the immune imbalance model (see 
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 section 1.3).  Unfortunately, because cytokines are involved in complex interconnected immune 
networks it may be difficult to identify the root causes of immune imbalance.  Genetics presents 
one method of parsing cause from effect. 
 In contrast to the infectious disease model, the immune imbalance model is most 
consistent with schizophrenia associated alleles also being associated with a strong protective 
immune response to infection; the strong immune response would prevent or quickly neutralize 
infection, but would also cause increased schizophrenia risk.  This balancing mechanism would 
explain the persistence of schizophrenia risk alleles through evolutionary time.  The 
schizophrenia associated alleles we see at MICB and IL-18 are also associated with lower HSV1 
antibody levels.  These findings would be consistent with the immune imbalance model of 
schizophrenia if observed lower HSV1 antibody titers are caused indirectly by a robust innate 
immune response to HSV1.  A robust innate immune response may prevent HSV1 infection from 
establishing latency or reactivation from latently infected cells allowing antibody levels to drop 
below threshold for seropositivity. 
 
9.2.2.4. The autoimmune model 
The autoimmune model is a specific case of the immune imbalance model.  Autoimmune 
disease happens when an immune response is mounted when an adaptive immune response is 
mounted against self-antigen (Janeway et al., 2005).  As in the immune imbalance model, 
autoimmune processes can be initiated or exacerbated by infectious disease (Obermayer-Straub 
et al., 2001; Thacker et al., 2006).  The accepted hypothesis is that an infectious agent with an 
antigen similar to a self-antigen may initially stimulate T-cells, which can then kept active as 
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 they attack self-antigens.  This hypothesis is most consistent with involvement of one or a few 
specific infections.  
Several lines of evidence suggest that schizophrenia may be an autoimmune disease 
including high serum levels of autoantibodies, association with other autoimmune diseases, and 
possible associations of MHC haplotypes with schizophrenia (Ganguli et al., 1993; Jones et al., 
2005; Wright et al., 2001).  The Th2 predominance that is seen in schizophrenia is consistent 
with the stimulation of antibody producing cells (Gaughran, 2002).  Nevertheless, 
inconsistencies between studies investigating the autoimmune hypothesis of schizophrenia have 
been common, and several unanswered questions remain, such as: How do autoantibodies cross 
the blood brain barrier? Or, why are antigen-antibody complexes not detectable in the brain 
(Jones et al., 2005)? 
 The presence of gene-virus interaction could be consistent with autoimmune disease.  
Specific to our work, IL-18 has been associated with rheumatoid arthritis, autoimmune diabetes, 
and lupus nephritis (Calvani et al., 2005; Gracie et al., 2005; Novota et al., 2005).  If the MICB 
protein is involved in autoimmunity it is likely to do so in an indirect or non-traditional manner.  
MICB is known to activating natural killer T-cells (NKT cells) and NK cells, which can protect 
against autoimmune disease (Cardell, 2006; Liu et al., 2006).  MICB polymorphisms associated 
with schizophrenia that cause decreased or deficient activation of NK cells would be consistent 
with this hypothesis. 
 
9.2.3  Biological Pathways Suggested by Observed Associations 
We identified alleles of rs1051788 in MICB and rs2272127 in IL-18RAP that are associated with 
schizophrenia and are also associated with HSV1 antibody seronegativity.  It is intriguing that 
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 we found alleles associated with schizophrenia and lower HSV1 antibody titers in two 
independent genes.  The similarity between the patterns of association suggests the two genes 
may act via a common pathway.  As presented in section 5.2.4 MICB interacts through the 
NKG2D pathway, which activates NK and NKT cells to recognize and kill virus infected and 
tumor cells.  Interestingly, NK cell activation and IFN-gamma production via NKG2D 
mechanisms has been shown to be dependent on IL-18 stimulation (Andoniou et al., 2005; 
Ortaldo et al., 2006; Smyth et al., 2004).  Furthermore, NK cell cytotoxic activity to murine 
CMV infected cells is greatly enhanced by IL-18 (Andoniou et al., 2005).  This literature 
suggests a mechanism whereby alleles in MICB and IL-18 pathway genes could logically be 
associated with decreased HSV1 antibody titers.  If associated alleles in both IL-18RAP and 
MICB genes cause increased NK activation, activated NK could directly act to kill infected cells 
and prevent the spread of HSV1, resulting in less reactivation and lower antibody titers.  This 
mechanism leading to decreased HSV1 is consistent with the immune imbalance model of 
schizophrenia presented in section 9.2.3.3.  A more specific diagram of this model is shown in 
Figure 9.3. 
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Figure 9.3.  Specific Model of Immune Imbalance and Schizophrenia Risk. 
 
This model shows HSV1 infection because it was also found to be associated with 
schizophrenia risk alleles, but this model is consistent with a wide array of infections being 
involved in schizophrenia, as many infections could activate CNS NK cells. 
Published studies of NK cell activity in schizophrenia patients have shown mixed results, 
with some articles showing significantly higher NK cell activity (Theodoropoulou et al., 2001; 
Yovel et al., 2000), and others finding significantly lower (Vasil'eva et al., 2002) or unchanged 
NK cell activity (Caldwell et al., 1991; McDaniel et al., 1992; Mizruchin et al., 1999).  Each of 
these studies has been small and only a few have controlled for antipsychotic treatment and 
smoking, which are known to influence NK cell activity (Yovel et al., 2000; Zeidel et al., 2002). 
NK cell populations are heterogeneous (Peritt et al., 1998).  If NK cells are involved in 
schizophrenia pathogenesis it is possible that one of several recently identified specific subsets of 
NK cells is responsible.  For example: NK2 cells can be distinguished from NK1 cells by their 
expression of predominantly cytokines associated with a Th2 response(Peritt et al., 1998); 
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 cytokine imbalance findings in schizophrenia discussed in section 1.3 would be consistent with 
selective activation of this population of NK cells.  Another population of NK cells, adherent 
natural killer (A-NK) cells, are defined by their expression of a specific isoform of N-CAM, can 
be stimulated by IL-2, and are present in solid tissues more frequently than in circulation (Li et al 
journal of leukocyte biology 2004); activation of this subset of cells could be consistent with 
findings of elevated IL-2 and with N-CAM disregulation has been observed in schizophrenia 
(Vawter, 2000). 
Further research will be necessary to identify the mechanism by which NK cells could 
cause schizophrenia.  If replicated, the associations identified by this project could become a 
starting point for additional research.  
 
9.3 ONGOING AND PLANNED STUDIES TO FURTHER REFINE MODELS OF GENE-
VIRUS INTERACTION 
9.3.1.  Replicate Studies 
The importance of replicate studies in complex genetics cannot be understated.  The first goal of 
replicate studies is confirming or rejecting initial findings in additional samples.  In addition 
well-designed replicate studies can also refine estimates of the magnitude of risk and location of 
risk alleles.  We are in the process of investigating polymorphisms in MICB and IL-18RAP in a 
large schizophrenia trio sample collected in India.  This investigation was designed to confirm 
the presence of schizophrenia risk loci in these genes.  In addition a study of MICB and IL-
18RAP polymorphisms associated with HSV1 and CMV risk are being investigated in a sample 
of normal control individuals obtained from the United States military. 
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 9.3.2. Refining Associations 
With the exception of rs1051788 in MICB and perhaps rs16944 in IL1β, none of the alleles we 
found to be associated with schizophrenia has a known functional effect.  These alleles could be 
markers of schizophrenia risk that are in LD with functional variants.   There is extensive LD on 
chromosome 6p that spans for hundreds of kilobases, so SNP rs2523651 could be in LD with 
functional variants in MICB, MICA, or more distant genes.  Associated SNPs in the IL-18R1-
LI18RAP region are all part of an extended haplotype that covers almost 200kb, polymorphisms 
anywhere in this haplotype block could cause the functional changes involved in schizophrenia 
risk.  Further work will be necessary to identify functional variants.  If the genes are sufficiently 
covered, information from other populations with different LD structure may be useful in 
identifying functional variants. 
 
9.3.3. Functional Assays of Associated Polymorphisms 
Steinle et al (Steinle et al., 2001) showed how non-synonymous variations in MICA had different 
binding affinities for the NKG2D receptor, and thus activate NK cells to at different levels.  
Similar studies of non-synonymous polymorphisms in MICB would indicate whether 
schizophrenia associated alleles are those that cause more or less activation of NK cells.  
Understanding the nature of the MICB associations would clarify models of schizophrenia 
pathogenesis, and may help identify risk pathways for additional candidate genes. 
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 APPENDIX A: PAIRWISE LINKAGE DISEQUILIBRIUM AT EVALUATED GENES 
 
 
 
 
Figure A1:  Haploview Diagram of Pair-wise D’ Between Genotyped TNF SNPs 
 
 
Table A1: Calculated Pairwise r2 and D’ Values for TNF 
 
     r2     
  rs2844482 rs3093543 rs1799964 rs1800630 rs1799724 rs1800629 rs361525 rs1800610
 rs2844482 - 0.423 0.707 0.955 0.024 0.037 0.010 0.023 
 rs3093543 1.000 - 0.320 0.443 0.410 0.006 0.020 0.008 
 rs1799964 0.966 1.000 - 0.723 0.032 0.049 0.184 0.031 
D' rs1800630 1.000 1.000 1.000 - 0.023 0.036 0.009 0.022 
 rs1799724 1.000 0.971 1.000 1.000 - 0.023 0.006 0.956 
 rs1800629 1.000 0.641 1.000 1.000 1.000 - 0.009 0.022 
 rs361525 1.000 0.303 1.000 1.000 1.000 1.000 - 0.006 
 rs1800610 1.000 0.897 1.000 1.000 1.000 1.000 1.000 - 
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Figure A2: Haploview Diagram of Pairwise r2 of 100kb on Chromosome 6p Region 
Flanking D6S2672. 
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 Table A2:  Calculated Pairwise r2 and D’ Values for Chromosome 6p Region Flanking D6S2672. 
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rs2523685 - 0.40 0.32 0.22 0.23 0.37 0.30 0.34 0.28 0.15 0.49 0.44 0.07 0.51 0.05 0.09 0.20 0.08 0.73 0.04 1.00
rs2243621 0.09 - 0.19 0.18 0.06 0.24 0.15 0.15 1.00 0.26 0.36 0.49 0.27 0.41 0.41 0.09 0.60 0.05 0.06 0.34 1.00
rs2543674 0.07 0.01 
 0.00
- 0.24 
  
0.02 0.33 0.03 0.44 0.52 0.72 0.04 0.11 1.00 0.07 1.00 1.00 0.70 0.73 0.97 0.89 1.00
rs2596453 0.01  0.03 - 0.76 1.00 0.85 0.02 0.08 0.91 0.48 0.39 0.87 0.43 0.59 0.35 0.43 0.58 0.37 0.64 0.94
rs2244839 0.05 0.00 0.00 0.07 - 0.92 0.94 0.07 0.06 0.45 0.52 0.57 0.66 0.34 0.55 0.54 0.34 0.48 0.68 0.49 0.59
rs14597 0.04 0.01 0.04 0.20 0.26 - 0.96 0.04 0.18 0.03 0.05 0.07 0.48 0.18 0.26 0.40 0.31 0.66 0.56 0.48 1.00
rs1055569 0.07 0.01 0.00 0.11 0.72 0.35 - 0.02
- 
0.01 0.36 0.70 0.63 0.64 0.33 0.45 0.23 0.36 0.29 0.77 0.51 0.77
rs2248372 0.08 0.00 0.17 0.00 0.00 0.00 0.00 1.00
 
0.66 0.66 0.54 0.58 0.79 0.67 0.21 0.01 0.02 0.42 0.78 1.00
rs2248462 0.05 0.05 0.11 0.01 0.00 0.01
0.00
0.00 0.45 - 0.88
 
1.00 0.86 1.00
0.92
 1.00 0.58 0.31 0.01 0.83
0.55
0.38 0.75 1.00
rs2596536 0.01 0.03 0.18 0.15 0.15 0.11 0.14 0.11 - 0.91
 
0.98  0.70 0.93 0.77 0.46 0.16 0.58 1.00
rs2523651 0.05 0.02 
0.03 
0.00 0.12 0.06 0.00 0.14 0.12 0.12 0.27 - 0.92
 
0.84 0.83 0.69 0.31 0.25 0.36 0.09 0.48 0.92
rs2904776 0.04 0.01 0.08 0.08 0.00 0.12 0.08 0.09 0.31 0.85 - 0.94
 
 0.80 1.00 0.31
1.00
0.23 0.35
0.88
0.05 0.57 0.93
rs3094009 0.00 0.17 0.06 0.29 0.04 0.22 0.05
0.18
0.07 0.40 0.11 0.13 - 0.89
  
 0.91 1.00 0.69 0.74 1.00
rs2395038 0.05 0.02 0.01 0.10 0.03 0.01 0.03 0.13 0.16 0.68 0.63 0.12 - 1.00
08 - 
0.37 0.40 0.58 0.03 0.53 1.00
rs2242955 0.00 0.12 0.09 0.02 0.10 0.01 0.06 0.01 0.22 0.04 0.08 0.44 1.00 0.89 1.00 0.68 0.81 1.00
rs3131635 0.01 0.00 0.54 0.11 0.04 0.04
0.02
0.01 0.03 0.01 0.12 0.05 0.06 0.09 0.05 - 0.66 0.66 1.00 0.80 1.00
rs3130637 0.01 0.03 0.25 0.17 0.02 0.02 0.00 0.00 0.04 0.03 0.03 0.09 0.09 0.04 0.42 - 0.66 0.77 1.00 1.00
rs3130055 0.00 0.00 0.26 0.34 0.03 0.01 0.00 0.05 0.05
0.02
0.07 0.07 0.06 0.17 0.04 0.39 0.39 - 1.00 1.00 1.00
1.00rs2071594 0.11 0.00 0.28 0.02 0.10 0.23 0.16 0.05 0.02 0.01 0.00 0.07 0.00 0.04 0.16 0.09 0.14 - 1.00
rs2255798 0.00 0.08 0.07 0.02 0.09 0.03 0.08 0.05 0.02 0.09 0.02 0.03 0.32 0.02 0.62 0.03 0.05 0.04 0.08 - 1.00
r2 
rs3130062 0.02 0.01 0.10 0.19 0.01 0.04 0.02 0.03 0.01 0.04 0.09 0.10 0.02 0.11 0.01 0.19 0.18 0.21 0.03 0.01 - 
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Figure A3:  Haploview Diagram of Linkage Disequilibrium (D’) Between SNPs at IL10 .  
 
 
 
Table A3.  Linkage Disequilibrium Between Genotyped SNPs at IL10. 
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rs3024495 - 1 0.957 1 1 1 
rs3024492 0.054 - 1 1 1 1 
rs1518110 0.047 0.092 - 0.993 0.997 1 
rs3024491 0.213 0.378 0.24 - 1 1 
rs1800872 0.059 0.104 0.88 0.276 - 1 
r2 
rs1800894 0.006 0.012 0.011 0.045 0.013 - 
D’ and r2 were calculated using 979 combined cases and controls for all markers. 
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Figure A4:  Haploview Diagram of Linkage Disequilibrium (D’) Between SNPs in IL1β and IL1RN.
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 Table A4: Linkage Disequilibrium at IL1β and IL1RN. 
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rs3917365 - 1.00 1.00 1.00 1.00 0.49 0.57 0.58 0.44 0.13 0.22 0.90 0.51 0.66 0.22 0.10 0.06 1.00 0.16 0.54 0.51 0.42 0.35
rs2853550 0.92 - 1.00 1.00 0.86 0.53 0.60 0.61 0.40 0.13 0.19 0.92 0.43 0.72 0.20 0.11 0.05 1.00 0.17 0.54 0.52 0.41 0.32
rs1143634 0.03 0.03 - 1.00 0.83 0.89 0.51 0.50 0.16 0.56 0.07 0.62 0.56 0.44 0.08 0.52 0.16 0.30 0.54 0.14 0.15 0.51 0.10
rs1143633 0.05 0.06 0.17 - 0.77 0.90 0.91 0.92 0.10 0.17 0.28 0.39 0.54 0.25 0.26 0.15 0.05 0.13 0.08 0.16 0.09 0.61 0.16
rs3136558 0.02 0.02 0.65 0.09 - 0.75 0.77 0.76 0.18 0.67 0.01 0.53 0.48 0.56 0.02 0.63 0.15 1.00 0.65 0.14 0.15 0.58 0.11
rs3917356 0.02 0.02 0.19 0.56 0.13 - 1.00 1.00 0.03 0.22 0.34 0.58 0.64 0.27 0.33 0.21 0.09 0.16 0.14 0.11 0.02 0.62 0.03
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rs16944 0.06 0.07 0.04 0.26 0.09 0.44 0.99 - 0.17 0.40 0.29 0.57 0.20 0.39 0.27 0.37 0.21 0.29 0.33 0.34 0.24 0.54 0.17
rs4251961 0.03 0.03 0.01 0.00 0.02 0.00 0.01 0.01 - 1.00 1.00 1.00 0.97 0.97 0.98 0.99 0.99 1.00 0.99 0.97 0.92 0.90 0.86
rs4251974 0.00 0.00 0.03 0.01 0.04 0.02 0.11 0.11 0.21 - 1.00 0.96 1.00 0.86 0.98 0.98 1.00 1.00 0.98 0.94 0.70 1.00 0.96
rs2637988 0.00 0.00 0.00 0.03 0.00 0.06 0.07 0.07 0.36 0.57 - 0.97 0.99 0.83 0.97 0.94 0.99 0.92 0.86 0.09 0.08 0.94 0.95
rs315934 0.02 0.02 0.03 0.07 0.02 0.11 0.05 0.05 0.15 0.09 0.16 - 1.00 1.00 1.00 1.00 1.00 1.00 0.70 0.74 0.59 1.00 0.41
rs3087262 0.00 0.00 0.15 0.02 0.12 0.05 0.00 0.00 0.08 0.05 0.22 0.04 - 0.87 0.99 0.96 1.00 1.00 0.96 0.98 0.93 0.91 0.98
rs3087263 0.00 0.01 0.01 0.00 0.01 0.01 0.03 0.03 0.06 0.21 0.11 0.03 0.01 - 1.00 1.00 1.00 1.00 1.00 0.92 0.91 0.98 1.00
rs1794066 0.00 0.00 0.00 0.03 0.00 0.06 0.06 0.06 0.36 0.53 0.92 0.17 0.21 0.16 - 1.00 1.00 1.00 0.91 0.13 0.08 1.00 0.99
rs1794068 0.00 0.00 0.03 0.01 0.04 0.01 0.10 0.10 0.21 0.92 0.52 0.10 0.05 0.28 0.57 - 1.00 1.00 1.00 0.97 0.72 1.00 0.99
rs2232354 0.00 0.00 0.02 0.00 0.02 0.00 0.01 0.01 0.44 0.09 0.16 0.07 0.04 0.03 0.17 0.10 - 1.00 1.00 1.00 0.93 0.98 0.83
IL1RN(86bp) 0.00 0.00 0.01 0.00 0.11 0.01 0.08 0.08 0.20 0.95 0.42 0.10 0.08 0.29 0.48 1.00 0.10 - 1.00 0.75 0.56 1.00 1.00
rs451578 0.00 0.00 0.03 0.00 0.05 0.01 0.08 0.08 0.23 0.85 0.47 0.05 0.05 0.26 0.51 0.92 0.10 0.90 - 0.79 0.54 1.00 0.99
rs380092 0.01 0.01 0.01 0.02 0.01 0.01 0.03 0.03 0.26 0.15 0.00 0.31 0.28 0.04 0.01 0.17 0.12 0.11 0.12 - 0.88 1.00 0.85
rs315952 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.01 0.20 0.08 0.00 0.22 0.28 0.04 0.00 0.08 0.09 0.06 0.05 0.69 - 1.00 1.00
rs4252041 0.00 0.00 0.04 0.01 0.06 0.02 0.01 0.01 0.07 0.02 0.03 0.01 0.01 0.01 0.03 0.02 0.18 0.02 0.02 0.02 0.02 - 1.00
I
L
1
R
N
 
rs315949 0.02 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.65 0.22 0.38 0.03 0.09 0.07 0.42 0.24 0.27 0.22 0.26 0.23 0.28 0.07 - 
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Figure A5:  Haploview Diagram of Pairwise r2 Between Genotyped SNPs at IL-18 
 
Table A5: Linkage Disequilibrium at  IL-18. 
 
  D’ 
  r
s3
88
28
91
 
rs
57
44
28
0 
rs
54
99
08
 
rs
18
34
48
1 
rs
57
44
24
7 
rs
36
07
22
 
rs
20
43
05
5 
rs
18
72
38
 
rs
19
46
51
9 
rs3882891 - 1 0.997 1 1 1 0.783 1 0.891 
rs5744280 0.353 - 0.991 1 1 1 1 1 0.79 
rs549908 0.56 0.196 - 1 1 1 0.703 0.997 0.811 
rs1834481 0.243 0.16 0.137 - 1 1 1 1 1 
rs5744247 0.169 0.06 0.051 0.041 - 1 1 1 0.989 
rs360722 0.206 0.073 0.062 0.05 0.82 - 1 1 0.972 
rs2043055 0.25 0.867 0.114 0.185 0.069 0.084 1 0.817 
rs187238 0.475 0.168 0.839 0.115 0.043 0.052 0.194 - 1 
r2 
rs1946519 0.757 0.211 0.388 0.232 0.173 0.204 0.26 0.498 - 
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Figure A6: Haploview Diagram of Pairwise r2 Between IL18R1 and IL18RAP SNPs 
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Table A6: Linkage Disequilibrium at  IL-181-IL18RAP 
 
  IL18R1 
 
             D'       
 
 
 
   r2 
 r
s1
14
65
56
7 
rs
93
08
85
7 
rs
11
46
55
72
 
rs
11
46
55
76
 
rs
15
58
62
7 
rs
11
46
55
97
 
rs
75
79
73
7 
rs
65
43
12
4 
rs
11
46
56
08
 
rs
75
58
01
3 
rs
22
41
11
6 
rs
48
51
57
0 
rs
14
20
09
5 
rs11465567 - 1.00 1.00 1.00 1.00 0.93 0.93 0.97 1.00 0.85 1.00 1.00 1.00
rs9308857 0.07 - 1.00 1.00 1.00 0.82 0.48 0.98 1.00 0.97 1.00 0.99 0.96
rs11465572 1.00 0.07 - 0.99 1.00 0.93 0.93 0.97 1.00 0.86 1.00 1.00 1.00
rs11465576 0.01 0.04 0.01 - 1.00 0.94 1.00 1.00 1.00 1.00 1.00 1.00 1.00
rs1558627 0.04 0.19 0.04 0.02 - 1.00 1.00 1.00 0.23 1.00 1.00 1.00 1.00
rs11465597 0.84 0.05 0.84 0.01 0.04 - 0.96 0.90 1.00 0.74 1.00 1.00 1.00
rs7579737 0.24 0.16 0.24 0.03 0.13 0.26 - 0.46 1.00 0.84 0.98 0.98 0.97
rs6543124 0.06 0.93 0.06 0.04 0.19 0.06 0.15 - 1.00 0.98 1.00 0.99 0.96
rs11465608 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 - 1.00 1.00 1.00 1.00
rs7558013 0.02 0.38 0.02 0.02 0.08 0.02 0.42 0.40 0.00 - 1.00 1.00 1.00
rs2241116 0.03 0.16 0.03 0.02 0.08 0.03 0.11 0.15 0.00 0.06 - 1.00 1.00
rs4851570 0.05 0.23 0.05 0.17 0.12 0.05 0.16 0.22 0.00 0.10 0.67 - 1.00
IL
18
R
1 
rs1420095 0.01 0.13 0.01 0.01 0.03 0.01 0.20 0.14 0.00 0.02 0.03 - 
rs4851581 0.01 0.14 0.01 0.01 0.03 0.01 0.21 0.15 0.00 0.38 0.02 0.04 0.93
rs1420105 0.12 0.65 0.12 0.06 0.29 0.13 0.44 0.64 0.00 0.27 0.24 0.35 0.10
rs2293225 0.03 0.16 0.03 0.02 0.08 0.03 0.11 0.15 0.00 0.07 1.00 0.67 0.02
rs1420100 0.12 0.65 0.12 0.06 0.29 0.13
0.05 
0.44 0.64 0.00 0.27 0.24 0.35 0.10
rs3755268 0.04 0.20 0.04 0.02 0.99 0.04 0.13 0.19 0.00 0.08 0.08 0.12 0.03
rs2272127 0.01 0.21 0.01 0.02 0.07 0.01 0.01 0.21 0.00 0.05 0.06 0.09 0.02
rs887972 0.05 0.26 0.05 0.15 0.07 0.05 0.17 0.25 0.00 0.11 0.60 0.88 0.04
rs2058660 0.03 0.19 0.03 0.02 0.93 0.03 0.13 0.19 0.00 0.08 0.07 0.11 0.03
rs11465702 0.01 0.27 0.01 0.01 0.06 0.01 0.06 0.29 0.00 0.04 0.05 0.07 0.02
rs6748390 0.09 0.24 0.09 0.03 0.13 0.09 0.70 0.23 0.01 0.61 0.10 0.16 0.22
rs6543135 0.02 0.38 0.02 0.02 0.08 0.01 0.42 0.40 0.00 0.99 0.07 0.09 0.35
rs11465723 0.01 0.27 0.01 0.01 0.06 0.01 0.06 0.29 0.00 0.04 0.05 0.07 0.02
rs11465724 0.23 0.01 0.23 0.00 0.01 0.16 0.06 0.02 0.00 0.00 0.01 0.01 0.00
IL
18
R
A
P
 
rs11465732 0.01 0.01 0.84 0.03 0.01 0.03 0.05 0.00 0.02 0.02 0.20 0.01
0.35
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 Table A6 (continued) 
 
  IL18RAP 
 
             D'     
 
 
 r
s4
85
15
81
 
rs
14
20
10
5 
rs
22
93
22
5 
rs
14
20
10
0 
rs
37
55
26
8 
rs
22
72
12
7 
rs
88
79
72
 
rs
20
58
66
0 
rs
11
46
57
02
 
rs
67
48
39
0 
rs
65
43
13
5 
rs
11
46
57
23
 
rs
11
46
57
24
 
rs
11
46
57
32
 
rs11465567 1.00 0.99 1.00 0.99 1.00 0.13 1.00 0.93 0.79 0.55 0.78 0.80 0.92 1.00
rs9308857 0.96 0.99 1.00 0.99 1.00 0.74 0.99 0.99 0.97 0.59 0.96 0.97 0.82 1.00
rs11465572 1.00 0.99 1.00 0.99 1.00 0.13 1.00 0.94 0.80
1.00 1.00 
rs1558627 
1.00
1.00
0.55 0.78 0.80 0.92 1.00
rs11465576 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1.00 1.00 1.00 1.00 1.00 1.00 0.69 0.98 1.00 1.00 1.00 1.00 1.00 1.00
rs11465597 1.00 0.99 1.00 0.99 1.00 0.12 1.00 0.93 0.82 0.55 0.69 0.82 0.77 1.00
rs7579737 0.98 0.98 0.98 0.98 0.97 0.37 0.98 0.96 0.92 0.85 0.84 0.92 0.90 1.00
rs6543124 0.96 1.00 1.00 1.00 1.00 0.74 1.00 1.00 0.98 0.58 0.97 0.98 1.00 1.00
rs11465608 1.00 1.00 1.00 1.00 0.22 1.00 1.00 0.22 1.00 1.00 1.00 1.00 1.00 1.00
rs7558013 1.00 1.00 1.00 1.00 1.00 0.97 1.00 1.00 1.00 1.00 1.00 0.56 1.00
rs2241116 1.00 1.00 1.00 1.00 0.98 1.00 1.00 0.91 0.98 1.00 1.00 1.00 1.00
rs4851570 1.00 1.00 1.00 1.00 0.99 1.00 0.99 0.93 1.00 0.99 0.98 1.00 1.00 1.00
IL
18
R
1 
rs1420095 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
rs4851581 - 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
rs1420105 0.10 - 1.00 1.00 1.00 1.00 1.00 0.99 1.00 1.00 0.99 1.00 1.00 1.00
rs2293225 0.02 0.24 - 1.00 0.98 1.00 1.00 0.91 1.00 0.98 1.00 1.00 1.00 1.00
rs1420100 0.10 1.00 0.24 - 1.00 1.00 1.00 0.99 1.00 1.00 0.99 1.00 1.00 1.00
rs3755268 0.03 0.30 0.08 0.30 - 1.00 0.69 0.98 1.00 1.00 1.00 1.00 1.00 1.00
rs2272127 0.02 0.25 0.06 0.25 0.07 - 1.00 0.97 1.00 0.96 0.97 1.00 1.00 1.00
rs887972 0.04 0.40 0.60 0.40 0.07 0.10 - 0.64 1.00 0.99 0.98 1.00 1.00 1.00
rs2058660 0.03 0.29 0.07 0.29 0.94 0.07 0.06 - 1.00 1.00 1.00 1.00 1.00 1.00
rs11465702 0.02 0.19 0.05 0.19 0.06 0.76 0.08 0.06 - 1.00 1.00 1.00 1.00 1.00
rs6748390 0.23 0.45 0.10 0.45 0.13 0.09 0.17 0.13 0.07 - 1.00 1.00 1.00 1.00
rs6543135 0.37 0.27 0.07 0.27 0.08 0.05 0.10 0.08 0.04 0.61 - 0.56 1.00
rs11465723 0.02 0.19 0.05 0.19 0.06 0.76 0.08 0.06 1.00 0.07 0.04 - 1.00 1.00
rs11465724 0.00 0.03 0.01 0.03 0.01 0.01 0.01 0.01 0.01 0.08 0.00 0.01 - 1.00
IL
18
R
A
P
 
rs11465732 0.01 0.07 0.02 0.07 0.03 0.02 0.18 0.03 0.01 0.03 0.02 0.01 0.00 - 
 
2    r
1.00
1.00 
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Figure A7: Haploview Diagram of Pairwise r2 Between SNPs at IL12A. 
 
 
 
 
Table A7: Linkage Disequilibrium at IL12A. 
 
  D' 
  rs2243123 rs583911 rs640039 rs2243147 rs2243154
rs2243123 - 1 1 0.997 1 
rs583911 0.311 - 1 1 1 
rs640039 0.065 0.129 - 1 1 
rs2243147 0.606 0.51 0.107 - 1 
r2 
rs2243154 0.041 0.131 0.017 0.067 - 
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Figure A8: Haploview Diagram of Pairwise r2 Between SNPs at IL12B. 
 
 
Table A8: Linkage Disequilibrium at  IL12B. 
 
  D' 
  r
s1
36
84
39
 
rs
28
53
69
7 
rs
32
13
11
9 
rs
91
97
66
 
rs
28
53
69
4 
rs
32
13
09
6 
rs
32
13
09
4 
rs
25
69
25
3 
rs
31
81
21
8 
rs
31
81
21
6 
rs
32
12
21
7 
rs1368439 - 1 1 1 0.991 0.998 1 0.99 1 1 1 
rs2853697 0.041 - 1 1 1 1 0.973 1 1 0.977 1 
rs3213119 0.005 0.006 - 0.976 0.931 1 0.635 1 0.631 1 0.631 
rs919766 0.026 0.027 0.197 - 1 0.329 1 0.985 1 0.965 1 
rs2853694 0.212 0.19 0.022 0.121 - 1 1 0.301 1 0.988 0.993 
rs3213096 0.002 0.002 0 0 0.007 - 1 1 1 1 1 
rs3213094 0.06 0.059 0.003 0.04 0.276 0.026 - 0.994 1 1 0.997 
rs2569253 0.18 0.223 0.025 0.118 0.09 0.007 0.274 - 1 0.992 0.994 
rs3181218 0.059 0.062 0.003 0.039 0.276 0.026 0.997 0.277 - 1 1 
rs3181216 0.089 0.089 0.012 0.055 0.479 0.003 0.135 0.479 0.135 - 1 
r2 
rs3212217 0.059 0.062 0.003 0.04 0.272 0.026 0.994 0.274 0.997 0.135 - 
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 APPENDIX B: PROTOCOLS, PRIMERS, AND LABORATORY METHODS 
 
 
Sequencing Protocol 
 
1x PCR Mix 
dH2O   9.7 µL 
10X PCR buffer 2.0 µL 
dNTP (5µm)  0.8 µL 
MgCl2 (25µm) 2.4 µL 
F-primer (5µm) 1.0 µL 
R-primer (5µm) 1.0 µL 
Taq polymerase 0.1µL 
DNA (10ng/µL) 3.0 µL 
Total Volume  20.0 µL 
 
PCR thermocycler conditions 
1.  95°C  10 min 
2.  94°C  45 sec 
3.  55, 60, or 65 °C 45 sec 
4.  72°C  1 min 
5.  repeat 2-4   34 times 
6.  72°C  10 min 
7.  4°C   forever 
 
1x SAP Treatment 
PCR product 2.5µL    
SAPH  1.25µL 
Exo I  0.05µL 
dH2O  1.2µL 
Total Volume 5.0µL 
 
 
Incubate at 37°C for 1hr, then at 75°C for 15 min 
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 1x Sequencing Reaction 
SAP treated product  3.0µL 
Big Dye 3.1 Terminator Mix 1.0µL 
Sequencing primer (5µm) 0.7µL 
dH2O    5.3µL 
Total Volume   10.0µL 
 
Sequencing Thermocycler Conditions 
1.  96°C 10 sec 
2.  50°C 5 sec 
3.  60°C 4 min 
4.  repeat 1-3. 24times 
5.  4°C  forever 
 
Precipitate sequencing reaction products using isopropanol precipitation. 
Run ABI 3100 or 3300 automated sequencer with 50 or 85 cm capillaries using corresponding 
settings. 
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 Table B1:  Primers Used for Pooled Sequencing and Preparation of TNF Promoter 
Expression Constructs. 
 
Primers used for pooled TNF sequencing   
F Primer Sequence R Primer Sequence 
TNFSeq01_F CCAGGCTGGAATACAGTGGT TNFSeq01_R GATGCCCTCCATCTCTTCCT 
TNFSeq02_F TCACCCATGTGGAATTCTGA TNFSeq02_R GCGACTGAGTTCTGGGAAAG 
TNFSeq03_F CGCCTCCTCTCTGAATTGAC TNFSeq03_R AAGGTGAGCAGAGGGAGACA
TNFSeq04_F GGGTTTGGTTTTGGTTTCCT TNFSeq04_R GACATGTCTGGGAGGTCAGG 
TNFSeq05_F CCCCCTCAACTCTGTTCTCC TNFSeq05_R GGAGGAGAAGAGCTGGACCT
TNFSeq06_F CCCACCAGTGGCATCTACTT TNFSeq06_R TGCTCTTCCTCTGTGTGTGG 
TNFSeq07_F TGATGTCTGTCTGGCTGAGG TNFSeq07_R TCAGCTTCTCCTTTGCTTCC 
TNFSeq08_F GTGAGAACTTCCCAGTCTATCTAAGG TNFSeq08_R GGGAATTCACAGACCCCACT 
TNFSeq09_F GAAGATATGGCCACACACTGG TNFSeq09_R AAAGTTGGGGACACACAAGC 
TNFSeq10_F ACCTGGTCCCCAAAAGAAAT TNFSeq10_R AAGAGGCTGAGGAACAAGCA 
TNFSeq11_F CTCTCTCCCCTGGAAAGGAC TNFSeq11_R TCTTCTGTGTGCCAGACACC 
TNFSeq12_F GAGACAGATGTGGGGTGTGA TNFSeq12_R TAGCCCTCCAAGTTCCAAGA 
TNFSeq13_F GAGGATGGATGGAGGTGAAA TNFSeq13_R TTGATGGCAGAGAGGAGGTT 
TNFSeq14_F ATCAGAGGGCCTGTACCTCA TNFSeq14_R CAGGGATCAAAGCTGTAGGC 
TNFSeq15_F TCGGAACCCAAGCTTAGAAC TNFSeq15_R CAGAGGCTCAGCAATGAGTG 
TNFSeq16_F TAGGCTGTTCCCATGTAGCC TNFSeq16_R TCACATGCCCTATGTGTGGT 
TNFSeq17_F CTTCCAGAGATTCGGGTGTC TNFSeq17_R GCCCCACCCTTATTTGTCTT 
TNFSeq18_F GTCCCACTGGTCTTTGTGGT TNFSeq18_R CCCCATTACTTCATGGCTGA 
TNFSeq19_F AACCATGTGGTAGGCTGAGG TNFSeq19_R ACATGGTCCCAACCAGACTC 
TNFSeq20_F GCAGCTCTAGGGGGAGAAGT TNFSeq20_R AGGGAATATGAGTGCGTGGT 
TNFSeq5b_F AACTTCCCCCACGCTAAAAA TNFSeq5b_R CGAAGGCTCCAAAGAAGACA 
TNFSeq11b_F GAGACAGGATGTCTGGCACA TNFSeq11b_R TTTCACCTCCATCCATCCTC 
TNFSeq19b_F AAGCCCAGGAGTTTGAGGTT TNFSeq19b_R GGAGGAGGCTGAAGGAGAAA
    
Primers used for preparation of expression 
constructs   
TNF_Kpn1 ggggtacccc  tatgattgctcttcagggaac   
TNF_Nhe1 ctagctagctag  gtgtcctttccaggggagag   
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 Table B2.  SNPs Estimated to be Present with Minor Allele rFequency Greater than 5% in 
Caucasian Case and Control by Pooled Sequencing. 
 
SNP Amplicon used Sample Estimated MAF
rs2844482 TNFseq01 control 0.15 
 TNFseq02 case 0.15 
rs2071290 TNFseq01 control 0.30 
 TNFseq02 case 0.29 
rs1800683 TNFseq02 control 0.48 
 TNFseq03 case 0.50 
rs2239704 TNFseq02 control 0.24 
 TNFseq03 case 0.20 
rs3093546 TNFseq02 control 0.09 
 TNFseq03 case 0.14 
rs909253 TNFseq03 control 0.27 
 TNFseq04 case 0.35 
rs746868 TNFseq04 control 0.35 
  case 0.35 
rs2857713 TNFseq04 control 0.36 
  case 0.29 
rs3093543 TNFseq05 control 0.16 
  case 0.12 
rs1041981 TNFseq05 control 0.40 
  case 0.47 
control 0.20 
  case 0.19 
rs1800630 TNFseq08 control 0.15 
  case 0.13 
rs1799724 TNFseq08 control 0.16 
  case 0.16 
rs1800629 TNFseq09 control 0.21 
  case 0.26 
rs1800610 TNFseq11 control 0.16 
  case 0.15 
rs3091257 TNFseq17 control 0.16 
  case 0.19 
control 0.19 
 TNFseq19b case 0.16 
rs3093559 TNFseq19b control 0.08 
  case 0.09 
rs1799964 TNFseq08 
rs769178 TNFseq18 
 
The dbSNP identification number is shown in the first column, the primer from Table B1 used 
for sequencing is indicated in the second column.  Minor allele frequency was estimated by 
averaging calculated allele frequencies from sequencing with forward and reverse primers. 
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 SNAPSHOT protocol 
 
1x PCR Mix 
dH2O   3.9 µL 
10X PCR buffer 1.0 µL 
dNTP (5µm)  0.5 µL 
MgCl2 (25µm) 1.2 µL 
pooed primers  1.3 µL 
Taq polymerase 0.13µL 
DNA (10ng/µL) 2.0 µL 
Total Volume  10.0 µL 
 
PCR thermocycler conditions 
1.  95°C 10 min 
2.  94°C 45 sec 
3.  60°C 45 sec 
4.  72°C 1 min 
5.  repeat 2-4 34 times 
6.  72°C 10 min 
7.  4°C  forever 
 
1x SAP Treatment 
PCR product 2.5µL    
SAPH  1.25µL 
Exo I  0.05µL 
dH2O  1.2µL 
Total Volume 5.0µL 
 
 
Incubate at 37°C for 1hr, then at 75°C for 15 min 
1x SNaPshot Extension 
SAP treated product  1.5µL 
SNaPshot Multiplex Kit 1.5µL 
Pooled internal primers 0.5µL 
dH2O    1.5µL 
Total Volume   5.0µL 
 
SNaPshot Thermocycler Conditions 
1.  96°C 10 sec 
2.  50°C 5 sec 
3.  60°C 30 sec 
4.  repeat 1-3. 24times 
5.  4°C  forever 
 
 146
 1x Post Extension 
SnapShop product 2.0µL  
SAPH   1.0µL 
dH2O   7.0µL 
Total Volume  10.0µL 
 
Incubate at 37°C for 1hr, then at 75°C for 15 min 
 
1x SNaPshot for ABI 
Formamide  8.85µL 
LIZ120 Size Standard 0.15µL 
Product  1.0 µL 
Total Volume  10.0µL 
 
Denature at 95°C for 5 min before placing in ABI machine.  Run on 25 or 35 cm capillaries 
using corresponding settings. 
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 APPENDIX C: ASSOCIATIONS OF ANALYZED GENES WITH TOXOPLASMA 
GONDII 
 
Table C1: Association Analysis of SNPs in TNF Comparing Toxoplasma gondii Seropositive 
Schizophrenia Cases with Community Based Controls. 
 
    
  
TOX+ Case
(n = 31) 
  
  
Control 
(n = 276) 
  
Minor allele frequency 
  
ID# Marker 11 12 22 11 12 22
Genotype-
wise 
p-value 
 case control 
Allele-wise
p-value 
 
1 rs2844482 (C/T) 24 6 1 189 74 7 0.491 0.182 0.163 0.489 
2 rs3093543 (A/C) 26 5 0 228 44 1 0.921 0.097 0.084 0.923 
3 rs1799964 (C/T) 2 6 23 11 93 170 0.370 0.227 0.210 0.369 
4 rs1800630 (A/C) 1 6 24 8 84 174 0.250 0.176 0.188 0.255 
5 rs1799724 (A/G) 1 7 23 3 55 213 0.447 0.091 0.113 0.447 
6 rs1800629(-G308A) (A/G) 0 7 24 8 73 195 0.323 0.142 0.161 0.320 
7 rs361525 (A/G) 0 2 29 3 24 249 0.488 0.051 0.054 0.458 
8 rs1800610 (C/T) 24 6 1 214 55 3 0.692 0.909 0.112 0.691 
 
 
1/1, 2/2, 1/2: Individuals homozygous for allele1, allele2 and heterozygous, respectively.  
Nucleotides were labeled 1 or 2 in alphabetical order, nucleotide identity is indicated in the 
second column. Serum was not available for controls, so TOX seropositive cases were compared 
to all controls. 
 
 
Table C2:  Association of MICB SNPs with Toxoplasma gondii in Baltimore Controls and 
Schizophrenia Cases. 
 
TOX positive TOX negative TOX + TOX - Baltimore controls 
11 12 22 11 12 22
Genotype
-wise pval freq_1 freq_1 
Allele-
wise pval 
rs2523651 0 1 5 15 38 42 0.05 0.08 0.36 0.07 
rs1055569 1 5 0 43 43 9 0.49 0.58 0.68 0.48 
rs2596536 2 4 0 49 34 12 0.84 0.67 0.69 0.85 
rs2596453 3 3 0 50 38 7 0.86 0.75 0.73 0.86 
rs1051788 0 4 2 8 32 55 0.54 0.33 0.25 0.55 
Baltimore SZ cases           
9 18 22 30 100 81 0.83 0.37 0.38 0.83 
rs1055569 18 23 9 94 82 32 0.27 0.59 0.65 0.30 
rs2596536 19 24 6 93 85 28 0.64 0.63 0.66 0.65 
rs2596453 32 14 4 108 81 22 0.13 0.78 0.70 0.15 
rs1051788 5 28 17 19 91 101 0.15 0.38 0.31 0.14 
rs2523651 
 
 
 
 
 148
 Table C3.  Associations of IL10, IL1β, and IL1RN SNPs with Toxoplasma gondii in 
Schizophrenia Cases. 
 
Toxo + (N=45) Toxo – (N=305) SNP Gene 
freq_1 freq_2 freq_1 freq_2 
Genotype-
wise pval
rs1800894 IL-10 0.0667 0.9333 0.0328 0.9672 0.1200 
rs3024491 IL-10 0.5667 0.4333 0.4623 0.5377 0.0700 
rs1518110 IL-10 0.1556 0.8444 0.2169 0.7831 0.2034 
rs1800872 IL-10 0.1778 0.8222 0.2475 0.7525 0.1751 
rs3024492 IL-10 0.3000 0.7000 0.2319 0.7681 0.1343 
IL-10 0.1444 0.8556 0.1623 0.8377 0.6697 
rs1143627 IL1β 0.6111 0.3889 0.6776 0.3224 0.1980 
rs1143633 IL1β 0.4222 0.5778 0.3705 0.6295 0.3621 
rs1143634 IL1β 0.1667 0.8333 0.2312 0.7689 0.1506 
rs16944 IL1β 0.3778 0.6222 0.3230 0.6771 0.2886 
rs2853550 IL1β 0.0889 0.9111 0.0820 0.9180 0.8259 
rs3136558 IL1β 0.8444 0.1556 0.7813 0.2188 0.1531 
rs3917356 IL1β 0.4667 0.5333 0.4689 0.5312 0.9699 
rs3917365 IL1β 0.0889 0.9111 0.0820 0.9180 0.8259 
rs1794066 IL1RN 0.6000 0.4000 0.6066 0.3934 0.9068 
rs1794068 IL1RN 0.2889 0.7111 0.2689 0.7312 0.6965 
rs2232354 IL1RN 0.7667 0.2333 0.7747 0.2253 0.8656 
rs2637988 IL1RN 0.6111 0.3889 0.6082 0.3918 0.9587 
rs3087262 IL1RN 0.1111 0.8889 0.1279 0.8721 0.6386 
rs3087263 IL1RN 0.1444 0.8556 0.0872 0.9128 0.0876 
rs315934 IL1RN 0.7667 0.2333 0.7967 0.2033 0.5075 
rs315949 IL1RN 0.4111 0.5889 0.4000 0.6000 0.8450 
rs315952 IL1RN 0.6778 0.3222 0.6869 0.3131 0.8625 
rs380092 IL1RN 0.3333 0.6667 0.3180 0.6820 0.7656 
rs4251961 IL1RN 0.6444 0.3556 0.6234 0.3766 0.7033 
rs4251974 IL1RN 0.7111 0.2889 0.7344 0.2656 0.6501 
rs4252041 IL1RN 0.0778 0.9222 0.0492 0.9508 0.2441 
rs451578 IL1RN 0.2889 0.7111 0.2853 0.7148 0.9451 
rs3024495 
 
Coding for individual SNPs is shown in Table 7.1 
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 Table C4.  Associations of IL-18 Pathway SNPs with Toxoplasma gondii in Schizophrenia 
Cases. 
 
    Toxo + (N=45) Toxo - (N=305) 
Genotype-
wise 
SNP Gene freq_1 freq_2 freq_1 freq_2 pval 
rs1834481 IL-18 0.300 0.700 0.243 0.757 0.248 
rs187238 IL-18 0.656 0.344 0.757 0.243 0.042 
rs1946519 IL-18 0.422 0.578 0.398 0.602 0.664 
rs2043055 IL-18 0.689 0.311 0.615 0.385 0.161 
rs360722 IL-18 0.044 0.956 0.125 0.875 0.027 
rs3882891 IL-18 0.589 0.411 0.585 0.415 0.948 
rs549908 IL-18 0.633 0.367 0.710 0.290 0.138 
rs5744247 IL-18 0.044 0.956 0.107 0.893 0.063 
rs5744280 IL-18 0.289 0.711 0.339 0.661 0.328 
rs3814721 IL18BP 0.944 0.056 0.938 0.062 0.807 
rs11465567 IL18R1 0.889 0.111 0.911 0.089 0.488 
rs11465572 IL18R1 0.111 0.889 0.089 0.911 0.494 
rs11465576 IL18R1 0.956 0.044 0.930 0.070 0.361 
rs11465597 IL18R1 0.856 0.144 0.908 0.092 0.115 
rs11465608 IL18R1 1.000 0.000 0.997 0.003 0.586 
rs1420095 IL18R1 0.967 0.033 0.910 0.090 0.061 
rs1558627 IL18R1 0.722 0.278 0.769 0.231 0.340 
rs2058623 IL18R1 0.667 0.333 0.696 0.304 0.640 
rs2241116 IL18R1 0.200 0.800 0.225 0.775 0.614 
rs4851570 IL18R1 0.733 0.267 0.693 0.307 0.473 
rs6543124 IL18R1 0.311 0.689 0.373 0.627 0.262 
rs7558013 IL18R1 0.222 0.778 0.226 0.774 0.931 
rs7579737 IL18R1 0.667 0.333 0.705 0.295 0.470 
rs9308857 IL18R1 0.344 0.656 0.375 0.625 0.579 
rs11465673 IL18RAP 0.856 0.144 0.926 0.074 0.025 
rs11465702 IL18RAP 0.911 0.089 0.865 0.135 0.243 
rs11465723 IL18RAP 0.089 0.911 0.135 0.865 0.243 
rs11465724 IL18RAP 0.089 0.911 0.031 0.969 0.007 
rs11465732 IL18RAP 0.067 0.933 0.080 0.920 0.670 
rs1420100 IL18RAP 0.456 0.544 0.462 0.538 0.909 
rs1420105 IL18RAP 0.544 0.456 0.538 0.462 0.909 
rs2058660 IL18RAP 0.727 0.273 0.758 0.242 0.525 
rs2272127 IL18RAP 0.089 0.911 0.161 0.839 0.092 
rs2293225 IL18RAP 0.193 0.807 0.226 0.774 0.515 
rs3755268 IL18RAP 0.722 0.278 0.769 0.231 0.340 
rs4851581 IL18RAP 0.944 0.056 0.905 0.095 0.203 
rs6543135 IL18RAP 0.222 0.778 0.227 0.773 0.918 
rs6748390 IL18RAP 0.633 0.367 0.702 0.298 0.201 
rs887972 IL18RAP 0.322 0.678 0.322 0.678 0.998 
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 Table C4 (continued) 
 
  Toxo + (N=45) Toxo - (N=305) 
Genotype-
wise 
SNP Gene freq_1 freq_2 freq_1 freq_2 pval 
rs2243123 IL12A 0.711 0.289 0.708 0.292 0.952 
rs2243131 IL12A 0.778 0.222 0.762 0.238 0.803 
rs2243147 IL12A 0.567 0.433 0.605 0.395 0.487 
rs2243154 IL12A 0.089 0.911 0.105 0.895 0.656 
rs583911 IL12A 0.600 0.400 0.554 0.446 0.397 
rs640039 IL12A 0.878 0.122 0.879 0.121 0.980 
rs1368439 IL12B 0.811 0.189 0.839 0.161 0.515 
rs2569253 IL12B 0.544 0.456 0.487 0.513 0.312 
rs2853694 IL12B 0.511 0.489 0.502 0.498 0.864 
rs2853697 IL12B 0.844 0.156 0.821 0.179 0.591 
rs3181216 IL12B 0.300 0.700 0.338 0.662 0.471 
rs3181218 IL12B 0.289 0.711 0.198 0.802 0.039 
rs3212217 IL12B 0.711 0.289 0.803 0.197 0.037 
rs3213094 IL12B 0.289 0.711 0.198 0.802 0.039 
rs3213096 IL12B 0.022 0.978 0.005 0.995 0.068 
rs3213119 IL12B 0.011 0.989 0.028 0.972 0.342 
rs919766 IL12B 0.944 0.056 0.877 0.123 0.066 
 
For allele coding see Table 8.1. 
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